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Abstract 
Metabolic syndrome is a precursor to non-communicable diseases including type 2 
diabetes and cardiovascular disease. Diet and lifestyle choices are major contributors 
to the development and progression of metabolic syndrome. Adding functional foods 
and functional compounds into the diet of those at risk of developing metabolic 
syndrome will improve metabolic status and, in the long term, minimise the incidence 
of the disease. This research aims to identify and quantify the impacts that sorghum 
and phloretin have on diet-induced metabolic syndrome.   
Methods: A 16 week rat model of diet-induced metabolic syndrome was used to 
determine responses to 5% whole red sorghum, 20% red sorghum flour, 20% black 
sorghum flour, 20% wet cake sorghum, or phloretin at 50mg/kg/day or 200mg/kg/day. 
Cardiovascular, physiological, and metabolic variables were measured. Studies were 
conducted to determine whether there were changes in intestinal permeability caused 
by alterations in colonic tight junction proteins which would lead to reduced serum 
LPS concentrations and TLR4-mediated inflammation which is known to contribute 
to metabolic syndrome.  
Results: Phloretin, a glucose transporter 2 inhibitor, normalised post-prandial blood 
glucose responses when consumed at 200mg/kg/day showing potential for the pre-
diabetes aspect of metabolic syndrome. On the contrary this dose increased total 
plasma cholesterol which is considered to be a risk factor for increased cardiovascular 
events in metabolic syndrome.  
Whole sorghum reduced total cholesterol concentrations in a rat model of diet-induced 
metabolic syndrome, showing potential for reducing risk of cardiovascular events. 
Black and red sorghum flour showed remarkably few changes in a high fat-high 
carbohydrate diet, and the implications for metabolic syndrome are low. 
Improvements were observed in the liver and gastrointestinal tract, with reduced 
steatosis and a modest reduction in small intestinal permeability.  
Wet cake sorghum, the waste product of ethanol fermentation, showed the greatest 
changes of all the sorghum products with normalisation of post-prandial glucose, 
improved liver morphology, reduction in left ventricular collagen, and a modest 
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reduction in small intestinal permeability. A number of changes were seen when 
adding sorghum into the control diet which did not develop metabolic syndrome. The 
outstanding change was a distinct increase in lean mass. 
There was little evidence to suggest that changes in the gastrointestinal tract were 
major contributors to improving metabolic syndrome through reducing metabolic 
endotoxaemia.  
Conclusions: Overall both phloretin and sorghum products show benefits to their 
consumption for attenuation of metabolic syndrome, which can be used as leverage for 
further clinical studies and for promotion of sorghum as a health food.  
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Chapter 1 - Introduction 
Chapter 1.1 – Sorghum Literature Review - An ancient grain with modern 
potential 
1.1.1 Sorghum in traditional diets 
Sorghum is a grass of the Poaceae genus, producing round, edible grains with between 
12000 and 16000 seeds per pound (1). Modern cultivated sorghum compared with its 
traditional, undomesticated counterpart is shown in Figure 1.2.1.  
 
Figure 1.2.1:Wild type sorghum originating in Africa (left) (2), and modern 
domesticated sorghum grown on the Darling Downs (Photo courtesy of Patricia 
Balzer).  
Sorghum is not considered one of the major cereal grains for human consumption, 
outcompeted by wheat, maize, oats and rice. Only approximately 50% of the 60MMT 
(million metric tonnes) of the sorghum produced worldwide is used for human 
consumption, while around 70% of the 650MMT of wheat is consumed by humans 
(3). Despite this, sorghum remains a staple food for 500 million people in 30 countries 
(4), partly due to its tolerance to environmental conditions and the diverse ways it can 
be prepared as food.  
Prior to agricultural domestication, sorghum is believed to have been consumed by 
humans as early as 8000BC in its wild form, with domestication following somewhere 
between 4000BC and 3000BC (5). The original domestication of sorghum occurred in 
Africa, which then spread throughout the world, and became part of the diets of India 
and Asia (6). Traditional dishes made from sorghum include fermented beverages such 
as Mahewu (7), fermented porridges in South Africa (8), ground sorghum boiled 
porridges in Sudan (9), baking of Dduk cake in Korea (10) and boiled sorghum ‘on the 
cob’ in Botswana (11).  
Sorghum, on the scale of breeding, was described as having more underdeveloped 
genetic potential than any other major food crop in the world (4). This suggests that 
the current genetic status of sorghum will allow breeding for specific human 
consumption. Sorghum’s potential as a nutraceutical or health food is still in its 
infancy.  
1.1.2 Sorghum significance 
Almost all sorghum grown in Australia is produced in the Northern Grains Region of 
Queensland and New South Wales, with less than 1% estimated to be produced in 
other states (12). Sorghum is one of the major crops of Queensland, with value of 
agricultural production being an average of $340 million per year over a 5-year period 
to 2017. This was the second highest value cereal crop following wheat ($401 million) 
for the same period (13). Sorghum represents a high value commodity crop in the 
region and is important to the local economy, with 2200 producers in Queensland and 
3200 Australia-wide as of 2010-2011, as reported in the GRDC (Grain Research & 
Development Corporation) Australian Grains Focus 2010-2012 (14). Sorghum and 
wheat are both volatile in price due to overseas demand, production and local weather 
patterns. Production in the Queensland and northern New South Wales regions is 
shown in Figure 1.2.2 (15). 
Sorghum is primarily used in Australia for livestock feed, rather than human 
consumption. According to calculations based on FAO (Food and Agriculture 
Organization) statistics, domestic sorghum usage in Australia (including both imports 
and exports) has stabilised since 1994 with over 96% used as animal feed (16). Grain 
sorghum markets also exist for biofuel production. Any grains containing starches can 
be used for ethanol production, and sorghum is ideal for this purpose as it has one of 
the highest starch contents of grains (17). Ethanol from grain sorghum is produced 
locally by Dalby Bio-Refinery Limited (18), although current capacity is low (19).   
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The difficulties for sorghum to break into the human food consumption market in 
Australia come from traditional or cultural attitudes, in addition to market competition 
against stock feed and biofuel dominance. The conventional use of sorghum 
exclusively as stock feed means that promoting it for human consumption is likely to 
be difficult, especially when competing against more traditional cereals such as wheat. 
Traditionally, sorghum has been used by some communities as a staple cereal for 
human consumption, primarily Africa and India (20). The predominant regions for 
human consumption of sorghum are still Asia and Africa at around 97%, however 
Central and South America account for a small proportion (21).  
 
 
Figure 1.2.2: Long-term sorghum predicted average yields over a 115 year period in 
Queensland and northern New South Wales (15)  
1.1.3 Sorghum varieties and types 
Sorghum is considered to have an untapped genetic potential by many plant breeders 
and researchers (4). There is still significant variation in the types of sorghum that fall 
under the Sorghum biocolor species that are of commercial interest, all of which have 
their origins in Africa. Sorghum varieties which are commercially grown are typically 
classed by the colour of grain that they produce, although nomenclature is not 
standardised. The typical classes of grain colour are red, bronze or tan, and white. 
Although not commercially grown in Australia, black sorghum is also gaining traction 
as a niche crop overseas (22). Despite the “colour classes”, there are at least 10 genes 
which dictate the colour of the pericarp and glume (23). Further genes alter the 
appearance including pericarp thickness (8-160µm) and the presence or absence of 
testa (24). Due to the large number of possible combinations, there is an almost 
continuous range of colours (25). 
Other type-classes of sorghum are waxy and non-waxy sorghum which are defined by 
the presence or absence of amylopectin in the endosperm, respectively (26). The waxy 
trait in sorghum is controlled by a single gene where two recessive alleles will result 
in a “waxy” phenotype (26). High tannin sorghum is also controlled by one known 
gene, Tan1 (27). High levels of tannins are considered to be detrimental in most 
breeding cases, as high tannin content reduces protein digestibility, a detriment for 
stockfeed production (27). Reduced starch digestion due to tannins also occurs through 
interaction with amylase (28). However, tannins have been implicated as beneficial for 
human health (29). There are a number of Sorghum species that are native to Australia 
(30) and will act as a source of breeding material, or as a potential health-food source.  
For the purposes of this research, I have focussed on red and black sorghum as they 
have been used in the researched literature. White sorghum is also mentioned in this 
review as it is the type commonly used in the production of sorghum-based gluten-free 
flours, although not studied in the ensuing research.  
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Figure 1.2.3: A selection of the sorghum grain colours that can be produced (31). 
1.1.4 Sorghum proteins 
Sorghum is comparable in protein content to most other common cereal crops. White 
sorghum flour has a protein content of approximately 12.5% (32), with the sorghum 
wholegrain of around 12.1% protein (33). For comparison, corn, wheat and rice 
contain approximately 9-12%, 8-15% and 7-9% protein, respectively (34). Variation 
in sorghum proteins are significant being from 10% up to 15% (35), and 8.6% up to 
above 18% (36) depending on the variety and growing conditions. The storage protein 
fraction of grains are prolamins, called kafirins in sorghum. These account for up to 
50% of the total protein (37). Characteristically, prolamins are high in proline and 
glutamine, with low solubility (38). 
Other proteins include albumins, globulins and glutelins (36, 37). The non-kafirin 
proteins participate in formation of the endosperm matrix which contains starch, 
protein bodies, and functional proteins (39). Little research has been done on the 
potential health effects of kafirins, especially outside feedstock models however recent 
research is emerging (40-43). Sorghum is gluten-free, in that it does not contain the 
proteins glutenin or gliadin (44), which are unique glutelins, meaning that sorghum is 
suitable for patients with gluten intolerance or coeliac disease (45).  
The amino acid profile of sorghum varies depending on the cultivar and growth 
conditions, particularly those which change the protein content. As shown in Table 
1.2.1, sorghum is generally high in both leucine and glutamate (36, 46, 47). This 
content is higher than barley, wheat and rice which contain below 9g/kg leucine (48). 
Sorghum is considered as deficient in lysine, hence other dietary sources are required 
(49).  
Table 1.2.1: Amino acid composition of white sorghum (Liberty) and red sorghum 
(Buster)(47), and predicted amino acid requirements for adults (50),(51). Table 
adapted from Liu et al (47) and FAO (52). 
 
When compared with brown rice, wheat and maize, sorghum shows the highest 
content of leucine, phenylalanine and glutamic acid (Table 1.2.2). Both leucine and 
phenylalanine are essential amino acids.  
 
 
 
 
White Red White Red mg/kg requirement
Amino Acid g/kg g/kg
g/kg 
protein
g/kg 
protein (Adult, per day)
Arginine 2.5 3.2 28.7 27.1 -
Histidine* 1.7 2.5 19.5 21.2 8-12
Isoleucine* 3 4.1 34.5 34.7 10
Leucine* 10 14.6 114.9 123.7 12
Lysine* 1.7 2 19.5 16.9 12
Methionine* 0.9 1.1 10.3 9.3 13 (combined with cysteine)
Phenylalanine* 4 5.7 46 48.3 14 (combined with tyrosine)
Thrreonine* 2.4 3.2 27.6 27.1 7
Valine* 3.8 5.3 43.7 44.9 10
Alanine 6.3 9.2 72.4 78 -
Aspartate 4.8 6.7 55.2 56.8 -
Glutamine 15.7 23.4 180.5 198.3 -
Glycine 2.1 2.7 24.1 22.9 -
Proline 6.2 8.6 71.3 72.9 -
Serine 3.4 4.7 39.1 39.8 -
Tyrosine 1 1.4 11.5 11.9
Tryptophan* - - - - 3.5
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Table 1.2.2: Comparison of sorghum, brown rice, maize and wheat amino acid 
composition in proteins. Essential amino acids are indicated by as asterisk (53). 
 
1.1.4.1 Protein digestibility 
Protein digestibility of sorghum has been extensively studied using both in vivo and ex 
vivo models. Typically, the digestibility of proteins indicates how quickly and to what 
extent a protein will undergo proteolysis in the gastrointestinal system, and therefore 
bioavailability of amino acids (54). Sorghum has a low digestibility compared to other 
cereal proteins (55) (54). Estimated digestibility ranges from 75% (56) to as low as 
59% (55); however this changes with variety and preparation (56). In comparison, 
wheat, maize and rice have digestibility of over 85%, 85% and 83%, respectively (55). 
One of the causes of poor digestibility is the high degree of disulphide linkages in 
kafirin proteins (57). Some non-kafirin proteins of sorghum are indigestible, or have 
low digestibility by pepsin (35, 57). Research in animals models can only be 
considered indicative of human digestibility, as rats are more efficient at digesting 
proteins than humans (58).  
Brown Rice Wheat Maize Sorghum
% in protein % in protein % in protein % in protein
Tryptophan* 1.08 1.24 0.61 1.12
Threonine* 3.92 2.88 3.98 3.58
Isoleucine* 4.69 4.34 4.62 5.44
Leucine* 8.61 6.71 12.96 16.06
Lysine* 3.95 2.82 2.88 2.72
Methionine* 1.8 1.29 1.86 1.73
Cysteine 1.36 2.19 1.3 1.66
Phenylalanine* 5.03 4.94 4.54 4.97
Tyrosine 4.57 3.74 6.11 2.75
Valine* 6.99 4.63 5.1 5.71
Arginine 5.76 4.79 3.52 3.79
Histidine* 1.68 2.04 2.06 1.92
Alanine 3.56 3.5 9.95
Aspartic Acid 4.72 5.46 12.42
Glutamic Acid 13.69 31.25 17.65 21.92
Glycine 6.84 6.11 3.39
Proline 4.84 10.44 8.35
Serine 5.08 4.61 5.65 5.05
Methods to improve protein digestibility have been widely studied for sorghum use in 
stock-feeds. The process of fermentation improved the digestibility (32) and reduced 
the concentrations of phytates and tannins which may reduce digestibility (56). The 
protein digestibility was reduced with cooking (59-62) making sorghum unique when 
compared to other cereals (54) which do not have large decreases in digestibility with 
cooking such as maize (48, 62), rice (62, 63), legumes (64), barley and wheat (62). 
This is an important consideration when determining whether humans are likely to 
consume sorghum, and how processing or the preparation will affect protein 
digestibility and availability of other nutrients.  
The low digestibility may be benefical as there will be gastrointestinal effects of 
undigested proteins, and interactions with gut microflora. Although literature is 
currently scarce, some animal models have been studied. Pre-digesting samples with 
α-amylases increased digestibility of protein by improving enzymatic access which is 
more akin to an in vivo system (61). The interactions with starch granules can affect 
protein digestion; however, these interactions have not been fully elucidated (35). 
Decorticating to remove the bran layer (pericarp and germ layer) leaving only 
endosperm increases the percentage of digestible protein (61).  
1.1.4.2 Prolamins - kafirin 
Prolamin size is one reason sorghum protein has a such a low digestibility when 
compared to other cereal crops (61). Kafirin is the major prolamin in sorghum, and has 
4 subgroups defined as α- γ- β- and δ-kafirin (59). Kafirin accounts for a high 
proportion of the sorghum protein, so it is important to note the features of each group 
and how this affects their biological activity. The structures of kafirins are tightly 
connected to their role in the sorghum grain. The highly cross-linked β- and γ- kafirins 
encase the α-kafirin inside the protein body (65). α-Kafirin is the predominant kafirin 
and typically makes up the majority of kafirin protein bodies (59). Prolamin structure 
is indicated in Figure 1.2.4.  
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Figure 1.2.4 : Stylised indication of the structure of sorghum protein bodies (66) 
Cross-linking is important in kafirins, as it relates to their digestibility (59). The degree 
of cross-linking varies for each kafirin; with the relative proportions of uncross-
linked:cross-linked protein following the general trend α- > β- > γ-kafirin (35, 59).  
 
Figure 1.2.5: Predicted structure of α-prolamin structures indicating many α-helices  
(67, 68). 
The highly cross-linked β- and γ-kafirins encase the less cross-linked α-kafirins. α-
Kafirin is comprised primarily of alpha sheets, shown in Figure 1.2.5, and is typically 
the most digestible isolated kafirin (59). Due to its positioning in the protein body, α-
kafirin digestion is impaired by the β- and γ-kafirin coating. The surface proteins are 
the physically restricting factor for access to the chemically least resistant protein (59). 
β-Kafirin is high in methionine and cysteine, being 9.3 and 5.8% molar percentages of 
the molecule (69). This allows for moderate disulphide crosslinking and low solubility 
which impair digestion. The structure of the protein is a combination of α-helices and 
β-sheets. γ-Kafirin is primarily a mix of random coil structures and many β-sheets, and 
is high in cysteine which contributes to its high level of disulphide crosslinking (70). 
As with other kafirins, solubility is low which impairs digestion. The sizes of the 
kafirins also varies, with α-, β-, γ-, and δ- having molecular weights of 26000-27000Da 
(Daltons), 18745Da, 20278Da and 12961Da respectively (68).  
Kafirin digestion is further complicated by the presence of phenolics in the sorghum. 
Condensed tannins and tannic acid, which are present in certain non-white varieties, 
are able to bind to kafirins in vitro (71). This decreased digestibility, primarily through 
binding to granule surface γ-kafirins (72), and subsequently decreased digestion of the 
encased α-kafirin.  
As sorghum has a unique protein profile so peptidomics and proteomics may become 
of increasing interest, although little literature is currently available. In addition to 
kafirin proteins, sorghum also contains globulins, albumins and glutelins; these 
concentrations can vary but are consistently lower than the kafirins (73, 74). Little 
research exists on these proteins in their isolated forms.  
The interest in gluten-free flours has been spurred by the rise in diagnosis of coeliac 
disease, the somewhat questionable evidence for “gluten sensitivity” in the non-coeliac 
population, and the scapegoating of gluten as a driver in a number of metabolic 
conditions (75). Sorghum is considered a gluten-free grain. Gluten is comprised of two 
major prolamin proteins, glutenin and gliadin, neither of which exist in sorghum (76). 
1.1.5 Sorghum carbohydrates and fibres  
1.1.5.1 Starches – amylose, amylopectin, resistant and digestible starches, and 
glycaemic properties 
Starches in cereal grains are comprised of amylose and amylopectin, in differing ratios. 
Both are comprised of glucose units. Amylose is glucose units with α 1-4 glycosidic 
linkages in a helical structure. Amylopectin is glucose units which contain α 1-4 
glycosidic linkages, however has branching units from α 1-6 glycosidic linkages. 
Resistant starches have some chemical or physical property that results in resistance 
to this digestion. They are partially digested by the human gastrointestinal system, 
however final digestion occurs in the colon by microbial populations. 
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Figure 1.2.6: Structure of amylose and amylopectin (77). 
The waxy and non-waxy sorghums are two distinct classes of sorghum that differ 
considerably in starch composition. Waxy sorghum endosperm contains only 
amylopectin, whereas non-waxy sorghums contain a mixture of amylose and 
amylopectin (78). High amylose starches typically have a lower hydrolysis rate, and 
higher resistance to small intestinal digestion (79); this is important in human 
gastrointestinal function. Amylose content of non-waxy sorghum is usually around 
20% depending on the variety (80), with ranges between 18-30% (81). Amylose 
content typically shows an inverse relationship with digestibility (82).  
Amylose and amylopectin are chemically digestible by the human body by both 
salivary and pancreatic amylases. However, the physical structure of amylose can lead 
to a lack of digestion in the upper gastrointestinal tract which results in undigested  
amylose entering the colon where bacterial fermentation can occur (83). Sorghum is 
quite high in slowly digestible starch, at around 60-70% for waxy, heterowaxy and 
non-waxy sorghum. The percentage of resistant starch, however, differs greatly. 
Heterowaxy sorghum has 23.7% resistant starch on a dry weight basis, normal 
sorghum has 17.9%, and waxy sorghum less than 10% (78). Estimates in raw sorghum 
have been up to 43.7% of total starch in some studies (84). Among cereals, sorghum 
has a relatively high resistant starch as a proportion of its total starch, with estimates 
of above 40%, although this can be markedly decreased during preparation of 
foodstuffs (84).   
Digestibility is also affected by both branching and chain length of amylopectin (85). 
In sorghum the degree of polymerisation is variable with genotype and conditions. 
Polymerisation degree is heavily in favour of the regions 6-15, and 16-36 glucose units 
per branch, comprising approximately 90% of the amylopectin chains (78). Digestion 
by α-amylase increases with degree of polymerisation of up to a certain point, 
approximately 10 units, however decreases once this is surpassed (85).  
Resistant starches are important in colonic health and might influence metabolic 
syndrome and obesity. Resistant starch (RS) is divided into four classes RS1, RS2, 
RS3 and RS4. RS1 is physically inaccessible starch, which may be caused by 
inhibition to digestion by a non-digestible matrix (86). RS2 is found in raw starch 
granules and resistance is caused by the tightly packed nature of the amylopectin and 
amylose chains in the granules (86). RS3 is typically formed after cooking and 
dehydration to produce a crystalline amylose structure (87) and RS4 is chemically 
modified. In the case of sorghum, RS1 and RS2 are the most important for unprocessed 
grains. Typically, wholegrains will have higher concentrations of RS1 than flours, due 
to the intact nature of the starch granules (88). Sorghum also has a large starch granule 
size compared to other ceral grains (89). Both the amylose content and the starch 
granule size contribute to the resistance of starch polysaccharides to digestion (90, 91). 
A large portion of sorghum resistant starch is likely be RS1 as the starch granules are 
typically encased by a matrix of proteins with low digestibility. Milling and reduction 
of starch particle size in sorghum will improve digestion (92), such as is done in flour 
production which is important for the digestibility of RS2. Resistant starch type 3 may 
be relevant for cooking and preparation purposes. It has been shown that cooking of 
sorghum increases the amount of resistant starch (93). Resistant starch increased with 
soaking while resistant starch  decreased with autoclaving (94) which is akin to 
cooking. Raw non-waxy sorghum contained around 6g resistant starch per 100g 
wholegrain on a dry weight basis (94). Soaking allows permeation of water into starch 
granules to induce swelling, then subsequent re-association of starch into a crystalline 
form after dehydration, which is then resistant to enzymatic digestion (95). Cooking 
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disrupts native, crystalline starch structure which increases susceptibility to digestion 
(95).  
As with all cereals, methods of preparation affect the resistance of amylose and hence 
the level of resistant starch. Sorghum is unique in its starch granule structure which 
makes it of particular interest to resistant starch. In sorghum, proteins including 
albumins, globulins and glutelins attach a matrix of kafirins to the outside of starch 
granules (96). This protein matrix results in reduced digestibility of the granules (96). 
Processing will inevitably lead to alterations in the structure of these granules and must 
be considered when using sorghum as a functional food, with focus on starch and 
digestion. The effect of digestion on starch granules is shown in Figure 1.2.7. Even 
within the sorghum grain itself, there is differing structure and digestibility of different 
endosperm fragments. The whole food matrix is an important consideration when 
determining its functional properties.  
 
 
 
 Figure 1.2.7 : Scanning electron micrograph of sorghum starch granules throughout 
the digestion process, A) undigested x 1000, B) undigested x 2500, C) 30 minute 
digestion x 1000, D) 30 minute digestion x 2500, E) 60 minute digestion x 1000, and 
F) 60 minute digestion x 2500. Bar equals 1000µm (97).   
The carbohydrate and fibre composition of cereals is important in relation to the 
glycaemic index (GI) and glycaemic load (GL), in addition to their rate of hydrolysis 
by digestive enzymes. The glycaemic index is proportional to the concentration of 
rapidly available glucose (98). Glycaemic load is a representation of the effect of 
consumption determined by multiplying the glycaemic index by the quantity of 
carbohydrate in a meal (99). Non-waxy varieties of sorghum, having high 
concentrations of slowly digestible starch, are likely to fall into low glycaemic 
category. Interactions with tannins and phenolics of sorghum inhibit starch 
digestibility and can reduce the glycaemic index of starches (100). Additionally, the 
presence of phytic acids correlated negatively with starch digestibility and glycaemic 
index (101), with sorghum having concentrations of phytic acid above 300mg/kg (56). 
Similarly, sorghum has a-amylase inhibitory properties (56). This has been shown in 
other trials to be a plausible mechanism for the reduction of glycaemic index and 
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slowing digestion (102). Addition of brown sorghum bran to a food matrix reduced 
rapidly digestible starch content and increased the proportion of slowly digestible 
starch (103). 
Preparation affects the glycaemic values; for example, sorghum bread has a glycaemic 
load of approximately 10 (104). When compared with wheat counterparts, sorghum 
showed a lower glycaemic load when prepared as coarse or fine semolina, flakes or 
pasta (105). The glycaemic load of sorghum was also lower in a biscuit preparation, 
however higher when prepared as roti (105). The low glycaemic load and index of 
sorghum can be attributed to its slow digestibility.  
Colonic digestion has not been fully characterised and may add another level of 
complexity to the process of digestion of sorghum, and therefore its role in metabolic 
processes in the body. Interactions of sorghum components with starches from other 
ingested foods will be altered in the presence of tannins and proteins (103). These 
concentrations are important, as the sorghum grain is predominantly carbohydrates. 
The majority of metabolisable energy will be derived from carbohydrates when 
integrated into the diet. Some have noted that it is the interaction of the other 
components such as proteins, fats and phenols which may lead to the health benefits 
of sorghum, rather than the carbohydrate components (106). 
1.1.5.2 Fibre - Non-starch polysaccharides, soluble fibre, insoluble fibre  
Polysaccharides that contain sugars other than glucose are considered as non-starch 
polysaccharides. They can be comprised of all other sugar monosaccharides, in 
differing sequences, with differing glycosidic linkages, with or without branching and 
are typically not digested fully by human enzymes (107). Soluble and insoluble fibre 
are both non-starch polysaccharides. Insoluble fibre includes cellulose, hemicellulose, 
chitin, lignin and xanthan. Soluble fibre includes arabinoxylans, fructans, pectins, 
polyuronides, alginates, raffinose, xylose and polydextrose.   
In sorghums, there can be important variations in the concentrations of carbohydrates, 
both digestible and indigestible. This can be due to varietal differences or 
environmental conditions. Different gentoypes of sorghum cultivated under the same 
conditions show arabinoxylan content from 0.95-1.35%, with environmental 
conditions responsible for between 5-14% of this variation, and genotype 69-74% 
(108). Similarly, genetics and environment affect total starch content (108), amylose 
content (109) and fibre content (110). Most of the fibre is concentrated in the bran 
fraction of the grain, so removal of this layer in processing will remove a major 
proportion of these compounds. In sorghum brans, the apparent range is 20-40% 
hemicellulose, 10-20% cellulose and <10% lignin on a dry basis (111).  In sorghum, 
the predominant form of fibre is insoluble as opposed to soluble at a ratio of around 
90:10 (112).  
Non-starch polysaccharides are not able to be cleaved by human enzymes. The 
enzymes required to break down the sugar linkages are lacking in the human digestive 
tract although these polysaccharides are comprised of monosaccharides that are a 
normal part of the human diet including glucose, fructose, arabinose, xylose, mannose, 
rhamnose and galactose (113). The most typical way for these non-starch 
polysaccharides to be assessed is by their differing sugar content, with the ability to 
characterise sequential linkages and structural characteristics having taken major steps 
forward in recent years. The primary sugars in these fractions are xylose, arabinose 
and glucose with much lower percentages of the other sugars (113, 114). In sorghum, 
the composition can vary depending on the method of extraction and processing. 
However, in all cases with sorghum arabinoxylans, the ratio of arabinose to xylose is 
generally high (113, 115). These can also contain glucose (116). Mannose and 
galactose are uncommon (117, 118). In total, sorghum contains 2.6-6.5% pentosans or 
non-starch polysaccharides on a dry weight basis. Arabinoxylans from sorghum have 
a xylan backbone with β 1-4 linkages, as shown in Figure 1.2.8, with substitutions to 
the xylan backbone at the O-3 position (113, 114). 
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Figure 1.2.8: An example of the anticipated structure of sorghum non-starch 
polysaccharides (113).  
Sorghum contains β-glucans but the concentration of 0.12g/100g dry weight (94) is 
much lower compared with 4.0% in wholegrain oat flour on a dry weight basis (14).  
Structural characteristics are important with relation to fermentation. Ethanol 
extractable arabinoxylans from sorghum have rapid faecal fermentation when 
compared with endoxylanase-hydrolyzates of corn, wheat arabinoxylan, and corn 
arabinoxylans (119). As with most arabinoxylans, there is preferential production of 
acetate, over propionate, and even more so butyrate (119). There is a suggestion that 
slow-fermenting arabinoxylans have a higher degree of terminal xylose units (119), 
such as is found in sorghum at around 70% compared with wheat at around 56% (117).  
Glucuronoarabinoxylans from sorghum varieties are not necessarily fermented by the 
same species as arabinoxylans from other cereals (120), an indication that structural 
differences may produce different biological effects.  
1.1.6 Lipids & lipid soluble sterols & alcohols   
Although grain sorghum is low in fat, the composition of the lipid-soluble fraction may 
still have relevance to health. The fat content of wholegrain sorghum was around 3% 
(121), and approximately 10% (122, 123) to 14% in sorghum dry distillers grain (124). 
Sorghum lipids are comprised of triacylglycerides, diglycerides, policosanols, sterols, 
free fatty acids, tocopherols and fatty aldehydes (125, 126). 
1.1.6.1 Phytosterols 
Phytosterols are present in sorghum wholegrains, where they can account for around 
50mg/100g grain weight, however these values can increase approximately four-fold 
after distillation (123). This is similar to the median value associated with cereal flours, 
grains and germs (127). Total sterols as a percent of dry distiller grain lipid extract 
have been calculated at 9.9mg/g (126). These may prove to be an economical source 
of these compounds. In sorghum, the specific sterols found are campesterol, 
stigmasterol and sitosterol (123, 126), with structures indicated in Figure 1.2.9. 
Genotype and growing conditions alter the composition of the phytosterols in sorghum 
(128). Sigmasterol and sitosterol are found in quantities typically around twice that of 
campesterol (126). Although sorghum contains these compounds, it contains 72-93% 
less than maize (129).  
   
 
Figure 1.2.9: Structures of sorghum sterols (130). 
1.1.6.2 Policosanols 
Policosanols are long-chain alcohols found in many plants. Policosanols differ based 
on their chain length which may affect their biological activity. Policosanols are 
particularly high in sorghum dry distillers grain when compared with maize dry 
distillers grain and wholegrains, with up to 100mg/g of dry material (123). The ratio 
of chain lengths shifts during the fermentation process to produce DDGS (dry distillers 
grain with solubles) (123, 131). In dry distillers grain, 3.9% of the lipid fraction may 
be policosanols (126). In sorghum, the chain lengths of policosanols are predominantly 
28:0 and 30:0, which are present at over 40% each (131).   
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1.1.6.3 Tocochromanols 
Tocochromanols encompass tocopherol and tocotrienol compounds, or “Vitamin E” 
(132). Tocopherols are a group of compounds found in many plants with a basic 
structure as shown in Figure 1.2.10. The α-, δ-, β-, and γ- tocopherols differ in their 
methylation patterns at positions R1 and R2. 
 
Figure 1.2.10: Structure of tocopherols & tocotrienols (133) 
Some tocopherols are in quite high abundance in the lipid fraction of red and white 
sorghums. γ-Tocopherol, δ-tocopherol, α-tocopherol and β-tocopherol are present in 
sorghum but concentrations vary (122, 128). These tocopherols can be present at 
concentrations up to several hundred µg/g dry distillers grain weight (122, 128) and 
476.5-2515.5 µg/100g of grain (134). Growing conditions alter the composition, based 
on geography, however distinct effects of climate and location have not been defined 
(128).  
Tocotrienols resemble the structure of tocopherol but the hydrophobic tail is 
unsaturated at three positions (Figure 1.2.10). Raw, red sorghum had an a-tocotrienol 
content of 241.7 µg/100g and d-tocotrienol content of 37.6µg/100g (135). The 
concentration of tocotrienol is affected by processing (135), and genotype (132). 
Ranges for different genotypes were 37.2 µg/100g to 160.9 µg/100g a-tocotrienol, 
undetectable to 135.3 µg/100g b-tocotrienol, 4.2 to 32.8 µg/100g g-tocotrienol and 
undetectable to 43.2 µg/100g d-tocotrienol (132).  
1.1.6.4 Fatty acids  
Fatty acid composition of the lipid fraction from sorghum differs between white and 
red varieties. In both varieties, the percentage of unsaturated fatty acids is around 80-
90% (122). The predominant fatty acids are C18:1 and C18:2 unsaturated fatty acids, 
and C16:0 saturated fatty acid (122, 126, 136). Total saturated fatty acids vary between 
12.82-22.46%, polyunsaturated fatty acids between 27.9-53.7% and monounsaturated 
fatty acids between 31.63-49.52% of total fatty acids (137). A high proportion of 
linoleic acid (C18:2) is present, with one study suggesting up to 42-56% of the oil 
fraction (138).  
1.1.7 Other bioactive compounds 
1.1.7.1 Phenolics 
Phenolic compounds are any compounds which contain a phenol ring, either single or 
multiple. These have varying constitutive moieties at different positions on the 
phenolic rings, as indicated in Figure 1.2.11. Many metabolites fall into this class of 
compound. These are mostly secondary plant metabolites and many also elicit a 
biological response (139). Plant polyphenols are chemically classed into subgroups of 
flavonoids, phenolic acids, esters, stilbenes and tannins. Interest in these compounds 
has been due to the large variety and noted antioxidant, antimicrobial and anti-
inflammatory properties (140-142).  
 
Figure 1.2.11: Basic structures of phenolic acids and flavonoids (143) 
Sorghum is high in total phenolics compared to many other cereal grains. Reported 
values vary markedly depending on the extraction and analysis methods, as shown in  
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Table 1.2.3: Total phenolic content of sorghum types, and FRAP (ferric reducing 
ability of plasma) value, an indicator of “antioxidant” capacity (144).  
 
1.1.7.1.1 Phenolic acids and phenolic esters 
Phenolic acids present in red sorghum are ferulic (145, 146), vanillic (145), p-coumaric 
(145, 146), caffeic (146, 147), protocatechuic (146) and 4-hydroxybenzoic (146) acids 
(Table 1.2.4). Phenolic acids are descrbed as being present either as their “free” or 
“bound” forms (145). Bound phenolic acids may be bound to cell walls and non-starch 
polysaccharides. Although bound to these large compounds, they may still elicit a 
biological effect, particularly if released on ingestion by hydrolysis. Their 
quantification and detection is improving with better methods of release and 
assessment. In sorghum, the concentration of free and bound acids, and the phenolic 
acid composition can also vary with genotype, environment and processing (145, 148). 
They also vary depending on the specific phenolic acid, and how they respond to 
processing. For example, vanillic acid exists almost exclusively in the unbound form, 
whereas caffeic acid exists almost exclusively in the bound form (145). Phenolic acids 
tend to be in lower concentrations than many of the flavonoids.  
  
 Table 1.2.4: Phenolic acids content of various sorghum products.  
 Reference  Phenolic acids detected 
Free 
(µg/g) 
Bound 
(µg/g) 
Total 
(µg/g) 
Hahn, et al. [115] 
Gallic, protocatechuic, r-hydroxybenzoate, 
vanillic, caffeic, p-coumaric, ferulic, cinnamic 
54.1-
230.4  
276.7-
598.3 
  
Chiremba, et al. 
[116] 
caffeic, r-coumaric, ferulic, sinapic   
2711-
4395 
Chiremba, et al. 
[112] 
r-coumaric, ferulic   
107-383 
(flour) 
Salazar-Lopez, et 
al. (149) 
Caffeic, r-coumaric, ferulic, sinapic 784.3 2107.9  
 
The major phenolic ester associated with sorghum is coumaroyl-glycerol. The newly 
identified phenolic esters of caffeoyl-glycerol (147, 150), dicaffeoyl-glycerol (147, 
150), coumaryl-caffeoyl glycerol (147, 150), ferruloyl-caffeoyl (147, 150) and 
coumaroyl-feruloylglycerol (150) are present in some red and white sorghum varieties. 
These phenolic esters are much lower in black sorghum (147) varieties however 
present at varying concentrations in red and white sorghums. As more powerful 
chemical analysis techniques become available, the identification of the more complex 
and lower concentration compounds is improving the knowledge of the cereal’s 
chemistry.  
The phenolic acid aldehyde, p-hydroxybenzoic acid aldehyde, present in sorghum is 
now joined by a list of others including protocatechuic acid aldehyde (150). Whether 
these exist in high enough concentrations to elicit a biological effect is still yet to be 
studied. However, in extracts, there is an indication that they may have involvement 
in apoptosis (147). 
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1.1.7.1.2 Flavonoid-based polyphenols 
Sorghum is very rich in bioactive phytochemicals, particularly the coloured bran layer 
that gives the characteristic colours of red, brown and black sorghums (151). White 
sorghum typically has lower concentrations of polyphenols (152) but still contains 
many other potentially bioactive compounds. The profiles vary significantly 
depending on the type (22, 153), variety (154), growing conditions (22, 151, 153, 155), 
processing and age of samples (156). There are several major recurring components 
that may have health effects. Processing impacts the concentration and bioavailability 
of these compounds. Typically, soaking decreases the concentrations of polyphenols 
and their in vitro antioxidant capacity (148), hence these processes will need to be 
taken into account when discussing the biological activities of sorghum and how 
human altering and processing can enhance or reduce potential health effects.  
Flavonoid-based polyphenols have structures as indicated in Figure 1.2.12.  
 
Figure 1.2.12: Structure of flavonoids. Different classes contain substituents at 
differing positions of the molecule (139). Hydroxyl groups are present at one or more 
positions 1 through 6’.  
Flavonoids consist of several different subclasses. In sorghum, the predominant 
classes are flavonols, catechins, proanthocyanidins, 3-deoxyanthocyanidins and 
flavones.   
1.1.7.1.2.1 Flavanols/catechins/proanthocyanins 
Flavanols, or catechins, are built from the same backbone as noted above but with a 
hydroxyl moiety located at carbon 3 of benzene ring C (Figure 1.2.13). Substituent 
groups at other positions lead to a wide array of molecules in this class. 
Stereochemistry can affect their biological activity (157).  
 
Figure 1.2.13: Catechin (left) and epicatechin (right) (158), indicating hydroxyl 
substituents on carbon 3, changing their stereochemistry. Methylated derivatives have 
methoxy moieties at positions 3’ and 4’.  
In sorghum, there are many flavanols, which will vary depending on the sorghum type. 
Catechin (146, 159) and epicatechin (159) were present in addition to their methylated 
derivatives. 3’-O-methylcatechin, 4’-O-methylcatechin, 3’-O-methylepicatechin and 
4’-O-methylepicatechin have been identified in many varieties of coloured sorghums 
(159). Proathocyanidins are oligomers of flavanols. Typically, in sorghum, the degree 
of polymerisation ranged from 2 to >10 (160), with many having degree of 
polymerisation over 10. Catechins and epicatechins were close to absent in white 
sorghum, when compared with red varieties (152, 159). Extrusion of sumac and bran 
combinations reduced proanthocyanidin content but increased their bioavailability, as 
indicated by plasma concentration after ingestion (159). Table 1.2.5 indicates the 
expected ranges of flavanols/procyanidins in sorghum varieties. Oligomeric 
procyanidins are considered to be tannins, and are generally referred to as condensed 
tannins.  
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Table 1.2.5: Indicative flavanol/proanthocyanidin concentrations in sorghum and 
sorghum fractions. 
Sorghum Product Reference Concentration  
Red sorghum Gu, et al. (161) 447.3-1919.5 mg/100g wholegrain    
Hi Tannin Bran Gu, et al. (162) 23.3mg/g   
    
Hi-tannin sorghum 
grain 
Awika, et al. (160) 
20.5 mg/g   
Sumac sorghum Awika, et al. (160) 21.97 mg/kg  
White sorghum  Gu, et al. (159) Not detected  
Sumac sorghum  Gu, et al. (159) 36.2mg/kg  
 
1.1.7.1.2.2 Flavanones  
Flavanones are classed based on their ketone substituent on position 4. They are 
distinct from flavones as they lack planarity and do not contain a double bond between 
carbons 2 and 3, shown in Figure 1.2.14.   
 
Figure 1.2.14:  Structures of naringenin (left) (163) and eriodictyol (right) (164). 
In sorghum, the predominant flavanones include naringenin (146), eriodictyol (146, 
153) and eriodictyol glycosides (146). Concentrations can range from undetectable, to 
combined total flavanone concentration of over 48µg/g (153). At present, there does 
not appear a correlation with colour and concentration so this may be a factor of 
growing conditions, as most polyphenols are secondary plant metabolites.  
  
Table 1.2.6: Concentration ranges of naringenin and eriodictyol in sorghum 
Reference Concentration Range 
Dykes, et al. (153) 0-48.4 µg/g 
Dykes, et al. (154) 0-1779.6 µg/g 
Taleon, et al. (22) 96-164 µg/g 
Dykes, et al. (165) 88.6-119.1 µg/g 
Cardoso, et al. (134) 51.2-267.3 µg/100g dry basis 
 
1.1.7.1.2.3 Flavones – apigenin and luteolin 
Flavones have structures which include a ketone substituent at position 4, and varying 
hydroxyl additions at other positions. In addition, they are planar molecules, resulting 
from the double bond between carbons 2 and 3 on the 2-phenylchromen-4-one 
backbone, Figure 1.2.15.  
 
Figure 1.2.15: Structures of apigenin and luteolin (166), indicating keto-substituents 
at position 4, and hydroxyl-substituents at the 3’ and 4’ carbons.   
In sorghum, apigenin (146) and luteolin (146) are two common flavones. These can 
vary from undetectable to up to 385µg/g in certain red-appearing varieties (153), while 
they appear to be completely absent in some other red varieties (147). Red sorghums 
are typically free of isoflavones, which are structurally distinct from flavones based on 
the positioning of the phenyl group being at C4 as opposed to C2 (146). Indicative 
contents of flavones in sorghum types are shown in Table 1.2.7. 
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Table 1.2.7: Indicative content of the flavones luteolin and apigenin in sorghum. 
Values show combined concentrations of apigenin and luteolin.   
Reference Concentration Colours/varieties 
Dykes, et al. (153) 0-385.9 µg/g Red, tan, black 
Dykes, et al. (154) 0-362.2 µg/g Lemon yellow varieties 
Taleon, et al. (22) 14-48 µg/g Black varieties 
Dykes, et al. (165) 18.2-56.1 µg/g Black varieties 
Cardoso, et al. (134) 13.9-44.9µg/100g Red varieties 
 
1.1.7.1. 3-deoxyanthocyanidins  
3-deoxyanthocyanidins are unique due to their stability in the environment. They can 
exist in their non-glycosylated form unlike their oxygenated counterparts, the 
anthocyanins which will exist as anthocyanidins. Luteolinidin and apigeniniden are 
the major 3-deoxyanthocyanidins present in red sorghum (147, 153) and black 
sorghum (22, 147, 165) varieties. Tan or white varieties contained very low 
concentrations of this class of compound (147, 153), while total concentrations can 
reach over 600µg/g in varieties with a black kernel appearance (153). In contrast, the 
concentrations of flavones luteolin and apigenin were lower in black than white/tan 
and red varieties (153). Typically 3-deoxyanthocyanidins are at the highest 
concentrations in the black varieties of sorghum (147, 153). Some varieties of black 
sorghum contained over 1mg of total 3-deoxyanthocyanidins per gram of grain weight 
(165). Their relationship to their flavone counterparts lutelin and apigenin is the loss 
of the ketone at position 4, and they typically exist as a salt with a positive charge on 
the oxygen at position 1 (Figure 1.2.16).  
 Figure 1.2.16: Structure of 3-deoxyanthocyanidins (167).  
As discussed further in this review, the biological activities of 3-deoxyanthocyanidins 
have huge potential. Black sorghum represented a more economically accessible 
source of these compounds compared to other highly promoted sources such as 
blueberries (168). Two of the major deoxyanthocyanins, luteolinidin (orange pigment) 
and apigeniniden (yellow pigment), exist in non-glycosylated forms and represent a 
major component of the phytochemical profile of black sorghum (151),  
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Table 1.2.8.  
 
 
 
 
 
 
 
 
 
 
 
Table 1.2.8: Concentrations of 3-deoxyanthocyanidins in different sorghum grain 
types.  
Reference Predominant Compounds Concentration 
Dykes, et al. 
(153) 
Luteolinidin, apigeninidin, 5-
methoxyluteolinidin, 7-methoxyapigenidin 
0-679.7 ug/g 
Dykes, et al. 
(154) 
Luteolinidin, apigeninidin, 5-
methoxyluteolinidin, 7-methoxyapigenidin 
0-186.9 ug/g 
Taleon, et al. 
(22) 
Luteolinidin, apigeninidin, 5-
methoxyluteolinidin, 7-methoxyapigenidin 
251-804 ug/g 
Dykes, et al. 
(165) 
Luteolinidin, apigeninidin, 5-
methoxyluteolinidin, 7-methoxyapigenidin 
329.1-1053.9 ug/g 
Cardoso, et 
al. (134) 
Luteolinidin, apigeninidin, 5-
methoxyluteolinidin, 7-methoxyapigenidin 
50.6-342.4 ug/100g 
(dry basis) 
 
Anthocyanins can exist in either polymerised or un-polymerised forms (151), which 
may alter their bioavailability and activity, and their in vivo effects. Similarly, de-
glycosylated procyanidins in sorghum have varying degrees of polymerisation (169). 
However, it has been difficult to characterise the individual combinations of 
anthocyanins in these compounds.  
1.1.7.2 Other compounds – stilbenoids, anthraquinones, terpenoids, alkaloids 
Stilbenoids have also been identified in sorghums at very low concentrations, for 
example 1 mg/kg concentrations of trans-piceid and up to 0.2 mg/kg trans-resveratrol 
(170). 
Sorghum varieties also contain anthraquinones, terpenoids, carotenoids and alkaloids 
(171). Carotenoids are higher in red varieties when compared to white, and 
anthraquinones are absent in white sorghums from the few lines tested (171). The 
major carotenoids found in sorghum are lutein, zeaxanthin and β-carotene. These occur 
in quantities of approximately 0.112-0.309 mg/kg in coloured varieties, with yellow 
endosperm types being the most concentrated, and white endosperm types being the 
lowest containing 0.010-0.016 mg/kg (172). Anthraquinones and terpenoids in 
sorghum have not been well-studied. 
1.1.8 Potential for metabolic syndrome and health 
1.1.8.1 Metabolic syndrome  
Metabolic syndrome is caused by a cluster of pathologies that lead to increased risk of 
type 2 diabetes mellitus and cardiovascular disease. The diagnosis is based on the 
presence of central adiposity and dyslipidaemia, hypertension and raised fasting 
glucose concentrations (173, 174). Additional measurements which are of importance 
include dysregulated adipose tissue biomarkers or hormones (such as adiponectin and 
leptin), fatty liver, insulin resistance, elevated free fatty acids in plasma, vascular 
dysregulation, endothelial dysfunction, pro-inflammatory state indicated by high 
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concentrations of inflammatory cytokines, pro-thrombotic state, fibrinolytic factors 
and clotting factor dysregulation, and hormonal characteristics (173). It has been 
suggested that there are links between gastrointestinal health and the development of 
metabolic syndrome (175-179) which are also discussed.  
1.1.8.2 Normalisation of blood lipids 
1.1.8.2.1 Clinical and animal trials 
Dyslipidaemia is a key pathology of metabolic syndrome and has been linked to high 
cardiovascular risk (180). Sorghum, its fractions and extracts of sorghum can improve 
the blood lipid profile. Ethyl acetate extracts of Sorghum bicolor reduced serum 
triglycerides and total cholesterol in rats with diet-induced obesity (181). Similar 
results have been found in hamster models of atherosclerosis using hexane-extractable 
lipids, where plasma non-HDL (high-density lipoprotein) cholesterol was reduced, in 
addition to reduced esterified cholesterol in the liver. This was found to be due to 
reduction in cholesterol reabsorption (182). These results appear consistent with the 
reductions caused by sorghum distillers dried grain lipids (183) and non-wax lipids 
(184). Methanol extracts have similar effects on serum triglycerides in mouse models 
(185). Isolated kafirin fractions of white sorghum improved serum cholesterol profiles 
in rat models, however equivalent sorghum flour-based studies increased total 
cholesterol, primarily HDL cholesterol (186). Unrefined sorghum consumed at a rate 
of 100g per day in human studies improved serum lipid profiles (187). Extruded 
Sorghum bicolor reduced degree of steatosis and liver cellular fat by 30% in a diet 
induced obesity model of rat (188).   
1.1.8.2.2 Mechanism and potential  
The most likely mechanism by which sorghum reduced serum triglycerides and 
cholesterol was by alteration of the reabsorption of bile and bound fats. The major 
effect is likely to be the prevention of reabsorption of cholesterol. Sorghum contains 
sterols which have been shown to prevent the reabsorption of cholesterols. 
Policosanols, also found in sorghum (131), reduced plasma cholesterol concentrations 
by inhibition of the absorption of bile acids (189). In addition, the presence of 
policosanols reduced endogenous cholesterol synthesis, although this has been proven 
only in in vitro studies (190). Although it is not completely clear, it is believed that the 
mechanism lies in changes to either the synthesis or degradation of HMG CoA (3-
hydroxy-3-methyl-glutaryl-coenzyme A) reductase (190), the rate-limiting step in 
cholesterol biosynthesis. It has been further suggested that policosanols increase the 
phosphorylation of AMP (adenosine monophosphate) (191), by the activation of AMP 
kinase (192). The effects of policosanols are restricted to serum, rather than to 
particular tissues (189). The favourable policosanol profile of sorghum containing a 
high ratio of C24-C38 chains (193) may have beneficial effects for cardiovascular 
health. Policosanols improved serum cholesterol profiles in human studies (194, 195) 
although this has been disputed by some studies (196, 197). These results indicate that 
the lipid fraction of sorghum could be responsible for the reduction in triglycerides 
and normalisation of blood lipids. 
Further, catechins and tannins have been implicated in the regulation of blood lipids. 
Although direct studies of sorghum tannins on cholesterol regulation have not been 
carried out, several other tannins have been studied, with promising results. Structural 
similarities indicate that there is potential for the sorghum tannins to have similar 
effects. High molecular weight persimmon tannin improved lipid profiles by 
increasing the activity of key enzymes required for the synthesis and transport of 
cholesterol and its esters (198). These promising results in vivo suggest that high tannin 
foods such as sorghum may help improve serum lipid profiles, one of the key 
diagnostic criteria for metabolic syndrome.   
Oxidation of LDL (low-density lipoprotein) cholesterols has been implicated in the 
development of atherosclerosis. This is initiated by a lipoprotein, followed by 
adherence and penetration of monocytes which mature into macrophages. Oxidised 
cholesterols then lead to development of plaques (199). Macrophage-mediated 
oxidation of LDL cholesterols were reduced both in vitro (200-202) and in vivo (202, 
203) by flavonoids. Although these studies were not conducted with sorghum 
flavonoids, this may be one mechanism by which sorghum reduces cardiovascular risk.  
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1.1.8.3 Anti-diabetic effects 
1.1.8.3.1 Clinical and animal trials/current evidence 
Sorghum has similarly been linked to hypoglycaemic effects (204) and is a low 
glycaemic index food with slow digestion. The development of pathologies of 
metabolic syndrome is increased with high glycaemic index and load foods in the 
overweight population (205). Ingestion of whole sorghum flour muffins lowered 
insulin fluxes more than a wheat-based counterpart and marginally reduced 
fluctuations in glucose (206) as a mechanism for the management and prevention of 
development of type 2 diabetes mellitus, associated with metabolic syndrome.  
Whole sorghum food consumption caused a lower rise in plasma glucose than the 
dehulled version and similar rice and wheat foodstuffs (204). Methanol extracts of 
sorghum in models of insulin resistance in mice reduced fasting glucose and insulin 
concentrations when administered in a high lipid diet designed to induce dysfunction 
of glucose regulation (185). This was correlated with increased PPAR-γ (peroxisome 
proliferator-activated receptor gamma) expression in adipose tissue (185). Ethanol 
extracts showed insulin-independent normalisation of glucose responses in diabetic 
rats (207). In addition, there were minor improvements in plasma glucose 
concentrations, which were similar to that of glibenclamide, when sorghum extract 
was administered (208). Fermented and dried whole-grain red sorghum flour reduced 
severity of alloxan-induced diabetes, with blood glucose as low as half that of diabetic 
controls (209). Human trials showed that consumption of extruded sorghum beverage 
containing proanthocyanidins and 3-deoxyanthocyanidins reduced peak postprandial 
glucose and total insulin release of a subsequent meal by up to a half (210). 
Diabetic complications such as reduced endothelial reactivity can arise from glycation 
of proteins (211). Sorghums high in phenolics, such as red or black varieties, reduced 
the glycation of these proteins in vitro (144).  
1.1.8.3.2 Mechanisms and potential 
The reversal of type 2 diabetes is possible with the primary requirement being re-
establishment of pancreatic b-cell function. In the progression of type 2 diabetes, there 
are distinct changes in the release and activity of insulin (212). These are caused by 
the dysfunction of many factors with b-cell dysfunction being one of the earliest 
changes (213). Apoptosis of pancreatic b-cells has been implicated in the impaired 
insulin release associated with type 2 diabetes mellitus. The presence of proteins 
associated with apoptosis and histological assessment of apoptotic pancreatic cells was 
markedly reduced by treatment with anthocyanins extracted from black soybeans 
(214). This may be one mechanism by which flavonoids, especially the 
deoxyanthocyanidins found in sorghum, result in reduced progression or potential 
reversal of the disease with long-term consumption.  
Inflammation of the pancreatic cells, mediated by several pathways, can lead to cell 
death. Inflammatory responses have been implicated in the development of type 2 
diabetes mellitus. In instances where dietary or genetic susceptibility has led to 
development of type 2 diabetes mellitus, inflammation has been implicated as one of 
the mechanisms at play. In vivo, flavonoids such as apigenin and luteolin reduced 
NFκB (nuclear factor kappa-B) activation and subsequently reduced b-cell damage, 
albeit in an in vitro setting (141). These results are promising, especially given that 
apigenin is absorbed from the gastrointestinal tract (215). Hydrolysed kafirin proteins 
similarly show in vitro oxygen radical scavenging properties, suggested to be due to 
the release of bound compounds within the protein matrix (42).  
Ethyl acetate extracts of rice bran containing over 50% phenolic acids, dosed at 
0.2g/kg per day, reduced fasting blood glucose concentrations in diabetic rats, linked 
to the presence of ferulic acid (216). Rice bran extract contains similar phenolic acids 
to sorghum such as m-hydroxybenzoic acid, benzoic acid, p-coumaric acid, ferulic acid 
and sinapic acid. 
Further to this, inflammation may be regulated, at least to some degree, by the colonic 
microflora, the colonic environment and the interaction with the host (217, 218). 
Faecal lipopolysaccharide concentrations were increased with high fat feeding, in 
addition to the concentrations of pro-inflammatory cytokines in faecal lysates (219). 
The consumption of wheat-derived arabinoxylans has the potential to reduce 
circulating endotoxins (220). Sorghum, containing galacturoarabinoxylans, may result 
in similar effects. These studies, however, were unable to determine whether these 
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changes were due to reduced production, increased degradation, or reduced 
permeation. 
1.1.8.4 Effect on central adiposity and obesity  
Whole sorghum has not been correlated with weight reduction or improvements in 
body composition (186). In a rat model of diet induced obesity, extruded sorghum flour 
consumption reduced the weight of epididymal adipose tissue and adipocyte diameter 
(221). Long-term consumption has been linked to improvements in hormonal 
regulation of satiety and food consumption (222).  
Sorghum resistant starch, however, decreased body weight and abdominal fat pads 
(223). With this change, there was an altered gastrointestinal microflora with a 
decrease in Bifidobacterium and Lactobacillus and an increase in Enterobaceriaceae 
(223). Although food intake did not change, there were decreased leptin and increased 
adiponectin responses with sorghum resistant starch administration (223), which may 
help to regulate food intake.  
Due to the high proportion of leucine, interest in sorghum may grow due to the 
increasing evidence of the “leucine threshold” required for muscle growth that has 
been implicated as a potential way of managing obesity (224). The provision of 2.5g 
of leucine is sufficient to initiate this response when ingested in a single meal (224).  
1.1.8.5 Effects on cardiovascular disease and hypertension 
1.1.8.5.1 Clinical trials  
The effects of sorghum and its extracts on hypertension have not been extensively 
studied. A review of literature has found no evidence to date of sorghum being 
specifically linked to improvements in blood pressure. There have, however, been 
studies which link several of the chemical compounds in sorghum to improved blood 
pressure. Sorghum vinegar extracts which contain phenolic acids protected from 
pulmonary thrombosis in animal models through anticoagulation and platelet activities 
(225). Thrombosis has a higher risk factor in those with metabolic syndrome (226). 
The process behind this is thought to be the induction of hypercoagulability, 
potentially through increased activity of PAI-1 (plasminogen activator inhibitor-1) 
which is associated with higher visceral fat, and insulin release (227). 
1.1.8.5.2 Mechanisms and Potential 
Angiotensin converting enzyme (ACE) inhibition is a well-known mechanism by 
which compounds may improve hypertension. Apigenin and luteolin have shown 50% 
inhibition of ACE activity at 280 and 290µM concentrations in vitro, respectively 
(228). Further, endothelial dysfunction, which precedes the vascular dysfunction 
leading to hypertension (229), may be changed. Flavonoids reduced blood pressure in 
rat models and ex vivo vascular reactivity to acetylcholine (230).  
The development of hypertension in obesity is thought to be caused by the interaction 
of several pathways, as shown in Figure 1.2.17 (231). 
 
 
Figure 1.2.17: Development process of hypertension in metabolic syndrome (231) 
Reduction in the concentrations of inflammatory markers may be mediated by 
sorghum supplementation. Certain sorghum genotypes when integrated into diets of 
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rats reduced the transcription of TNF-α (tumour necrosis factor-alpha), IL-10 
(interleukin-10) and IL-8 (interleukin-8) (232). TNF-α protein expression was reduced 
with sorghum extract administration in high fat diets (185). Sorghum kafirin fractions 
extracted in ethanol reduced lipopolysaccharide-induced macrophage inflammation of 
TNF-a by up to 81.4% (41).  
1.1.8.6 Gastrointestinal health  
1.1.8.6.1 Clinical trials  
Very little information exists so far that sorghum, as a whole food supplement, 
moderates the endotoxaemic state. However, many studies suggest that sorghum has 
the potential, based on its composition, to improve metabolic syndrome via modulation 
of endotoxaemia (217, 233, 234).   
Sorghum lipid extracts are capable of increasing the Bifidobacteria genera in the colon 
(233). These micro-organisms are gram-positive, non-LPS (lipopolysaccharide) 
producing bacteria that increase short chain fatty acid production. They also ameliorate 
LPS-induced inflammation (234) which is associated with metabolic syndrome 
factors.  
Providing sufficient substrates for these beneficial bacteria is one way to enrich their 
population. Resistant starches and non-starch polysaccharides, such as those in 
sorghum and other wholegrain cereals, will improve gastrointestinal health (107, 235, 
236). Although not a controlled study, investigations into populations which consume 
large amounts of sorghum, such as the Mossi people of Africa, have shown a 
favourable gut microbial profile with large proportions of Bacteroidetes and higher 
concentrations of faecal short chain fatty acids (217). 
1.1.8.6.2 Potential mechanisms 
Recently, it has been suggested that intestinal microflora have an important role to play 
in the development of insulin resistance (237) by the initiation of inflammatory 
pathways caused by an endotoxaemic state (238). The term “low-grade endotoxaemia” 
is associated with metabolic syndrome (238), and management of this state markedly 
improved insulin resistance (239). Modulation of gastrointestinal dysfunction is one 
way by which prevention or reversal of aspects of metabolic syndrome is plausible. 
Inflammation of the gastrointestinal tract itself is mediated by flora in a high fat diet, 
and precedes many of the pathologies of metabolic syndrome (240).  
There are multiple pathways this state can be altered. One approach is the modulation 
of the gut bacteria to reduce the production of LPS. The “optimal” gut flora balance 
has not been characterised, and indeed may be different on an individual basis. It is 
generally accepted that the balance of Bacteriodetes:Firmicutes may be of importance, 
where a greater proportion of Bacteroidetes is desirable (217). Although this is an 
initial starting point, there are approximately 823 known species of bacteria that 
inhabit the human gastrointestinal tract (241). The composition varies greatly with 
geographical location, age, lifestyle and diet (242, 243). It will take a significant 
amount of time to determine what the “ideal” microbiome is and how to manipulate it 
for full health. Certain species and smaller groups of bacteria have been linked to 
improvements in pathologies of metabolic syndrome, including Akkermansia 
muciniphila, a mucin-degrading bacteria that is present at around 3-5% of the total 
community (244).  
Several studies have defined the alterations in the microbiome composition with high 
fat feeding. This typically leads to an unfavourable decrease in Bifidobacteria (239) 
and an increase in Firmicutes and Proteobacteria (245). This finding has been 
questioned, with some suggesting that obese individuals have a higher ratio of 
Bacteriodetes (246). Additionally, there has been interest in the role of Mollicutes, 
which show a significant increase in high fat, Western-style diets (247).  
Increasing the breakdown of LPS by intestinal alkaline phosphatase has also been 
suggested as a mechanism as intestinal alkaline phosphatase is responsible for 
detoxification of LPS (248). Concentrations of intestinal alkaline phosphatase are 
negatively correlated with obesity and high fat diets (175). Restricting the movement 
of LPS through the gastrointestinal barrier, by reduction of intestinal permeability, and 
improvement in tight junctions reduced the circulating LPS concentrations (237). The 
development of inflammation cascades initiated by compounds such as LPS can then 
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lead to atherosclerosis, insulin resistance and impaired glucose tolerance (249). A high 
fat diet increased intestinal permeability and reduced tight junction proteins (175).  
Several purified non-starch polysaccharides improved the endotoxaemic state (220, 
250, 251), some of which may be derived from sorghum. Increased consumption of 
resistant starches is linked to increased short chain fatty acid production, and increased 
Bifidobacteria (252). The increased short chain fatty acids lead to increased hepatic 
adipogenesis and subsequently control of satiety and feeding hormones. Sorghum does 
not appear to damage intestinal morphology, and assists in maintaining changes 
associated with a high fat diet (232, 253). 
1.1.9 Sorghum integration into diets 
Sorghum is being investigated as a potential replacement for wheat in many food 
products. The popularity of “gluten-free” diets has been increasing in recent years 
(254, 255). This movement has helped sorghum gain traction as a grain for human 
consumption (256). The use of sorghum in products such as Gluten Free WeetBix™ 
is potentially the beginning of the evolution of sorghum from “feed” to “food”. Studies 
have indicated that it is an appropriate substitute, or partial substitute, in wheat-based 
products including breads, cakes, biscuits and cereal flakes (257). Bobs Red Mill™ 
sorghum flour, commercially available in Australia, contains 33.5% resistant starch 
and can be used in the preparation of muffins and other products (206).  
1.1.10 Cautions 
Sorghum has the potential to act as a chelating agent for trace minerals and contains 
“anti-nutritive compounds”, but this is likely only when consumed in excessive 
amounts (258, 259). Sorghum is prone to ergot infections, but, with appropriate 
management and processing, products will be free of toxic compounds, of particular 
concern are fumonisins and other mycotoxins (260). Processing of sorghum will alter 
its composition and potentially change the concentration and total contents of 
beneficial compounds. This is also especially true for glycaemic responses after 
ingestion. The preparation method can change the insulin and glucose responses (261). 
Consumers should be aware that any increase in processing of flours will likely reduce 
the benefits, similar to the case of white wheat flour, compared to whole wheat grains 
(262). Concentration of phytochemicals and sorghum extracts are likely to enhance 
certain aspects of sorghums functionality in the context of metabolic syndrome 
parameters.  
1.1.11 Processing, growth, and breeding 
Sorghum is a wide-scale, commercially produced crop, with multiple varieties 
available for use, so this variability needs to be addressed when promoting sorghum 
for health. Sorghum grown in different locations, and under different environmental 
conditions, can vary drastically in the concentrations of flavonoids. Environmental 
variability can account for almost 60% of the variance component of total flavanones, 
21% for flavones and approximately 16% of 3-deoxyanthocyanidins (22). These 
differences are not trivial, with one study showing that environmental conditions can 
consistently result in less than half the comparable flavone, flavanone or 3-
deoxyanthocyanidin concentrations when the same genotype is grown under less 
favourable conditions (22). Since the concentrations in the bran fraction of sorghum 
are highest for flavonoids, phenolics and tannins (263), any process which removes 
the bran layer will reduce the potential health effects associated with these compounds. 
The research into processing methods has become increasingly of interest over recent 
years, as knowledge of how these methods change the nutritional and nutraceutical 
profile have been recognised (91, 264-267). With the increased consumption of pre-
prepared and packaged foods, this knowledge is required for promotional purposes and 
education of consumers. 
Sorghum is often fermented for the purpose of ethanol production (268), gluten-free 
beer production (170), for spirit production (269), and for gluten-free sourdough 
production (150). Improved bioavailability of phenolics has been found after 
fermentation in oat and millet (270), and fermentation with strains of Lactobacilli can 
both increase and decrease availability of catechin, quercetin and gallic acid depending 
on the strain (271). The fermentation process will also alter the existing profile of 
phenolics (160, 272, 273).  
Sorghum tea is also noted to be a traditional way for sorghum to be prepared, while 
the preparation can also alter the chemical profile of sorghums (145). Cooking 
typically reduces flavonoid concentrations as shown during the preparation of 
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“porridges” (146) and alters the profile by increasing certain flavonoids and decreasing 
others (146). The cooking process also decreased phenolic acid concentrations (146).   
Conscious efforts have been made to breed for higher flavonoid sorghums with the 
potential use as a functional food or for nutraceutical supplements. This is in stark 
contrast to previous efforts to reduce these compounds for use in the stockfeed 
industry, where they are often considered “anti-nutritive”, and are associated with 
impaired weight gain in cattle, pigs and poultry (274-276).  
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1.3 Phloretin Literature Review 
Dietary-induced glucose dysregulation is one of the key parameters of metabolic 
syndrome, an affliction which results in a significant burden to the health care industry. 
Sugar transport inhibitors have been tested as a potential treatment target for pre-
diabetes and type 2 diabetes mellitus (277, 278). Phloretin, a flavonoid isolated from 
apples, is an inhibitor of solute carrier family 2 (facilitated glucose transporter), 
member 2 (SCLA2) also called GLUT2 (glucose transporter 2). It is a weaker inhibitor 
of the sodium/glucose co-transporter 1 (SGLT1). Its glycoside, phlorizin, inhibited 
sodium/glucose co-transporter 1 and 2 (SGLT1 and SGLT2).  
 
Figure 1.3.18: Structure of phloretin and phlorizin (279) 
As functional glucose transporters are present in almost all living cells in the body, the 
administration of phloretin, and other sugar transport inhibitors, has the potential to 
inhibit several pathways to diabetes and metabolic syndrome. In vivo effects have not 
been fully studied and the beneficial and detrimental effects on the symptoms of 
metabolic syndrome have not been elucidated.  
Sugar transporters have substrate selectivity. SGLT1 is an active transporter capable 
of transporting glucose and galactose, present in the intestine tract, kidney, heart, brain, 
testis and prostate. SGLT2 is also responsible for glucose and galactose transport, 
however in the kidney, brain, liver, thyroid, muscle and heart (280). SGLT1 is non-
mobile and is sodium-dependent (Figure 1.3.19).  
 Figure 1.3.19: Function of SGLT1 in glucose transport (280) 
GLUT2 is a mobile sugar transport element, which is non-sodium dependent (Figure 
1.3.20). It is present in the gastrointestinal tract, pancreas, liver, brain and other parts 
of the nervous system (281). It is not only responsible for sugar transport of glucose, 
galactose and fructose (282), but hepatoportal glucose sensing, pancreatic sensing, 
taste preference and thermoregulation (281).  
 
Figure 1.3.20: The role of GLUT2 is gastrointestinal glucose uptake as a mobile 
element (283) 
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Flavonoids including quercetin, isoquercetin and myricetin have been implicated in 
the inhibition of sugar transporters (284). Catechins (flavonols/proanthocyanidins) 
competitively inhibit SGLT1-mediated transport (285) and are found in sorghum, 
barley, blueberries, cranberry, chokeberry, apples, peaches, nectarines, pinto beans, 
chocolate, red wine, and walnuts among others (161). Flavanones also show sugar 
uptake inhibiting properties. Naringenin inhibits gastrointestinal uptake of glucose 
(286-288), however eriodictyol can improve glucose uptake in hepatocytes (289) 
which show benefits for both glucose uptake regulation and peripheral clearance. 
Flavanones are found in food such as sorghum (153), lemon juice (290), orange juice 
and grapefruit (291). The flavone apigenin inhibits GLUT1-mediated sugar uptake 
(292, 293), while luteolin inhibits GLUT2-mediated sugar transport (284). Apigenin 
and luteolin can be found in sorghum (153), parsley, celery and capsicum (290).  
1.3.2 Sugar transporter expression in metabolic dysfunction 
1.3.2.1 Gastrointestinal lumen 
Phloretin is an inhibitor of GLUT2-mediated glucose uptake, while phloridzin is an 
inhibitor of SGLT1-mediated uptake in the gastrointestinal lumen (294). SGLT1 and 
GLUT2 work in conjunction to absorb glucose from the gastrointestinal lumen. 
SGLT1, unlike GLUT2, is a non-mobile membrane element responsible in part for the 
apical uptake of glucose and other hexoses from the lumen (295). GLUT2 is primarily 
responsible for the basolateral flux of glucose and fructose (296). GLUT2 is a mobile 
element of the sugar transport system, which is present in the apex of brush border 
cells in response to food ingestion (283). Expression of GLUT2 in the gastrointestinal 
lumen is typical, however location of the protein is altered under certain metabolic 
conditions. Translocation of GLUT2 is stimulated by the ingestion of meals and the 
concentration of glucose in the lumen (282).  
Obesity and insulin resistance result in apical presence of GLUT2 in gastrointestinal 
enterocytes, whereas in lean phenotypes, the primary location is the basolateral 
membrane, with transient localisation in the apex upon ingestion of foods (297). In 
diabetic rat models, SGLT2 expression was increased with presence in the brush 
border membrane of jejunal epithelial cells (298).  
1.3.2.2 Pancreas 
GLUT2 is the primary glucose sensor of pancreatic β-cells in rats (299). Preceding 
pancreatic β-cell death, there is an indication of dysregulation of sugar transporter 
function. Transcription and expression of GLUT2 was decreased in animal models of 
streptozotocin-induced diabetes (300). GLUT2 had a reduced expression in pancreatic 
β-cells of diabetic mice, however was reversible at least to some extent (301, 302). 
Serum non-esterified fatty acids also reduced GLUT2 expression in the pancreas (303). 
Similarly a high fat diet resulted in reduced pancreatic GLUT2 expression in rats and 
suggested that a high fat diet, rather than a high-carbohydrate diet, resulted in impaired 
insulin secretion (304, 305). The loss of GLUT2 appeared to be reversible (306) (301, 
302). This reduction was prevented by the administration of a known GLUT2 inhibitor, 
5-thio-D-glucose (300). 5-thio-d-glucose acts via competitive inhibition (307) while 
phloretin acted to inhibit glucose transport by preventing translocation of the GLUT2 
from vesicle to the apical and basolateral cell membranes (308). Although the 
mechanisms differ, the potential for improvement must be investigated.  
Rat models indicated that GLUT2 is the primary sugar glucose transporter in 
pancreatic β-cells, however conflicting evidence exists in human models where 
GLUT2 does not appear altered with diabetes (309, 310). GLUT1 and 3 are present in 
higher concentrations and may be the primary glucose transporters or sensing 
molecules in human islet cells (311). This may have implications for transfer to human 
models.  
1.3.2.3 Liver 
GLUT2 is expressed in the liver and, in a normal physiological model, its role is to 
control blood glucose concentrations (312). The role of GLUT2 in peripheral glucose 
clearance was primarily in liver tissue (313, 314). Expression of GLUT2 was variable, 
where expression was dose-dependent with respect to glucose, which suggests a role 
in glucose metabolism (315). On the contrary, insulin presence had an inhibitory short-
term effect on GLUT2 expression in the liver (316). In the liver, it appears that GLUT2 
has a role in regulating blood sugar, by releasing glucose into the bloodstream (317) 
but also for uptake (312). 
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The expression of GLUT2 in the liver with diabetes and pre-diabetes has not been 
unequivocally defined. Many researchers suggest that GLUT2 is not affected by the 
pre-diabetic state (301, 318). However, the expression may fluctuate depending on the 
insulin and glucose status of the rat (319). Research has suggested that increased 
PPAR-γ,  responsible for adipogenesis, was able to bind the GLUT2 promoter region 
and upregulate expression, linking the adipogenic state and glucose uptake (320). 
GLUT2 expression in the liver of streptozotocin-induced diabetic rats was almost 
doubled, yet was reduced by the presence of phlorizin (313). Similar increases have 
been seen in Wistar diabetic rats and Zucker fatty rats (321), models of oleic-induced 
fatty liver (322). While normal fluctuations occur with glucose and insulin in a 
“healthy” liver, the increases seen in obese and diabetic rats occur independently of 
these controls, contributing to the dysregulation of glucose control (321). A number of 
treatments for diabetes correct or improve the elevated liver GLUT2. These have 
included ginseng (323) and vanadate (324), while other treatments failed to correct the 
upregulation including pioglitazone (325).  
1.3.2.4 Kidney 
SGLT1 is present at low levels in the late part of the proximal renal tubule, and SGLT2 
is highly expressed in the early proximal renal tubules (326). The primary roles of 
SGLT1 and SGLT2 in the renal tubules are the re-uptake of glucose with 
approximately 90% reabsorbed by SGLT2 (327). GLUT2 was significantly 
upregulated in proximal tubular epithelial cells from patients with type 2 diabetes, 
when hyperglycaemia was present (328), and in Zucker diabetic rats (329).  Similar 
studies have suggested that this facilitates glucose reuptake under high glucose load in 
the kidney brush border, which is transient in the diabetic state (330).  
Renal uptake inhibitors such as dapaglifozin, a synthetic dihydrochalcone, are 
effective as inhibitors of renal SGLT2 uptake and in the treatment of diabetes (331).  
1.3.3 Phloretin biological activity 
Early studies indicated that phloretin was an extremely effective glucose and fructose 
transport inhibitor in isolated hepatocytes (332). Phloretin inhibited glucose uptake in 
erythrocytes with concentrations as low as 1µM inhibiting approximately 20% of 
glucose uptake, where 72 and 100 percent inhibition were achieved at 10µM and 100 
µM (333). Inhibition of glucose transport by 50% at 20µM phloretin has been recorded 
in adipocytes, however transport can be increased with exposure to insulin (334). 
Comparative studies indicated that phloretin is a better hexose transport inhibitor than 
phlorizin in models of hepatocyte transport, where 1mM concentration of phloretin 
reduced uptake to a greater extent than phlorizin (332). This may be due to the 
expression or efficiency of the respective transporters the two compounds interact with 
(283). GLUT2 is the major glucose transporter in the liver, and GLUT2 is inhibited by 
phloretin (308).  
Phloretin ingested in meals typically resulted in circulating conjugated forms of 
phloretin. Urinary excretion after an acute dose in the form of a meal is estimated to 
be approximately 10.4% (294). In vivo studies indicated that absorption of phloretin 
occurs primarily in the small intestine, with approximately 25% being absorbed (335). 
Phloretin is generally considered as a safe food flavouring ingredient by the Flavour 
Extract Manufacturers Panel (Flavouring Substances 23), number 4390, therefore its 
ingestion should be of limited concern.  
The systemic effects of phloretin with relation to metabolic syndrome have not been 
fully characterised. Oral ingestion with food is one mechanism by which phloretin may 
ameliorate the progression of type 2 diabetes mellitus, or alter the manifestation of 
some of the associated pathologies of metabolic syndrome.  
1.3.3.1 Anti-diabetic potential for phloretin 
The vast majority of research has focused on the anti-diabetic effects of phloretin due 
to its sugar transport inhibiting properties.  
In vivo, SGLT inhibitors lowered post-prandial blood glucose concentrations in 
diabetic rats (331, 333). In streptozotozin-induced diabetic rats, phloretin at 
25mg/kg/day corrected blood glucose and insulin concentrations to the same extent of 
glibenclamide (336). The effects on diabetes in streptozotozin-induced rats appeared 
to be dose dependent, even at low concentrations between 5 and 40mg/kg/day (337).  
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Some ingested phloretin was converted to its glycoside within the lumen, and prior to 
absorption into the blood stream (335). Dietary ingestion of phlorizin at 0.05% of the 
diet reduced fasting glucose concentrations by 23%, and showed that approximately 
88% of the dihydrochalcone ingested circulated as the aglycone, phloretin (338). Other 
studies where phloretin was ingested at 75mg/kg/day resulted in normalised fasting 
glucose, and greatly reduced glycation of proteins in the kidney and heart, which is a 
major cause of oxidative stress and diabetic complications (339).  
It has been shown that inhibition of GLUT2 can assist in ameliorating loss of its 
expression in pancreatic β-cells in rat models of streptozotocin-induced diabetes, 
exhibiting potential for phloretin (300).  
1.3.3.2 Anti-lipidaemic potential for phloretin 
Dyslipidaemia is one of the pathologies of metabolic syndrome. In  a mouse model of 
dietary induced metabolic syndrome, there was no improvement on blood lipid profiles 
despite improvements in fat infiltration in the liver (340). In diets of choline-induced 
hepatic damage and vascular changes that mimic the changes in metabolic syndrome, 
phloretin at a dose of 200mg/kg reduced triglyceride concentrations and alanine 
transferase activity. At 400mg/kg/day, phloretin reduced total cholesterol 
concentrations and liver non-esterified fatty acids, and at 100mg/kg/day, it reduced 
plasma aspartate transferase activity (341).  
1.3.3.3. Cardio-protective potential of phloretin 
In vitro, phloretin corrected impaired arterial vaso-relaxation that is caused by human 
immune-virus protein (342). The cause may differ, however this shows potential in a 
metabolic syndrome context. Phloretin ingestion has been shown to maintain vascular 
tone and nitric oxide release (341). Phloretin reduced expression of pro-inflammatory 
cytokines, in addition to adhesion molecules intercellular adhesion molecule-1 
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte 
adhesion molecule-1 (E-selectin) involved in the progression of atherosclerotic lesions  
(343).  Although the study was done in tissue culture, it may be transferrable to in vivo 
applications.  
1.3.3.4 Anti-inflammatory potential of phloretin 
Inflammation is one of the causes of the progressive decline in pancreatic b-cell mass 
that leads to type 2 diabetes. Further to this, chronic low-grade inflammation was been 
linked to multiple pathologies of metabolic syndrome. Inflammation caused 
progression of the diabetes and apoptosis/necrosis of insulin producing cells (344). 
Inflammation also caused vascular dysfunction (345), development of liver steatosis 
markers (346), and progressed atherosclerosis (347). Intestinal barrier function has 
been linked to the development of metabolic syndrome and systemic inflammation. 
Studies of colonic epithelial cell lines have shown that exposure to apple polyphenol 
phloretin results in increased expression of occludin mRNA (348).  
There is significant evidence that phloretin has anti-inflammatory activities in in vitro 
studies of LPS-stimulated mouse macrophages as indicated by reduced production of 
the pro-inflammatory cytokines, IL-6 (interleukin-6), TNFα and prostaglandin E2 
(349). Lu, et al. (350) indicated suppression of nitric oxide production in T-
lymphocytes stimulated by LPS and interferon. Production of pro-inflammatory 
cytokines was suppressed in cell lines exposed to phloretin (351).  
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Chapter 2 – Materials and Methods 
2.1 Ethics 
All animal handling and experimentation was approved by the Animal Ethics 
Committee (AEC) of the University of Southern Queensland. Experiments were 
carried out under the AEC approval numbers 13REA005 (10/9/2013-10/9/2015), 
15REA001 (11/3/2015-11/3/2017) and 15REA005 (20/7/2015-20/7/2018). All rats 
were treated and housed as per the NHMRC (National Health and Medical Research 
Council) 2014 guidelines for the ethical treatment of animals (352). All rats were 
individually housed in temperature-controlled, 12hr light-dark conditions and 
provided ad libitum access to food and water, except for periods of specific 
experimentation as indicated in procedural details. Food and water consumption, and 
body weight were assessed daily. 
2.2 Rat Diet and Experimental Structure 
Male Wistar rats weighing between 330 and 340g were sourced from the Animal 
Research Centre (Perth, Australia) and were divided randomly into experimental 
groups. CS and HCHF diets were as described by Panchal et al (353). The CS diet was 
composed of 570 g of corn starch (Agri Food Ingredients, Kew East, Victoria 
Australia), 155 g of powdered rat food (Specialty Feeds, Glen Forest, Western 
Australia, Australia), 25 g of Hubble, Mendel, and Wakeman salt mixture (MP 
Biomedicals LLC, Illkirch, France), and 250 g of water per kilogram of diet. HCHF 
diet consisted of 175 g of fructose (Tate & Lyle ANZ Pty Ltd, Wacol, Qld, Australia), 
395 g of sweetened condensed milk (Coles, Australia), 200 g of beef tallow (Carey 
Brothers Butchers, Warwick), 155 g of powdered rat food (Specialty Feeds, Glen 
Forest, Western Australia, Australia), 25 g of Hubble, Mendel and Wakeman salt 
mixture (MP Biomedicals LLC, Illkirch, France) and 50 g of water per kilogram of 
diet. The energy of the diets were 11.2 kJ/g food for the CS diet and 17.8 kJ/g for the 
HCHF diet (353). An additional 3.85kJ/mL energy was added to energy calculations 
for the HCHF diet to account for fructose water intake.  
The total metabolisable energy of the mCS diet was determined to be 9.94 kJ/g, and 
the mHCHF diet was 14.65 kJ/g. An additional 3.85 kJ/mL energy for water intake 
was added to any energy intake for rats consuming the mHCHF diet or mHCHF with 
added interventions. The mCS diet was composed of 570g corn starch (Agri Food 
Ingredients, Kew East, Victoria Australia), 25g Hubbel, Mendel & Wakemen Salt 
Mixture (MP Biomedicals LLC, Illkirch, France), 45g skim milk powder (Coles, 
Australia), 5g Vitamin Diet Fortification Mixture (MP Biomedicals LLC, Illkirch, 
France), 5g canola oil (Coles, Australia) and 350mL of water per kilogram. mHCHF 
diets were composed of 395g sweetened condensed milk (Coles, Australia), 175g 
fructose (Tate & Lyle ANZ Pty Ltd, Wacol, Qld, Australia), 25g Hubbel, Mendel & 
Wakemen Salt Mixture (MP Biomedicals LLC, Illkirch, France), 45g skim milk 
powder (Coles, Australia), 5g Vitamin Diet Fortification Mixture (MP Biomedicals 
LLC, Illkirch, France), 5g canola oil (Coles, Australia) and 200mL of water per 
kilogram. 
Individual dietary inclusions and interventions are described in Chapters 3 through 6. 
Interventions replaced the water portion of the diet, while all other components 
remained the same.  
Rats were in the protocol for 16 weeks in total, with control rats ingesting the same 
diet for the duration, and intervention rats ingesting the intervention or supplement in 
food for weeks 8-16, Figure 2.21.  
Figure 2.21: Experimental diet groups.  
 
2.3 Oral Glucose Tolerance 
Rats were fasted for 12 hours and all groups were given ad libitum access to normal 
water with no fructose. Blood glucose concentrations were assessed prior to glucose 
administration and at 30 minute intervals after administration for a period of two hours. 
Glucose was administered by oral gavage (USQ AEC SWP (University of Southern 
Queensland Animal Ethic Committee Standard Work Procedure) HP006) at a dose of 
2.0g/kg body weight as a 40% D-glucose (Sigma Aldrich, St Louis, USA) solution. 
Blood glucose concentrations were determined in blood drawn by tail prick (USQ AEC 
SWP HP001) and analysed using a Medisense Precision Q.I.D glucose meter (Abbott 
Weeks 0 8 16
CS Diet
CS Diet CS Diet + intervention
HCHF Diet
HCHF Diet HCHF Diet + intervention
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Laboratories, Bedford, MA). Fasting glucose concentrations and total area under the 
curve were analysed by one-way and two-way ANOVA (GraphPad Prism 6.0, 
GraphPad Software, La Jolla, California USA). 
2.4 Body Composition (Dual Energy X-Ray Absorptiometry) 
Body composition was determined by Dual Energy X-ray Absorptiometry using a 
Norland XR36 Densitometer (Norland Corporation, Ft. Atkinson, Wisconsin, USA) 
and Illuminatus 4.2.4a software. Rats were anaesthetised by intra-peritoneal injection 
of tiletamine HCl 15mg/kg and zolazepam HCl 15mg/kg (Zoletil®; Virbac, Milperra, 
New South Wales), and xylazine 10mg/kg (Ileum Xylazil-100®, Troy Laboratories) 
prior to scanning. Rats were scanned at a resolution of 1.5 x 1.5mm at a rate of 30mm/s 
to determine bone mineral density, bone mineral content, body area, lean mass and fat 
mass. Outcomes were analysed by one-way and two-way ANOVA (GraphPad Prism 
6.0, GraphPad Software, La Jolla, California USA). 
2.5 Systolic Blood Pressure 
Sedation was achieved by intra-peritoneal injection of 0.1-0.13mL Zoletil® (Virbac, 
Carros, France) equivalent to tiletamine HCl 10mg/kg and zolazepam HCl 10mg/kg 
(USQ AEC SWP HP003). Systolic blood pressure was recorded using a MLT1010 
Piezoelectric Pulse Transducer connected to an MLT844 Physiological Pressure 
Transducer and PowerLab data acquisition unit (ADInstruments, Sydney, New South 
Wales, Australia). An inflatable tail cuff was placed at the base of the tail, adjacent and 
proximal to the pulse transducer until a steady pulse rate was identified. The tail cuff 
was inflated to 200mmHg and slowly deflated, to identify the pressure (mmHg) of 
steady systolic flow return (USQ AEC SWP DP003). Outcomes were analysed by one-
way and two-way ANOVA (GraphPad Prism 6.0, GraphPad Software, La Jolla, 
California USA). 
2.6 Termination Process 
2.6.1 Euthanasia 
Rats were euthanised by intra-peritoneal injection of pentobarbital sodium 325mg/mL 
(Virbac, Carros, France) at a dose of 100mg/kg body weight. Rats were placed in a 
soft, dark box to minimise stress of euthanasia. Adequate anaesthesia was determined 
by assessment of pedal reflex, tail reflex and palpebral reflex. Immediately following 
determination of anaesthesia, 200IU ammonium heparin of porcine origin 
(1.87mg/mL) (Sigma-Aldrich St Louis, USA) was injected through the femoral vein 
to prevent clotting. 
2.6.2 Serum collection 
The abdominal cavity was opened and upon exposure of the abdominal aorta, 
approximately 2mL of blood was drawn using a 5mL endotoxin free syringe (Terumo, 
Somerset, New Jersey USA) and a 30 gauge x ½ inch endotoxin-free needle (Terumo, 
Somerset, New Jersey USA). Blood was placed in a 10mL endotoxin-free tube and 
(Sarstedt Numbrecht, Germany) and held on ice for 20 minutes until clotting had 
occurred, followed by centrifugation at 5000g for 10 minutes. Endotoxin-free tips 
(Eppendorff, Hamburg, Germany) were used to aliquot 50µL samples of serum in to 
endotoxin-free tubes (Astral Scientific, New South Wales, Australia). Samples were 
stored at -20°C. 
2.6.3 Plasma Collection 
Upon exposure of the abdominal aorta, approximately 4mL of blood was drawn as 
noted in method 2.6.2 Serum collection and placed into heparinised tubes (16 I.U/mL 
lithium heparin) (Sarstedt, Numbrecht, Germany). Plasma was collected following 
centrifugation at 5000g for 10 minutes and stored at -20ºC. 
2.6.4 Left ventricular diastolic stiffness 
Left ventricular function was determined at termination by isolated heart preparation 
(USQ AEC SWP DP006). Prior to termination, the system was equilibrated such that 
the balloon catheter under normal atmospheric pressure with 500µL of fluid was equal 
to zero (0) mmHg (millimetres of Mercury). 
Hearts were removed with approximately 5-10mm of aorta attached and intact. Hearts 
were perfused (Figure 2.21) in modified Krebs-Henseleit bicarbonate buffer 
containing 119.1mM NaCl, 4.75mM KCl, 1.19mM MgSO4, 1.19mM KH2PO4, 
25.0mM NaHCO3, 11.0mM glucose and 2.16mM CaCl2. The buffer was oxygenated 
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by steady infusion with 95% O2 and 5% CO2 carbogen gas (BOC Australia, North 
Ryde, New South Wales) maintained at a temperature of 37ºC. 
 
Figure 2.22: Isolated heart perfusion schematic (354). 
Iso-volumetric ventricular function was determined by a Capto SP844 MLT844 
physiological pressure transducer and LabChart software on a MacLab system (AD 
instruments, Castle Hill Australia), connected to a latex balloon catheter inserted into 
the left ventricle of the isolated heart (Figure 2.22). All measurements were performed 
at an induced heart rate of 250 beats per minute. Pressure-volume relationships were 
determined at increments from 0 to 30mmHg by injection of water into the latex 
balloon catheter and determination of the resultant pressure. The end-diastolic stiffness 
function (κ, unitless) was calculated as described by Brown, Duce, Miric and Sernia 
(355).   
Pressure-volume data were used to generate stress and strain values. Stress was 
determined assuming sphericity and the hydrostatic pressure exerted on the left 
ventricle at each volume interval. Outcomes were generated in dynes/cm2. The 
differential of the curve generated at each pressure-volume point indicated the stress 
exerted by the fluid. 
Strain was calculated as described by Mirsky and Parmley (356). A line of the formula 
y=aebx was generated by the stress-strain relationship, such that the values of a and b 
were used to determine the differential equation and plot the tangent of the line at each 
point. This tangential line is equal to the elastic modulus of the heart at any given 
volume. The linear equation of the stress-strain relationship was determined of the 
formula y= mx + c, where m is equal to the diastolic stiffness constant.  Diastolic 
stiffness values were analysed by one-way and two-way ANOVA (GraphPad Prism 
6.0, GraphPad Software, La Jolla, California USA). 
2.6.5 Vascular reactivity 
Prior to experimentation, all pressure transducers were calibrated to a 15mN weight. 
A section of descending aorta was collected immediately after removal of the heart 
and placed in cold Tyrode’s buffer (136.9mM NaCl, 5.4mM KCl, 1.05mM MgCl2, 
0.42mM NaH2PO4, 22.6mM NaHCO3, 1.8mM CaCl2, 5.5mM D-glucose, 0.28mM 
ascorbic acid and 0.1mM Na2EDTA) with a steady flow of carbogen gas (BOC, 5% 
CO2, 95% O2). 3-4 mm sections of aorta were suspended in organ baths (schematic, 
Figure 2.23) equilibrated to 37°C, and rinsed twice in equilibrated Tyrode’s buffer. The 
force generated by contraction or relaxation was measured by a Chart MacLab System 
(ADInstruments, Castle Hill Australia). Aortic contraction or relaxation responses to 
sodium nitroprusside and acetylcholine were pre-contracted with a single addition of 
noradrenaline resulting in a 2 micromolar noradrenaline concentration in the organ 
bath; and allowed to stabilise to >95% maximum contraction. Cumulative 
concentration-response curves were generated for noradrenaline, sodium nitroprusside 
or acetylcholine at half-log units from 1x10-9mol/L to 3x10-5mol/L or until no further 
contractions were observed. Outcomes were analysed by one-way and two-way 
ANOVA (GraphPad Prism 6.0, GraphPad Software, La Jolla, California USA). 
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 Figure 2.23: Schematic of organ baths used for assessment of aortic vascular reactivity 
(357).  
2.6.6 Ileum and colon reactivity 
Approximately 10mm sections of ileum and proximal colon were collected from 
euthanised rats and washed gently in cold Tyrode’s buffer. Ileal sections were taken 
leaving approximately 10mm proximal to the ileocecal valve, and colon sections were 
collected approximately 10mm distal to the cecocolic valve. Remaining chyme and 
faeces were removed using cold buffer and syringe with gentle washing. Sections were 
strung to a tension of ~10mN in Tyrode’s buffer in 25mL organ baths, equilibrated to 
37°C, oxygenated by carbogen gas (BOC, 5% CO2, 95% O2). Force of contraction was 
measured by a Chart MacLab System (ADInstruments, Castle Hill Australia). 
Maximal force of contraction (mN tension) was measured at half-log increases in 
acetylcholine from 1x10-9mol/L to 3x10-5mol/L in a concentration-response manner or 
until no further increases in contraction force occurred. Tissues were washed twice in 
equilibrated Tyrode’s buffer between each addition and allowed to equilibrate at 
approximately 10mN tension. Outcomes were analysed by one-way and two-way 
ANOVA (GraphPad Prism 6.0, GraphPad Software, La Jolla, California USA). 
2.6.7 Organ weights (normalised to tibial length) and tissue collection 
The wet weights of organs (kidneys, liver, spleen, epididymal fat, omental fat, 
retroperitoneal fat, left ventricle plus septum and right ventricle) were determined and 
normalised against the tibial length of the individual rat. Tibial length was measured 
to the nearest 10th of a millimetre using vernier callipers. Outcomes were analysed by 
one-way and two-way ANOVA (GraphPad Prism 6.0, GraphPad Software, La Jolla, 
California USA). 
All samples were washed in cold (4°C) Tyrode’s buffer and placed in a sterile 1.5mL 
screw cap tube and placed on ice immediately. Samples were stored at -80°C long 
term. Sections of colon were taken from the distal colon containing the 3 terminal 
faecal pellets, rinsed in Tyrode’s buffer and stored similarly.   
2.7 Plasma Biochemistry 
2.7.1 Plasma ALT and AST activity 
Plasma was analysed for aspartate transaminase (AST) and alanine transaminase 
(ALT) activity using an Olympus AU400/AU480 analyser (Olympus, Tokyo, Japan) 
at The University of Queensland Veterinary School, Gatton with commercial kits and 
controls (Olympus OSR6107 kinetic UV test & Olympus OSR6109 kinetic UV test). 
Creatine kinase and lactate dehydrogenase were assessed using kinetic UV tests 
OSR6179 and OSR6128. All tests were carried out as per manufacturer’s instructions. 
Outcomes were analysed by one-way and two-way ANOVA (GraphPad Prism 6.0, 
GraphPad Software, La Jolla, California USA). 
 
2.8 Plasma Lipid Profile 
Plasma was collected as described in method 2.6.3. Lipid concentrations were 
determined using an Olympus AU400 analyser. Plasma concentrations of total 
cholesterol were determined using an Olympus OSR6216 enzymatic colour test and 
triglycerides were determined using an Olympus OSR6133 enzymatic colour test. 
Plasma NEFA (non-esterified fatty acids) were determined by a Wako Diagnostics HR 
Series NEFA-HR enzymatic kit (Wako, Osaka, Japan). Outcomes were analysed by 
one-way and two-way ANOVA (GraphPad Prism 6.0, GraphPad Software, La Jolla, 
California USA). 
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2.9 Histology analyses 
2.9.1 Tissue Collection 
Colon sections were taken immediately proximal to the cecocolic junction and were 
approximately 10mm in length. Ileum samples were collected immediately anterior to 
the ileocecal junction and were approximately 10mm in length. Samples of kidney, 
liver, spleen, pancreas, retroperitoneal fat, ileum and colon were washed in cold 
Tyrode’s buffer and placed immediately in 10% neutral buffered formalin, pH 7.0. 
Samples were stored in formalin for 72-96 hours prior to processing. 
Prior to processing, either automated or manual, sections were removed from the 
formalin solution and sectioned to no greater than 1.0 x 0.5cm sections. Samples were 
placed in labelled tissue cassettes and stored in 100% ethanol until processing. 
2.9.2 Manual Tissue Processing 
Manual tissue processing was carried out by removing residual formalin in running tap 
water for 20 minutes. The following sequence was carried out to fix sections: 45 
minutes in 70% ethanol; 45 minutes in 90% ethanol; 45 minutes in 100% ethanol, 45 
minutes in 100% ethanol, 45 minutes 100% in xylene and 45 minutes in 100% xylene. 
After removal from xylene, sections were placed in wax at 60°C overnight. Sections 
were embedded in paraffin wax at 60°C and allowed to cool completely prior to 
sectioning.    
2.9.3 Automated Tissue Processing 
Automated processing was carried out using a Thermo Scientific™ Shandon™ 
Pathcentre™ Tissue Processor (ThermoFisher Waltham, MA, USA). The following 
sequence was carried out: 1 hour each 70%, 90%, 95%, 100% x 3 washes of ethanol, 
followed by re-hydration with xylene 3 times. Samples were then soaked in four sets 
of wax (Tissue Embedding Medium (Paraplast® Regular, melting point 56°C) under 
vacuum for 1 hour each. 
Sections were allowed to remain in water at 60°C under a vacuum of 1000 millibar 
overnight before embedding into wax blocks (Paraplast® Regular, melting point 56°C). 
2.9.4 Tissue Sectioning 
Paraffin sections were sectioned to 5µm using a Leica Microtome (Wetzlar, Germany). 
3-5 concurrent sections were placed in a 60°C water bath and were collected on to a 
Superfrost™Plus (ThermoFischer Waltham, MA, USA) slide and allowed to dry at 
room temperature prior to storage.   
2.9.5 Staining 
Prior to staining, sections were dewaxed and rehydrated by pre-heating sectioned 
slides to 60°C for 15 minutes. Dewaxing was carried by 3 subsequent washes in 100% 
xylene. Rehydration was carried out by 2 consecutive washes in 100% ethanol, single 
washes in 90% ethanol, 70% ethanol and running tap water. All washes were carried 
out for 2 minutes. 
2.9.5.1 Hematoxylin and Eosin Staining 
Liver, left ventricle, ileum, colon, kidney, skeletal muscle, and pancreas were stained. 
Hematoxylin (Sigma Aldrich, Darmstadt, Germany) was prepared at a concentration 
of 6.4g/L in a solution of 20% ethanol, 16% glycerol and 0.6% aluminium persulfate, 
and allowed to stand for 6 weeks in the dark prior to use. Eosin Y (Sigma Aldrich, 
Darmstadt, Germany) was prepared at a concentration of 10g/L in 90% ethanol. Prior 
to use, the solution was diluted 1:1 in 90% ethanol. 
After dehydration, samples underwent the following sequence: hematoxylin (6 
minutes), running water (2 minutes), 70% ethanol (2 minutes), eosin Y (7 minutes), 
95% ethanol (2 minutes), 100% ethanol (2 minutes, 3 times), 100% xylene (2 minutes, 
3 times).  After removal of excess xylene, slides were fixed with a cover-slip using 
DPX Mountant for histology (Sigma Aldrich, St Louis, USA). 
2.9.5.2 Picrosirius red staining 
Only left ventricular sections were stained for collagen. Picrosirius red stain (specific 
for type I and III collagen) was prepared at a concentration of 1.0g/L Sirius Red (Sigma 
Aldrich, St Louis, USA) in saturated picric acid. 
After dehydration, samples underwent the following sequence: 0.5% 
phosphomolybdic acid (5 minutes), running water (2 minutes), 0.1% picrosirius red 
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(90 minutes), 0.1M hydrochloric acid (2 minutes), 95% ethanol (2 minutes), 100% 
ethanol (2 minutes, 3 times) and 100% xylene (2 minutes, 3 times).  After removal of 
excess xylene, slides were fixed with a cover-slip using DPX Mountant for histology 
(Sigma Aldrich, St Louis, USA).  
2.9.6 Microscopy and histological analysis 
2.9.6.1 Liver Histology Imaging 
Liver sections were imaged at 20x magnification using a standard white light for 
inflammatory cell presence and steatohepatitis indicators of ballooning, and fat 
deposition (steatosis).  
2.9.6.2 Picrosirius left ventricular histology imaging 
Picrosirius red slides were imaged using a UV light source and narrow band emission 
filter, to allow green light of the wavelengths 510-560nm to pass. Two non-overlapping 
fields per section were imaged. ImageJ (National Institute for Health, United States of 
America) software was used to determine the percent collagen deposition. Outcomes 
were analysed by one-way and two-way ANOVA (GraphPad Prism 6.0, GraphPad 
Software, La Jolla, California USA). 
2.9.6.3 Pancreatic islet imaging 
Pancreatic α and β cell density was determined by counting the number of nuclei in an 
islet, stained with hematoxylin and eosin. Counts were carried out using ImageJ 
(National Institute for Health, United States of America) by selecting the periphery of 
the islet and counting nuclei in an 8 bit image. Outcomes were analysed by one-way 
and two-way ANOVA (GraphPad Prism 6.0, GraphPad Software, La Jolla, California 
USA). 
2.9.6.4 Gastrointestinal histology imaging 
All gastrointestinal images were taken at a 10x magnification. A representative section 
was chosen to visualise any differences. Due to the highly variable nature of sectional 
morphology and microscale differences, no statistical analyses were performed on 
these sections. 
2.10 Endotoxin analysis 
Plasma endotoxin concentrations were assessed using the Lonza QCL1000 Limulus 
Amebocyte Lysate (LAL) kit (Lonza Basel, Switzerland) as per manufacturer’s 
instructions. All reagents were allowed to equilibrate to room temperature prior to 
preparation. Reference endotoxin was prepared by diluting endotoxin stock solution 
with supplied LAL endotoxin-free reagent water to produce a concentration of 
1.0EU/mL. A serial dilution was carried out to produce standard EU (endotoxin unit) 
concentrations of 1.0, 0.5, 0.25 and 0.1 EU/mL. 96 well endotoxin-free (Techno Plastic 
Products, Trasadingen, Switzerland) plates were pre-equilibrated to 37ºC. In each well, 
50µL of limulus amoebal lysate and 50µL of sample (plasma 1:10 dilution), blank 
(LAL reagent water) or standard (1.0, 0.5, 0.25, 0.1 EU/mL) was added. Each well was 
mixed by pipetting. Samples were prepared in duplicate. Plates were allowed to 
incubate at 37ºC for 10minutes. 100µL of chromogenic substrate solution (p-
nitroalanine, 2mM) was added to each well and allowed to incubate at 37ºC for 6 
minutes. The reaction was then stopped by the addition of 100µL of concentrated 
acetic acid in pyrogen-free water. Absorbance was read at 405nm using a FLUOStar 
Omega (BMG Labtech Offenburg, Germany). 
Absorbance was assessed against reactions of a standard curve of E. coli between 0.1 
and 1.0EU/mL endotoxin concentration. Outcomes were analysed by one-way and 
two-way ANOVA (GraphPad Prism 6.0, GraphPad Software, La Jolla, California 
USA). 
2.11 Intestinal permeability 
2.11.1 Urine collection 
For consistency, all starvation periods were initiated at approximately 6am each day. 
During intestinal permeability, rats were housed in individual metabolic cages and 
urine collected with separation from faeces. Initially rats were food-deprived for 4 
hours, during which time all rats had ad libitum access to normal tap water. At 4 hours, 
rats were dosed with 2.0 mL of probe containing 0.5 g/mL sucrose, 0.04 g/mL 
mannitol, 0.06 g/mL lactulose and 0.03 g/mL sucralose by oral gavage (USQ AEC 
SWP HP006). Following probe administration, water was withdrawn for 3 hours. 
Collection tubes were replaced at 3 hour, 8 hour and 20 hour intervals post-probe 
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administration. Collection was done in to 15mL tubes (Sarstedt Numbrecht, Germany) 
containing 100µL of 50mg/mL thymol in 1-propanol to retard bacterial growth. Food 
and water were returned ad libitum at 3 hours post-gavage, however all rats received 
normal water regardless of treatment group. Samples were stored at -20ºC until further 
analysis. 
2.11.2 Urine sample preparation and analysis 
Samples were thawed on ice. Volumes of urine were recorded to the nearest 100µL. A 
2.0mL sample was removed for further analysis and centrifuged at 12000rpm for 20 
minutes at 4°C. Samples were the filtered through a 0.45µm polytetrafluoroethylene 
(PTFE) (Grace Davidson Discovery Sciences, Maryland USA) into a 2.0mL glass 
screw-cap vial (ThermoScientific Massachusetts, USA), closed with a 0.25mm PTFE 
septum. Samples were analysed by HPLC-RID (high-performance liquid 
chromatography-refractive index detection). 
The system comprised a Shimadzu (Kyoto, Japan) DGU-20ASR degassing unit, LC-
20AT solvent delivery unit, SIL-20A Autosampler, CBM-20A communication bus 
module, CTO-20A column oven, RID-10A refractive index detector. The 
chromatography conditions were as follows: isocratic elution using 100% Milli-Q 
water, 10µL injection volume, 0.300mL/minute flow rate, 50°C column oven. 
Detection was by RID (refractive index detection). Percent recovery of each sugar for 
each rat was determined and used in analysis. Concentration of urine was assessed 
against an external curve generated for each compound. Concentration was multiplied 
by the total urine volume collected for each time period and determined as the percent 
recovery of the total amount of administered sugar. Outcomes were analysed by one-
way and two-way ANOVA (GraphPad Prism 6.0, GraphPad Software, La Jolla, 
California USA). 
2.11.3 Urine chromatography and analysis 
Each component was run individually to determine retention times. Retention times 
are shown in Table 2.9. 
  
 Table 2.9: Retention times of lactulose, sucrose, D-mannitol, and sucralose. 
Compound Retention time (minutes) 
Lactulose 18.341 
Sucrose 20.452 
D-Mannitol 22.41 
Sucralose 27.349 
 
Linearity was determined by preparation of solutions at 5 concentrations between 
0.02mg/mL and 2mg/mL. This curve was also used as the external curve for 
determination of sugar concentration. A contaminant of urine origin, determined by 
running blank urine samples, was found at elution time of 12 minutes however did not 
interfere with peaks identification of quantitation (Figure 2.24). 
 
Figure 2.24: Urine sample example chromatogram. Initially, a mixture of the gavage 
compounds was diluted to 1:100 in distilled water. This was used for optimisation of 
separation. 
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2.12 Semi-quantitative ELISA (enzyme-linked immunosorbent assay) 
2.12.1 Protein Extraction 
100mg of tissue samples were homogenised in RIPA buffer (150 mM sodium chloride, 
1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM 
Tris, pH 8.0) in 1% HaltTM EDTA-Free Protease Inhibitor (ThermoScientific 
Massachusetts, USA). Samples were homogenised for 2 minutes with a GentleMacs 
dissociator (Miltenyi Biotech, Bergisch Gladbach, Germany), and mixed for 2 hours 
on ice. Supernatants were retained after centrifugation at 12000g for 20 minutes (4°C), 
then stored at -80°C. Protein concentration was determined using a BCA 
(bicinchoninic acid) assay kit (ThermoScientific Massachusetts, USA). 
 
2.12.2 Protein Quantification 
Protein quantification was carried out using a ThermoScientific Pierce BCA protein 
Assay. Colon samples were diluted 1/10, and liver samples were diluted 1/20 for 
analysis. A BSA (bovine serum albumin) standard were prepared to manufacturer’s 
instruction at 2000, 1500, 1000, 750, 500, 250, 125, 25 and 0 µg/mL. Working reagents 
A (sodium carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartrate in 
0.1M sodium hydroxide) and B (containing 4% cupric sulfate) were combined at a 
ratio of 50:1. 
25µL of diluted sample or standard were added to each well of a 96 well TPP (Techno 
Plastic Products, Trasadingen, Switzerland) plate in duplicate. 200µL of working 
reagent was added to each well and incubated for 20 minutes at 37°C. Cooled plates 
were read using a FLUOStar Omega (BMG Labtech Offenburg, Germany) plate reader 
at 562nm. The sample’s protein concentration was determined from the standard curve. 
2.12.3 GLUT2 and TLR4 determination 
To determine relative GLUT2 and TLR4 (toll-like receptor-4) expression in liver, 
0.2µg/mL rabbit polyclonal antibody (Santa Cruz Biotechnology, Dallas Texas, USA) 
was prepared in coating buffer (15mM Na2CO3, 35mM NaHCO3, pH 9.6) and 100µL 
added to each well of a TPP 96 well cell culture plate (Techno Plastic Products, 
Trasadingen, Switzerland). Plates were coated overnight at 25°C in a ShelLab 
incubator (Sheldon Manufacturing Inc. Cornelius, USA). Each well was washed 3 
times with 200µL of Tris-buffered saline (TBS) (25mM Tris-HCl; 0.13M NaCl; 
2.7mM KCl; pH 7.0). Liver protein extracts were diluted to a concentration of 
100µg/mL in sterile distilled water based on the BCA assay. 10µg in 100µL was loaded 
per well. Positive control was a combined liver sample and the negative control was 
10µg/100µL BSA in sterile water. Plates were coated for 2 hours at 25°C for two hours, 
then washed 3 times per well with TBS. 0.2µg/mL primary antibody in sterile distilled 
water was loaded per well (100µL) and allowed to bind for 2 hours at 25°C. Each well 
was then washed 3 times with TBS. Goat anti-rabbit IgG-HRP (immunoglobulin-G 
horseradish peroxidase) conjugated secondary antibody was diluted to 0.1µg/mL and 
100uL added to each well and allowed to incubate at 25°C for two hours. Each well 
was washed 3 times with TBS. Substrate solution was prepared by diluting 10mg/mL 
OPD (o-phenylenediamine dihydrochloride) (Sigma Aldrich, Darmstadt, Germany), 
in 10x Stable Peroxide Buffer (ThermoScientific Massachusetts, USA) diluted 10x in 
distilled water. 100uL per well was added and allowed to mix at room temperature for 
15 minutes on an orbital shaker. Plates were then read using a FLUOStar Omega 
(BMG Labtech, Offenburg, Germany) plate reader to measure absorbance at 450nm. 
Analysis was based on the AU reading after deduction of the negative control value 
for each plate. Outcomes were analysed by one-way and two-way ANOVA (GraphPad 
Prism 6.0, GraphPad Software, La Jolla, California USA). 
The detection of the protein was determined to be linear across the range of 0-
1000ug/mL as indicated in Table 2.10. Percent relative standard deviation (%RSD) 
was determined using three replicates at each of the concentrations across the linear 
curve range. 
Table 2.10: Linearity and % relative standard deviation of a serial dilution of protein, 
assessed for GLUT2 and TLR4 protein expression. 
  
Linear range  
0-1000µg/mL Regression value % RSD range 
GLUT2 y = 5.8975x + 0.181  0.9588 5.92-11.90% 
TLR4 y = 8.9176x + 0.1604  0.9537 4.63-11.7% 
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2.12.4 Occludin and claudin-1 determination 
To determine relative occludin expression in colon, 0.2µg/mL rabbit polyclonal 
antibody (Santa Cruz Biotechnology, Dallas Texas, USA) was prepared in coating 
buffer (15mM Na2CO3, 35mM NaHCO3, pH 9.6) and 100µL added to each well of a 
clear, Greiner Bio-one (Kremstunster, Austria) 96 well polystyrene plate.  Claudin-1 
was treated similarly using a mouse monoclonal antibody (Santa Cruz Biotechnology, 
Dallas Texas, USA). 
Plates were coated overnight at 25°C in a ShelLab incubator (Sheldon Manufacturing 
Inc. Cornelius, USA). Each well was washed 3 times with 200µL of Tris-buffered 
saline (TBS) (25mM Tris-HCl; 0.13M NaCl; 2.7mM KCl; pH 7.0). Colon protein 
extracts were diluted to a concentration of 100µg/mL in sterile distilled water based 
on the BCA assay. 10µg in 100µL was loaded per well. Positive control was a 
combined liver sample and the negative control was 10µg/100µL BSA in sterile water. 
Plates were coated for 2 hours at 25°C for two hours, then washed 3 times per well 
with TBS. 0.2µg/mL primary antibody in sterile distilled water was loaded per well 
(100µL) and allowed to bind for 2 hours at 25°C. Each well was then washed 3 times 
with TBS. Goat anti-rabbit IgG-HRP conjugated secondary antibody was used for 
detection of occludin, diluted to 0.1µg/mL and 100uL added to each well and allowed 
to incubate at 25°C for two hours. Mouse anti-rabbit IgG-HRP was similarly used for 
claudin-1 detection. Each well was washed 3 times with TBS. Substrate solution was 
prepared by diluting 10mg/mL OPD (o-phenylenediamine dihydrochloride) (Sigma 
Aldrich, Darmstadt, Germany) in 10x Stable Peroxide Buffer (ThermoScientific 
Massachusetts, USA) diluted 10x in distilled water. 100uL per well was added and 
allowed to mix at room temperature for 15 minutes on an orbital shaker. Plates were 
then read using a FLUOStar Omega (BMG Labtech Offenburg, Germany) plate reader 
to measure absorbance at 450nm. Analysis was based on the AU (atomic unit) reading 
after deduction of the negative control value for each plate. Outcomes were analysed 
by one-way and two-way ANOVA (GraphPad Prism 6.0, GraphPad Software, La Jolla, 
California USA). 
The detection of the protein was determined to be linear across the range of 0-
1000ug/mL as indicated in Table 2.11. Percent relative standard deviation was 
determined using three replicates at each of the concentrations across the linear curve 
range. 
Table 2.11: Linearity and % relative standard deviation (precision) of a serial dilution 
of protein, assessed for occludin and claudin-1 protein expression. 
  
Linear range 0-
1000µg/mL Regression value % RSD range 
Occludin y = 40.097x + 0.6529  0.9900 10.40-21.71% 
Claudin-1 y = 48.598x + 0.286  0.9797 4.22-20.27% 
 
2.13 Sorghum extract analysis 
2.13.1 Sorghum phenolic extraction 
5.0g of whole sorghum, red sorghum flour, black sorghum flour or wet cake sorghum 
was weighed into 50mL Falcon tubes (Sarstedt Numbrecht, Germany). Samples were 
prepared in triplicate. Sorghum was extracted by addition of 10.0mL of 1% acetic acid 
in 100% methanol. Sorghum was mixed on a platform shaker for 2 hours and allowed 
to stand with intermittent mixing for 4 hours. Samples were centrifuged for 10 minutes 
at 3000g and supernatants retained. Extraction was repeated three times and 
supernatants pooled. Samples were evaporated to dryness and stored at room 
temperature until analysis.   
2.13.2 Sorghum phenolic analysis 
Samples were analysed by HPLC-DAD (high performance liquid chromatography – 
diode array detector) at 210nm, 330nm and 510nm. Approximately 1mg of sample was 
re-suspended in 1% acidified methanol. Samples were analysed by Southern Cross 
University Plant Science Analytical Research Laboratory (Lismore, New South 
Wales).   
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Chapter 3 – 5% Wholegrain sorghum in a rat model of diet-induced metabolic 
syndrome  
3.1 Introduction 
Poor diet and lack of physical activity are the major contributors to the development 
of the non-communicable disease of metabolic syndrome (358). Prevention and 
reversal of the disease rely heavily on changing dietary habits (359). Changes in 
metabolic function have been noted with dietary changes sych as switching to a 
Mediterranean diet (360, 361) or Nordic diet (362). A wholegrain-based diet improved 
metabolic disease with reduced insulin fluctuations, improved glucose regulation and 
lowered triglyceride concentrations (363-365). Changing diet is effective in reversing 
metabolic syndrome, and understanding the benefits of certain foods will allow better 
education of the public.  
The improved changes noted with wholegrain consumption have led to a wider variety 
of cereal products becoming popular for human consumption. Sorghum products have 
entered the Australian marketplace for human consumption in products like 
GlutenFree WeetBix (Sanitarium), Gluten Free Flour (Bobs Red Mill), Pearled 
Sorghum (SorgPlus) and Red Sorghum Puffs (Friendship Foods), and its inclusion into 
rice mixes, breakfast cereals and muesli bars.  
Consumption of sorghum in Australia has previously been limited to livestock animals 
(16). Overseas, the use of sorghum differs. According to FAO (16), in 2011, only 
41,000 tonnes of the domestic supply of sorghum in Australia of 1,959,000 tonnes was 
used in food manufacturing, representing 2.11%, and none as a direct food source for 
human consumption. Comparatively, in countries such as Nigeria, approximately 75% 
of sorghum is used as a direct food source with an additional 2.36% used in food 
manufacturing (16). The prevalence of metabolic syndrome between these countries 
vastly differs, as do their overall diets. The rural Nigerian community which consumes 
a more traditional diet has an estimated metabolic syndrome rate of 5% in females and 
8% in males by the IDF (International Diabetes Federation) criteria in 2015 (366), 
while in Australia the rates were 29.1% by these IDF criteria in 2015 (359). 
The physiological effects of sorghum consumption have been investigated 
predominantly in chickens and beef cattle (243-245). In livestock, the aim is to 
maximise weight gain and feed efficiency for profitability. However, in mono-gastric 
animals, such as pigs and broilers, sorghum is detrimental for maximising weight gain 
(243-245). The factors inhibiting the conversion of ingested sorghum to body weight 
include the large starch granules, inhibitory proteins around starch granules, and the 
presence of phytochemicals such as tannins and phenolic acids. Studies on mono-
gastric nutrition of livestock discuss the anti-nutritive properties of sorghum (103, 274, 
367). Although the term “anti-nutritive” may be a deterrent toward consumption in 
humans, these components may improve the physiological status of individuals 
following sorghum consumption. 
These components, although detrimental in commercial livestock production, may be 
useful in humans to circumvent the increasing obesity and metabolic syndrome 
epidemic in Western societies. The coloured compounds in sorghum have anti-
inflammatory actions (168, 253). In obesity and metabolic syndrome, alleviation of the 
inflammation can minimise long-term pathologies associated with being overweight 
including impaired glucose tolerance, dyslipidaemia, liver steatosis, high blood 
pressure and poor cardiovascular function (219, 240, 368-371). 
Sorghum contains compounds which may reduce the digestion of proteins and 
carbohydrates in vitro including flavonoids, phenolic acids, tannins and kafirin 
proteins (43, 54, 55, 59). These compounds have differing bio-accessibilities and bio-
availabilities, however many of the bioactive compounds appear in the plasma after 
dietary supplementation. Phenolic acids are bioavailable, however larger procyanidins 
(flavonoids, condensed tannins) and catechins undergo bacterial degradation in the 
colon prior to absorption (162). 3-deoxyanthocyanidins, one of the most effective 
antioxidant components of sorghum, and related anthocyanins are bioavailable and 
appear in plasma after ingestion (372). 
A diet high in fat increases metabolic endotoxaemia, leading to a cascade of 
inflammatory responses which progress to metabolic syndrome (373, 374). These diets 
have been linked to both dysbiosis in the gut and increased permeability of the colon 
to  lipopolysaccharides (373). Consumption of resistant starches and non-starch 
81 
 
polysaccharides reduced diet-induced endotoxaemia (375). Consumption of wheat-
derived arabinoxylans improved metabolic endotoxaemia and improved the reductions 
in colonic tight junction mRNA in animal models (220). The effects on endotoxaemia 
with consumption of wholegrain cereals containing these carbohydrates have not been 
widely studied. Reviews speculate that protection from type 2 diabetes with 
wholegrain consumption is mediated by the large intestine (218, 376, 377). LPS is a 
known cause of metabolic syndrome (238), and activator of TLR4, one of the innate 
immune receptors (219). Some evidence suggests that components of sorghum reduce 
LPS mediated inflammation (168, 378), yet little information is available on whether 
sorghum reduces the total plasma concentration of LPS.  
Components of wholegrain sorghum have theoretical potential to alleviate the 
pathologies of metabolic syndrome. This chapter investigates whether a supplement of 
5% sorghum into an obesogenic diet alters the pathology of metabolic syndrome in a 
rat model of diet-induced metabolic syndrome.  
3.1.1 Hypothesis 
My hypothesis is that consumption of 5% sorghum in the diet will correct 
dyslipidaemia, improve liver structure and function, improve cardiovascular health, 
and improve glucose tolerance.  
One of the mechanisms for this improvement is the reduction of circulating 
lipopolysaccharides concentration. This will result in changes to TLR4 expression in 
the colon and liver. There will be a reduction in gastrointestinal permeability with 
sorghum consumption and that will be linked to an increased expression of colonic 
tight junction proteins.  
3.2 Materials and Methods 
3.2.1 Ethics  
Approval for experimentation with 5% sorghum was granted under AEC approval 
number 13REA005 (10/9/2013-10/9/2015) by the Animal Ethics Committee of the 
University of Southern Queensland. Please refer to chapter 2.1 for further information.  
 3.2.2 Rat Diet and Experimental Structure  
Forty-eight male Wistar rats were divided into 4 experimental groups of n=12. Control 
diets were comprised as outlined in method 2.2. Experimental groups were CS (corn 
starch diet), HCHF (high carbohydrate, high fat diet), CSb (corn starch diet + 5% w/w 
Sorghum bicolor), HSb (high carbohydrate, high fat diet + 5% w/w Sorghum bicolor). 
For the first 8 weeks of the protocol, all CS and CSb rats received the CS diet and all 
HCHF and HSb rats received the HCHF diet as described by Panchal et al (353), 
detailed in Chapter 2. Energy contents of the diets were 11.2 kJ/g food for the CS diet, 
17.8 kJ/g for the HCHF  diet (353), 11.98 kJ/g for CSb diet and 18.58 kJ/g for HSb 
diet, based on an energy density for sorghum of 361 kJ/100g. An additional 3.85 kJ/mL 
was added to calculations for the HCHF and HSb diets for the fructose in the drinking 
water. 
At eight weeks, CSb rats were transferred to the treatment diet which included 
supplementation with 5% raw red sorghum, and similarly HSb treatment rats were 
placed on the HCHF diet supplemented with 5% raw red sorghum. Red sorghum was 
sourced from Crest Seeds (Toowoomba, Queensland) and is a commercially available 
stock feed supplement.  
After eight weeks, systolic blood pressure and oral glucose tolerance were determined 
prior to dietary intervention, and again after 8 weeks (at 16 weeks after start of 
protocol) on continuous supplementation.  
At 16 weeks, rats were assessed for the following parameters, with corresponding 
methods indicated in parentheses; oral glucose tolerance (method 2.3), dual x-ray 
absorptiometry (method 2.4), systolic blood pressure (method 2.4) and intestinal 
permeability urine collection (method 2.10.1). All rats were food-deprived for 2 hours 
prior to termination. Rats were euthanised as per method 2.6.1. At termination, rats 
underwent serum collection (method 2.6.2) plasma collection (method 2.6.3), vascular 
reactivity (method 2.6.5), ileum and colon contractility (method 2.6.6), measurement 
of organ weights (method 2.6.7) and histological tissue collection (method 2.8.1). A 
minimum of 8 rats per group underwent isolated heart perfusion (method 2.6.4), with 
the remaining two hearts preserved in formalin for histological analysis as per method 
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2.8.1. Plasma biochemistry was assessed on 8 rats per group for liver enzyme activity 
(method 2.7.1) and plasma lipid profile (method 2.7.2). Collected serum was analysed 
for presence of endotoxins as per method 2.9. Liver sections were assessed for 
expression of GLUT2 and TLR4 (method 2.11.3). Distal colon sections were also 
assessed for occludin and claudin expression using the method in method 2.11.4, and 
TLR4. Urine samples collected prior to termination were prepared (method 2.10.2) 
and analysed as per method outlined in method 2.10.3. 
Sorghum phenolics were extracted from 5.0g of whole sorghum (method 2.12.1) and 
analysed as in method 2.12.2.     
Histological tissue samples were processed manually (method 2.8.2) and sectioned 
(method 2.8.3). Liver, ileum, colon, pancreas and left ventricle were stained with 
haematoxylin and eosin (method 2.8.5.1). Separate sections of left ventricle were 
stained with picrosirius red (method 2.8.5.2). Microscopy and imaging were 
performed as per methods 2.8.6.1, 2.8.6.2, 2.8.6.3 and 2.8.6.4.   
3.2.3 Statistics 
Statistics were performed using GraphPad Prism (GraphPad Software, La Jolla, 
California USA). Individual groups were compared using a one-way ANOVA. Where 
data were normally distributed, a normal one-way ANOVA was used. Where data were 
not normally distributed, a non-parametric one-way ANOVA was used. Tests for 
normality were done using the D’agostino-Pearson normality test. Two-way ANOVA 
was carried out, where indicated, to determine the influence of the two categorical 
variables of “diet” (CS or HCHF), or “intervention” (5% sorghum, no sorghum).  
Multiple comparisons were carried out comparing all groups to test the following null 
hypotheses: 
There is no difference in the outcome of metabolic syndrome parameters between the 
CS, CSb, HCHF and HSb-fed groups at a given time point for a given parameter. 
For two-way ANOVA, we tested the following null hypotheses: 
There is no effect of diet on metabolic syndrome parameters, 
There is no effect of sorghum on the metabolic syndrome parameters, and 
There is no interaction between diet and sorghum, in affecting metabolic syndrome 
parameters.  
3.3 Results  
3.3.1 Sorghum extraction 
Whole sorghum extracts showed a range of compounds extracted by 1% acidified 
methanol.  
Detection of flavonoids can be carried out using a 210nm diode array absorbance 
(379). Furthermore, it will also detect compounds containing carboxylic acid, 
propylamide or ester fucntional groups (380). Acidified methanol extracts of whole 
red sorghum flour detected at 210nm (Figure 3.25) showed that there were 3 major 
compounds present at 2 minutes, 20.3 minutes and 20.8 minutes. The peak present at 
1.1 minute represents acetic acid in all 3 chromatograms of Figure 3.25, 3.26, 3.27.   
 
Figure 3.25:210nm UV detection of HPLC of acidified methanol extracts of whole red 
sorghum. 210nm detection detects primarily hydrophilic compounds. 
The 330nm profile (Figure 3.26) primarily indicates phenolic acids which are present 
(381). This wavelength is also suitable for detection of flavones (153) and flavonols 
(379).  
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Figure 3.26: 330nm UV detection of HPLC separated acidified methanol extracts of 
whole red sorghum. 330nm detection primarily indicates presence of phenolic acids.  
Detection of anthocyanins can be carried out by diode array absorbance at 510nm 
(379). Very few anthocyanin compounds appeared to be present in the extracts, with a 
minor peak at 7.5 minutes.  
 
Figure 3.27: 510nm UV detection of HPLC extracts of whole red sorghum. 510nm 
detection primarily indicates anthocyanin presence. 
3.3.2 Physiological and metabolic parameters 
After 8 weeks of the protocol, there were no differences in tested parameters between 
the HCHF and HSb groups, nor the CS and CSb groups, Table 3.12. The HCHF diet 
groups had higher body weight, increased basal blood glucose, impaired glucose 
tolerance, higher energy intake, lower food weight intake, and higher feed efficiency.  
 
Table 3.12: Physiological and metabolic variables of CS, CSb, HCHF and HSb fed rats.  
 
Results are expressed as mean±SEM. Values with the same superscript letter do not differ statistically at p<0.05 determined by one-way 
ANOVA.   Effect of diet, intervention or interaction at p<0.05, determined by two-way ANOVA. 
Parameter Diet Sorghum Interaction
Average weight gain week 8-16(g) 30.8 ± 3.0 a 42.08 ± 5.0 a 80.42 ± 7.2 a 62.55 ± 9.5 ab <0.0001 0.6183 0.0306
Body weight week 8 (g) 349.9 ± 5.45 a 355.8 ± 4.58 a 449.5 ± 8.46 b 450.7 ± 7.6 b <0.0001 0.6044 0.7296
Final body weight week 16 (g) 380.8 ± 6.8 a 397.8 ± 6.6 a 529.9 ± 12.1 b 508 ± 11.4 b <0.0001 0.8017 0.0475
Food intake week 1-8 (g/day) 36.6 ± 1.1 a 37.1 ± 0.8 a 25.4 ± 0.5 b 24.5 ± 0.7 b <0.0001 0.8507 0.377
Food intake week 8-16 (g/day) 36.3 ± 1.0 a 35.3 ± 1.0 a 24.3 ± 0.6 b 21.5 ± 0.6 b <0.0001 0.0266 0.2681
Energy intake week 1-8 (kJ/day) 410.4 ± 12.4 a 416.9 ± 9.1 a 540.6 ± 12.3 b 509.3 ± 13.2 b <0.0001 0.2992 0.1184
Energy intake week 8-16 (kJ/day 407.4 ± 10.7 a 423.2 ± 11.9 a 524.7 ± 13.3 b 483.6 ± 11.7 b <0.0001 0.2969 0.0218
BMI (g/cm2) 0.59 ± 0.01 a 0.62 ± 0.02 ab 0.75 ± 0.03 c 0.67 ± 0.02 bc <0.0001 0.2649 0.0155
Feed efficiency week 8-16 (g gained/kJ) 1.4 ± 0.1 a 1.8 ± 0.2 ab 2.7 ± 0.2 c 2.3 ± 0.3 bc <0.0001 0.9495 0.0777
Epididymal fat (mg/mm tibial length) 172.0 ± 11.8 a 183.0 ± 16.5 a 483.0 ± 53.6 b 435.0 ± 35.6 b <0.0001 0.5954 0.3855
Retroperitoneal fat (mg/mm tibial length) 96.4 ± 8.8 a 105.0 ± 7.5 a 231.0 ± 24.7 b 219.0 ± 14.8 b <0.0001 0.9364 0.5183
Omental fat (mg/mm tibial length) 123.0 ± 6.2 a 145.0 ± 11.7 a 251.0 ± 23.2 b 248.0 ± 15.6 b <0.0001 0.528 0.4147
Abdominal fat pad mass (mg/mm tibial length) 390.5 ± 22.8 a 433.6 ± 34.0 a 964.2 ± 98.9 b 902.4 ± 60.7 b <0.0001 0.8802 0.3997
Bone mineral density (g/cm2) 0.179 ± 3.E-03 ab 0.17 ± 2.E-03 a 0.187 ± 1.E-03 b 0.184 ± 2.E-03 b 0.0001 0.027 0.2928
Bone mineral content (g) 11.75 ± 0.28 a 11.71 ± 0.35 a 16.53 ± 0.51 b 15.69 ± 0.61 b <0.0001 0.3423 0.3873
Lean Mass (g) 276.8 ± 6.71 a 276.9 ± 8.28 a 269.3 ± 14.29 a 278.1 ± 13.7 a 0.7814 0.6952 0.7017
Fat Mass (g) 111.2 ± 6.4 a 114.0 ± 12.6 a 252.2 ± 29.8 b 223.9 ± 25.0 b <0.0001 0.5427 0.4586
CS Csb HCHF HSb
87 
 
Sorghum supplementation did not alter final body weight or body weight gain in either 
the CS or HCHF model determined by one-way ANOVA. There was a significant 
interaction of diet and 5% sorghum supplementation, whereby the direction that body 
weight in the two diet models were opposing. These results appear consistent with the 
significant interaction effect noted in body mass index (BMI) associated with sorghum 
supplementation. The lean body mass was maintained in all groups. Food intake by 
weight was not altered with sorghum supplementation, nor was energy intake by one-
way ANOVA. Two-way ANOVA showed a significant effect of sorghum and diet on 
week 8-16 feed intake, and interaction between diet and sorghum for energy intake, 
Table 3.12.  
3.3.3 Blood lipids, and glucose control  
At 8 weeks, the HCHF and HSb groups showed increased basal blood glucose 
concentrations and increased glucose TAUC. At 16 weeks, basal blood glucose 
concentrations were increased in the CSb group, above the value of the CS control.  
Sorghum normalised TAUC to the CS control in the HSb group (Table 3.13). No 
changes in fasting blood glucose concentrations were found with consumption of 
whole red sorghum. 
 
 
 
 
 
 
 
 
Pancreatic islet density, islet size and β-cell count did not differ between groups, 
Figure 3.28.  
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Figure 3.28: Pancreatic islet 
alpha and b-cell density, cell 
number per islet, and islet area. 
No significant differences were 
noted using one-way ANOVA 
and p<0.05.  
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Table 3.13: Blood glucose and lipid profiles with sorghum supplementation in a HCHF and CS diet.  
 
Letters on each row with differing superscript lower-case letters were statistically different at p<0.05 by one-way ANOVA. Significant 
effects of diet, intervention and interaction determined by two-way ANOVA. TAUC – total area under curve, LPS – lipopolysaccharide, 
NEFA – non-esterified fatty acids.  
  CS CSb HCHF HSb Diet Sorghum Interaction 
Basal blood glucose 8 week (mM) 3.6 ± 0.3 a 3.5 ± 0.10 a 5.4 ± 0.08 b 4.6 ± 0.19 ab <0.0001 0.0197 0.0651 
TAUC 8 week 615.2 ± 17.05 a 688.4 ± 34.97 a 805.2 ± 23.70 b 775.6 ± 14.17 b <0.0001 0.4618 0.0888 
Basal blood glucose 16 week (mM) 3.6 ± 0.18 a 4.3 ± 0.21 ab 4.8 ± 0.21 b 4.6 ± 0.19 b 0.0004 0.2575 0.0304 
TAUC 16 week  660.8 ± 11.76 a 681.5 ± 17.23 a 847.8 ± 35.1 b 736.3 ± 14.12 a <0.0001 0.2544 0.0504 
Plasma total cholesterol (mM) 1.46 ± 0.04 a 1.54 ± 0.05 a 1.79 ± 0.08 b 1.51 ± 0.06 a 0.0191 0.1085 0.0702 
Plasma triglycerides (mM) 0.45 ± 0.03 a 0.44 ± 0.04 a 1.6 ± 0.33 b 1.96 ± 0.16 b <0.0001 0.3551 0.3223 
Plasma NEFA (mM) 1.84 ± 0.20 a 2.16 ± 0.17 a 5.02 ± 0.61 b 5.49 ± 0.36 b <0.0001 0.3041 0.8408 
Serum LPS (EU/mL) 1.63 ± 0.84 a 2.26 ± 0.58 a 0.93 ± 0.23 a 1.61 ± 0.47 a 0.2069 0.1970 0.9651 
Plasma triglycerides and NEFA (non-esterified fatty acid) concentrations were 
increased in the HCHF diet from the CS control. The addition of 5% raw sorghum to 
the HCHF diet normalised plasma total cholesterol concentrations to the CS control, 
as shown in Table 3.13, however did not affect NEFA or triglycerides.  
3.3.4 Cardiovascular and liver parameters  
Liver weight was 50-60% higher in the HCHF and HSb groups than the CS control 
(Table 3.14). Liver weight was unchanged by sorghum consumption. There was a 
decrease in the indicators of liver steatohepatitis with the administration of 5% raw 
sorghum into the HCHF diet, determined by histology. This primarily came from a 
reduction in the steatosis of liver cells (Figure 3.29), reduced cell size, and apparent 
lack of fatty deposits. In HCHF rats, steatosis was typically macro-vesicular and very 
pronounced. There was no reduction in inflammatory cells with 5% sorghum 
supplementation, shown in Figure 3.29. Plasma ALT and AST activities were not 
different between any groups (Table 3.13).  
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Figure 3.29: CS (A), HCHF (B), CSb (C), HSb (D). Examples of haematoxylin and 
eosin-positive inflammatory cells are indicated by “INF”, and examples of fat vacuoles 
are indicated by “FV”.  
Log-transformed TLR4 expression in the liver was lower in the CS and CSb groups. 
Expression of TLR4 was increased in the HSb groups compared to HCHF, Figure 3.30. 
two-way ANOVA indicated a significant effect of diet (<0.0001), 5% whole sorghum 
(0.0167), and no interaction effect (0.3947).  
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Figure 3.30: TLR4 Expression in 
the liver determined by semi-
quantitative ELISA. Differing 
lower-case superscript letters 
indicate significant difference at 
p<0.05, determined by one-way 
ANOVA.  
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GLUT2 liver values were tested for outliers. One value was removed from the CS 
group, while two each were removed from the HCHF, CSb and HSb groups. Log-
transformed data showed that only the HSb group had increased GLUT2 expression, 
higher than the two control groups (Figure 3.31). Two-way ANOVA indicated that 
only intervention was a significant main effect (p=0.008). 
 
Left ventricle and septum, and right ventricle wet weights were increased in the high 
fat feeding model, but were not corrected by the 5% sorghum supplement (Table 3.14). 
Systolic blood pressure was increased by HCHF feeding, and not changed by sorghum. 
Collagen deposition in the heart did not differ between any groups. These changes are 
consistent with there being no difference in diastolic stiffness with 5% raw sorghum 
consumption, although correlation between the diastolic stiffness and collagen 
deposition was not significant (r2=0.3293, p=0.4261), as shown in Figure 3.32 and 
Figure 3.33.  
 
Figure 3.32: Diastolic stiffness constant (κ, unitless), and picrosirius red area %, 
ventricular sections of CS, HCHF, CSb and HSb. Different lower-case letters indicate 
a significant difference at p<0.05 by one-way ANOVA.  
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Figure 3.31: GLUT2 expression 
in the liver determined by semi-
quantitative ELISA. Differing 
lower-case superscript letters 
indicate significant difference at 
p<0.05, by one-way ANOVA.  
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Figure 3.33: Left ventricular sections of CS (A), HCHF (B), CSb (C) and HSb (D) 
stained with picrosirius red and illuminated under polarised light at 510-560nm at 20x 
magnification.   
A B 
C D 
Table 3.14: Hepatic and cardiovascular parameters of CS, CSb, HCHF and HSb-fed rats at 16 weeks of protocol.  
 
Differing superscript, lower-case letters indicate a significant difference at p<0.05 determined by one-way ANOVA. Significant sources 
of variation are indicated in the far left three columns determined by two-way ANOVA.  
 
Diet Sorghum Interaction
Liver wet weight (mg/mm tibial length) 215 ± 5 a 222 ± 7 a 339 ± 23 b 298 ± 8 b <0.0001 0.1965 0.068
Plasma ALT (U/L) 27.0 ± 2.0 a 25.4 ± 2.2 a 26.4 ± 1.4 a 23.1 ± 1.3 a 0.4173 0.1734 0.6458
Plasma AST (U/L) 70.4 ± 5.0 a 61.9 ± 2.1 a 67.8 ± 7.1 a 60.1 ± 4.0 a 0.6593 0.1117 0.9296
Systolic blood pressure (mmHg) 136 ± 2.0 ab 131 ± 1.0 a 140 ± 1.8 b 142 ± 1.5 b 0.0006 0.2648 0.0642
Left ventricle + septum (mg/mm tibial length) 20.1 ± 0.9 a 20.9 ± 1.0 ab 23.8 ± 0.5 b 22.4 ± 0.6 ab 0.0018 0.7269 0.1483
Right ventricle (mg/mm tibial length) 4.2 ± 0.3 a 4.6 ± 0.3 ab 5.32 ± 0.2 b 5.42 ± 0.2 b 0.0005 0.339 0.5469
CS CSb HCHF HSb
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Aortic relaxation in response to acetylcholine was impaired in the HCHF model 
compared to the CS. This was improved with the addition of 5% raw sorghum in the 
HCHF model, with no detrimental effects when sorghum was added to the CS diet 
(Figure 3.34). Diet and sorghum were major sources of variation in the noradrenaline 
curve based on a two-way ANOVA, however statistical significance was not reached 
between the HCHF and CS model responses. Maximal force of contraction in response 
to noradrenaline was increased in the HSb from HCHF. No difference was found for 
the potency or maximal responses between any groups for responses to noradrenaline, 
sodium nitroprusside or acetylcholine.   
 
3.3.5 Gastrointestinal structure and function  
No effects of diet were evident in ileal reactivity to acetylcholine (Figure 3.35). A 
HCHF diet increased maximum contraction force in the colon, and the presence of 
sorghum in the CS diet reduced the colonic reactivity to acetylcholine (Figure 3.35). 
Potency did not differ between any diet groups for either gastrointestinal section.  
Figure 3.34: Thoracic aortic contractions 
in response to noradrenaline, sodium 
nitroprusside and acetylcholine. Values 
with different lower-case letters had 
different maximal force of contraction at 
p<0.05, by one-way ANOVA.  
 
 Figure 3.35: Left; ex vivo proximal colon contractility in response to acetylcholine 
stimulation. Right; ex vivo ileal contractility in response to acetylcholine stimulation.  
 
Results shown are mean ±SEM, lines showing differing lower-case letters had a 
significantly different maximal force of contraction, by one-way ANOVA p<0.05. 
Sucrose acted as a representative test for permeability of the stomach, with lactulose 
and mannitol as tests for the permeability of the stomach and small intestine, and 
sucralose as a measure for the entire gastrointestinal tract. Recovery of sugars in the 
urine was higher in the HCHF model for lactulose, sucralose, mannitol and sucrose for 
the 8-20 hour time period, Figure 3.36. Only lactulose recovery differed between the 
HCHF and HSb groups, where recovery in the 8-20 hour bracket was higher in the 
HSb group. Intervention with 5% sorghum in the CS diet did not affect the urinary 
recovery of any sugar (Figure 3.36 and Figure 3.37). 
93 
 
 
Figure 3.36: Percent recovery of sugars in urine over time. Differing lower-case letters 
indicate significant difference at p<0.05, determined by two-way ANOVA.  
 
Identification of outliers for occludin expression resulted in removal of two values for 
the CS, CSb, and HSb groups, and one from the HCHF group. Expression of occludin 
was increased in CSb from CS control. CS and HCHF did not differ and no effect of 
sorghum on occludin expression occurred in the high fat diet.   
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mannitol recovery. No differences 
were found between any groups.  
 
  Two outlier values were removed from the CSb group data of claudin-1 expression. 
Claudin-1 expression was unchanged by diet or intervention with sorghum.   
 
One outlier was removed from the HCHF data, and two from the HSb TLR4 data. 
TLR4 expression did not differ between the CS and HCHF diets. Addition of sorghum 
showed no significant change in either diet.   
 
Occludin and colon expression changes did not correlate with the changes in sugar 
recovery from the intestinal permeability analysis, as shown in Table 3.15. 
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Figure 3.38: Occludin expression 
in the colon determined by semi-
quantitative ELISA. Differing 
lower-case superscript letters 
indicate significant difference at 
p<0.05, by one-way ANOVA.  
 
Figure 3.39: Claudin-1 expression in 
the colon determined by semi-
quantitative ELISA. Differing lower-
case superscript letters indicate 
significant difference at p<0.05.  
 
Figure 3.40: TLR4 expression in 
the colon determined by semi-
quantitative ELISA. Differing 
lower-case superscript letters 
indicate significant difference at 
p<0.05 by one-way ANOVA.  
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Table 3.15: Pearson’s correlation P-values indicating no significant correlation 
between urinary sugar recovery and expression of proteins in the colon.   
    Expression 
    TLR4 Claudin-1 Occludin 
%
 u
rin
ar
y 
re
co
ve
ry
 Lactulose 0.634 0.930 0.341 
Mannitol 0.481 0.982 0.369 
Sucralose 0.726 0.748 0.200 
Sucrose 0.557 0.925 0.320 
 
3.4 Discussion 
Supplementation of sorghum into an obesogenic diet showed modest changes in 
several parameters of metabolic syndrome. Cholesterol reduction, improved liver 
physiology and improved glucose tolerance were the major findings, while average 
weight gain, final body weight, energy intake and body mass index were the 
physiological changes noted. Biochemical changes included increased liver TLR4 
liver expression and increased GLUT2 liver expression. Sorghum had no impact on 
gastrointestinal permeability or serum lipopolysaccharide concentrations.  
Scaling equations from rat to human models based on body surface area (382) or body 
weight (383) show that 5% sorghum in food equates to a daily dose of approximately 
28g or 34g sorghum in humans. These calculations are based on an estimated rat 
dietary intake of ~25g of food per day containing 5% sorghum, for a 500g rat, scaled 
to a 70kg human. 
Dyslipidaemia  
The most significant changes in metabolic parameters was normalised total plasma 
cholesterol with 5% sorghum in the HCHF model. This has significant ramifications 
for promotion of sorghum as a health food, placing it in similar realms to oats for 
marketing purposes. Other literature has shown that the lipid fraction of sorghum can 
contribute by inhibiting cholesterol absorption from the gastrointestinal lumen (182, 
184). Although the lipid fraction in whole sorghum is low, this indicates that the 
wholegrain has similar effects, as this is generally how human consumption would 
occur. 5-20mg of long-chain fatty alcohols, sourced from wholegrain, can increase 
HDL and decrease LDL concentrations (384). Wholegrain sorghum contains around 
0.23% long chain lipids, of which 37-40% are policosanols (on a dry matter w/w basis) 
(131). Equivalent human consumption in this model is around 30g per day, which 
would equate to approximately 25.5mg of policosanol ingestion, well above the 5-
20mg requirement.   
There have been links established with resistant starch supplementation and the 
normalisation of plasma cholesterol (385). One way in which sorghum and other 
sources of resistant starches cause this is by reduction of intestinal cholesterol and bile 
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absorption (385). Comprehensive reviews of phytochemicals including anthocyanins, 
phenolics and flavonoids indicated that digestion is required for their release from the 
matrix (386, 387) and therefore will they will exert some of their effects in the colon 
(388, 389). Anthocyanin degradation products, specifically protocatechuic acid from 
cyanidin 3-glucoside, promoted cholesterol efflux by increased expression of two 
cholesterol efflux regulatory proteins (390). Cyanidin 3-glucoside is present in 
sorghum at low concentrations (146), and would rely on interaction with the 
appropriate microbial community. Protocatechuic acid is present in red sorghum as a 
free phenolic acid (391). Not all studies agreed that sorghum consumption alters 
cholesterol in a rat model as some cited no changes (232). Sorghum consumption led 
to increased total plasma cholesterol concentration in a rat model of obesity in one 
study (392). The lack of changes in triglyceride and NEFA concentration indicated 
that sorghum cannot fully correct the dyslipidaemia associated with metabolic 
syndrome. 
This study was unable to determine the changes in LDL and HDL cholesterol. Rat 
models are not ideal for cholesterol-based studies, with a low similarity to lipid profiles 
seen in humans. Zucker diabetic fatty rats on a high fat diet showed low similarity 
(393). However, studies in humans showed no improvement in plasma cholesterol in 
overweight subjects caused by sorghum consumption (394). 
Pre-diabetes 
Addition of 5% sorghum to this high fat, high simple carbohydrate diet normalised 
post-prandial glucose tolerance. This outcome is very promising for application to 
humans for improvement of pre-diabetes; however, in a human study, sorghum did not 
improve glucose tolerance with 45 grams of flaked sorghum consumption per day 
(394). Extracts of sorghum showed antidiabetic effects (185, 207, 208). Sorghum 
consumption reduced glucose concentrations and insulin secretion in overweight cats 
when compared to a wheat-based diet, which reduces progression of pre-diabetes 
(395). Wholegrain consumption in general has been associated with reduced diabetes 
development (396, 397).  
There was no change in the pancreas that was associated with sorghum consumption. 
It was expected that there would be changes associated with the improved glucose 
tolerance in HSb and the poor glucose tolerance in HCHF. Impaired insulin release is 
a major cause of the increased peak blood glucose concentration in a high-fat model, 
caused by destruction of pancreatic β-cells once disease has progressed (398). 
Apoptosis of pancreatic β-cells is increased in both lean and obese type 2 diabetic 
groups, and is generally accompanied by decreased β-cell mass (399). Regeneration 
of β-cells can restore glucose tolerance (400). In this study, islet cell density was not 
altered, and no statistical changes in cell count or islet size occurred due to diet or 
sorghum. It would suggest that a mechanism other than restoration or preservation of 
b-cell mass is responsible for sorghum’s role in improving glucose tolerance. The 
changes are more likely related to the function of β-cells. Future studies should 
evaluate this.  
Fasting hyperglycaemia was not improved by sorghum, which suggests a lack of 
change in the pulsatile insulin release, or lack of improvement in sensitivity to pulsatile 
insulin release (401). Reduced peak glucose concentrations could be affected by 
improved peripheral sensitivity to insulin, improved release of insulin, or conversion 
from pro-insulin to insulin (402). The cause of the glucose tolerance improvement 
have not been elucidated in this study but do not appear to be related to β-cell mass.  
The dysfunction of the pancreas in metabolic syndrome is contributed to by 
inflammation (403). Most recently, the Whitehall Study linked increased pro-
inflammatory IL-6 (interleukin-6) and CRP (C-reactive protein) with increased fasting 
glucose and poor insulin response (368). Interleukin-1 (IL-1) and interferon-γ as pro-
inflammatory cytokines are implicated in the dysfunction of β-cells by initiation of 
nitric oxide production in islets (404). Consumption of anti-inflammatory compounds 
may reduce the metabolic problems caused by sub-clinical inflammation, however the 
mechanisms appear complex (405). The addition of multiple components of sorghum 
might reduce the inflammatory state. Sorghum methanol extracts reduced 
inflammation by up-regulation of anti-inflammatory PPAR-γ and reduced TNF-α 
(185), and improved glucose tolerance through reduced hepatic gluconeogenesis 
(406). Peripheral glucose clearance and hepatic function should be noted as a possible 
driver in reduced TAUC after glucose challenge in this study, with changes occurring 
in HSb liver GLUT2 expression. Increased GLUT2 is typically associated with 
impaired glucose tolerance due to its ability to release glucose into the bloodstream. 
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This is paradoxical to the improved glucose tolerance seen in the HSb group and the 
increased GLUT2 expression. In other studies, reduced GLUT2 expression occurred 
with improvement in diabetes (305, 310, 319, 325) and in diet-induced fatty liver 
disease (322).  
Cardiovascular and liver changes 
Few cardiovascular changes occurred due to sorghum consumption. There was 
reduced hypersensitivity to noradrenaline and acetylcholine with sorghum 
consumption in aorta from this high fat model. This may be due to a reduction in 
oxidative stress and a reduction in inflammation, as components of sorghum are widely 
shown to reduce oxidative stress and inflammation. In diabetes, there have been links 
correlating high plasma markers of chronic inflammation with macrovascular 
endothelial dysfunction (407). In obesity and insulin resistance, similar associations 
with CRP (C-reactive protein) have been demonstrated, which closely correlated with 
concentrations of pro-inflammatory cytokines, interleukin-6 and TNF-α (408). 
Consumption of other cereals such as millet reduced CRP concentrations in 
hyperlipidaemic states (392). Sorghum has not yet been directly linked to this and this 
study did not study inflammatory cytokine concentrations. Future research assessing 
the plasma inflammation makers will add weight to this knowledge. 
As noted previously, increased PPAR-γ may play a role in improving insulin 
sensitivity, however this receptor has also been implicated in reducing inflammation, 
particularly in endothelial cells (409). Studies in mice have shown increased PPAR 
expression with sorghum extract consumption (185). Future studies would benefit 
from determining expression and activation of PPAR. Anthocyanin-rich foods in 
general appear to have beneficial effects on the heart (410, 411), with sorghum being 
relatively unique as a widely grown commercial cereal crop which contains high 
concentrations of 3-deoxyanthocyanidins. Sorghum fed to rats showed a better in vivo 
anti-oxidative effect than purple rice or rhubarb rice (412).    
Liver function is impaired in metabolic syndrome with deposits of fat, alteration of 
enzyme activity, and increased glucose release. Sorghum did not change liver weights 
or amino acid transfer enzyme activities. Liver histology indicated that there was 
reduced steatosis, ballooning and fat deposits with sorghum consumption in the high 
fat diet. Sorghum extracts reduced cholesterol concentrations in the liver of rats (183) 
and mice (406), and in a hamster model improvements in liver were associated with 
the lipid fraction of sorghum extract (182). Aqueous sorghum extracts showed no 
adverse effects in healthy rats and were haematopoeitic at doses of up to 1600mg/kg 
per day (413). Wholegrain sorghum increased liver weight in overfed ducks more than 
a maize equivalent (414). Sorghum flour fed to rats on a hyperlipidaemic diet did not 
change liver enzyme activity (253).  
Liver TLR4 expression increased on the HSb diet. Typically, increased expression of 
TLR4 would result in an increased inflammatory response. Reduced TLR4 expression 
reduced inflammation and metabolic changes associated with metabolic syndrome 
(415). However, the effects of sorghum on TLR4 have not been studied. The reason 
for the increase in this study is unclear, and the lack of difference between the high 
and low fat diet controls does not shed any light on the cause.  
Gastrointestinal function 
Gastrointestinal contraction, as assayed by acetylcholine responsiveness, did not 
produce a clear indication of how sorghum or diet affects colonic reactivity. If 
anything, there were increased responsiveness in high-fat fed models which were not 
anticipated. Some data suggest that, in situations such as distal colitis, there was an 
increased colonic contractility in the proximal colon, and reduced contractility in the 
distal colon (416). Inflammation upregulated the α7 nicotinic acetylcholine receptor in 
mouse colon (417) which may explain the increased responses to acetylcholine 
stimulation. This may be similar to the changes seen in obesity. Studies in humans 
have suggested that in obese subjects there was a faster colonic transit time (178), and 
that high force contractions in the colon may be caused by inflammation (418) while 
others suggest that obesity decreased contraction (419). Compounds isolated by 70% 
methanol from Sorghum bicolor leaf caused relaxation of the isolated ileum of guinea 
pigs (420) and a reduced intestinal propulsion (421).  
One hypothesis was that increased gastrointestinal permeability would occur in a high-
fat high-carbohydrate model of obesity, which appeared to be the case. This is 
consistent with other studies of obesogenic diets (373, 422). Supplementing with 
sorghum did not improve the gastrointestinal permeability, and therefore the 
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gastrointestinal benefits at this level of supplementation are not evident. Mannitol is 
considered an indicator of absorption, while lactulose is an indicator of permeability, 
being a large molecule not taken up by villi. The increased lactulose recovery in the 
HSb rats indicated possible poorer gastrointestinal integrity, specifically in the 
stomach and small intestine.  
There may be a decreased expression of tight junction proteins caused by a high fat 
diet in obese animal models (177, 375, 423, 424). Claudin expression did not alter in 
any diet or intervention, although these were only studied these in the colon with intent 
to investigate links between LPS and colonic permeability. Occludin was increased 
from the CS control with sorghum, with no change in intestinal permeability. This 
result was not consistent with the intestinal permeability measurements and therefore 
another mechanism may be influencing the intestinal permeability. The lack of 
differences in tight junction expression between HCHF and HSb were consistent with 
the intestinal permeability study. Sorghum can contain mycotoxins which reduce 
claudin expression (425). In sensitive individuals, prolamin protein may reduce 
zonulin expression in the gastrointestinal tract (426), while sorghum arabinoxylans 
restored intestinal barrier function through improving tight junction proteins, mediated 
by the production of short chain fatty acids (427).  
The tight junction protein, zonula occludin-1 (ZO-1), expression was reduced in 
patients with irritable bowel syndrome, which corresponded to increased permeability 
(428). ZO-1 is the soluble anchor protein, while occludin and claudin are both 
transmembrane proteins. The responses between claudin-1 and occludin differed. 
Occludin appears more susceptible to changes than claudin. Some studies suggest that 
the changes do not occur in the large intestine with a high fat diet (424), which is where 
expression was studied in this research. LPS, among other TLR activators, are 
generated in the large intestine where the vast majority of the microbial population 
resides. It may be that it is primarily the diet itself, rather than the microbial factors 
influenced by diet, that caused the changes in a HCHF model (424). As this study was 
focussed on the interaction of LPS and TLR4, and their influences on intestinal 
permeability leading in metabolic syndrome, small intestinal changes in tight junctions 
were not tested, however future research should incorporate this.  
  
Metabolic endotoxaemia 
Serum LPS concentrations did not differ between any groups, and therefore its changes 
could not be linked to intestinal permeability or inflammation which lead to metabolic 
syndrome. There appears to be no influence of sorghum on the circulating 
concentrations of LPS.  
Studies which implicated LPS in metabolic syndrome development such as that used 
by Cani, et al. (238) used an aggressive approach whereby intraperitoneal injections 
of LPS induced metabolic changes. Whether this is the case in a “normal” diet-induced 
development of metabolic syndrome was unclear. This study was unable to find a 
sound correlation between LPS concentrations and the glucose tolerance, or even an 
effect of diet on serum concentrations of LPS. TLR4-mediated inflammation is a 
known mediator of inflammation induced by LPS, and is expressed by β-cells (429). 
TLR4 mediated insulin resistance in knockout mice populations (430). The complexity 
of the inflammatory pathways that have been associated with β-cell dysfunction and 
impaired glucose tolerance is the likely reason that no direct correlation was found. 
All inflammatory triggers, not only LPS, are important in addition to TLR4-mediated 
inflammation (431). Lipids can trigger inflammatory mediators including protein 
kinase C, protein kinase R and TLR4. Many stressors in obesity can imitate the JNK 
pathway (431). The presence of macrophages, and their inflammatory responses which 
include TLR2, TLR6 and TLR4 also contribute (432). All mechanisms are at play and 
addressing a single inflammatory indicator is insufficient to explain the changes in 
glucose tolerance, particularly where no significant effect of diet was noted. In future, 
metabolomics will aid to assess all facets of the process simultaneously and will give 
a much clearer understanding of how sorghum affects glucose tolerance and 
inflammation. While the expression of TLR4 was studied, and concentrations of LPS 
were assessed, the study lacked by not addressing TLR4 activation, initiated by 
circulating free fatty acids which mimic LPS (433, 434). 
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I hypothesised that LPS concentrations would be altered with both diet and sorghum 
consumption. LPS is an inflammatory mediator in the gastrointestinal tract, where 
significant amounts of LPS are excised from Gram-negative bacteria. TLR4-deficient 
mice appeared resistant to changes is colonic occludin and claudin that occur in a high 
fat diet (219), implicating its role in the process. It is well known that in inflammatory 
bowel disease, intestinal permeability increases. In studies, ulcerative colitis and 
Crohn’s disease showed increased TLR4 in epithelial cells of both the colon and ileum 
(435). Sorghum had no influence on the outcome, therefore is unlikely to influence the 
status of colonic TLR4 expression when consumed by humans, nor alter serum LPS. 
Lappi, et al. (218) hypothesised the changes in the large intestine were partly 
responsible for improved type 2 diabetes mellitus with wholegrain consumption. In 
this study, the two could not be directly associated.  
Body composition 
Sorghum did not reverse obesity. There were indications that sorghum affects energy 
intake and body weight gain indicated by two-way ANOVA. In rats, the protein 
content of the sorghum added to rat diets was a significant source of variance in body 
weight gain (436). The diet-intervention interactions are of interest, where the 
indication is that adding small amounts of sorghum into a low-fat diet may increase 
food intake and feed efficiency, where the opposite is true for supplementing into a 
high fat, high simple carbohydrate diet. These interactions suggest that the 
composition of the entire diet is important, even when low amounts of sorghum were 
consumed. Although the changes were minor, the supplement level is relatively low, 
equivalent to approximately 30g per day for a 70kg adult human. Recent studies by 
Stefoska-Needham, et al. (394) using 45g of flaked sorghum per day showed no 
change in weight loss on a restricted diet when comparing with 45g of white wheat 
flakes. The results we achieved in an animal model were comparable to this and 
overall, low amounts of sorghum are unlikely to have a significant change on body 
weight in humans as the key driver of body weight is calorie intake (437). Wholegrain 
millet (Sorghum vulgare), which has a similar composition to sorghum, did not affect 
body weight in hyperlipidaemic rats (392).  
The low digestibility of sorghum compared to other cereal grains is a concern with the 
use of sorghum in production animal diets where the goal is to maximise weight gain 
(91, 438). This led to a reduced weight gain in a high sorghum diet (367). Lean mass 
and organ weight are two major drivers of metabolic rate. Sorghum supplements in 
rats did not reduce lean mass or organ weights, which would suggest that it is unlikely 
to have a detrimental effect on overall metabolic rate and energy expenditure. This 
could be confirmed in the future with the use of metabolic cages such as OxyMax.  
The composition of the two diets is likely to impact the nutrient availability in vivo. 
Red sorghum contains tannins which may inhibit amylase activity which will reduce 
the breakdown of starch and therefore its energy availability (28, 259), although in a 
rat model it does not appear to be the case. The effects on amylase activity have been 
well characterised however there may also be effects on lipases and proteases. The 
formation of tannin-enzyme complexes may have reduced the digestion, as has been 
shown in other animal models (439), and therefore availability of both fats and proteins 
to the animal. During the 8 weeks of sorghum addition, there was no loss of lean mass 
in either group which would suggest that there is minimal risk of reduced amino acid 
absorption which would affect lean body composition. Bone mineral density showed 
a diet-sorghum interaction. Chelating properties of tannins reduce biological 
availability of minerals necessary for bone health, particularly during stages of growth 
(258, 259). The outcomes are unlikely to be clinically significant.  
Other considerations 
Sorghum contains components which may affect the digestibility of other components 
of the diet, and the protein and carbohydrates of sorghum itself (103). There is a strong 
indication that the effect of sorghum in the diet differs depending on the diet as a 
whole, indicated by the differing effects in the CS and HCHF diets. The food matrix 
components contribute to the bioavailability (440). Again, this is a complex response 
that requires more investigation. The matrix itself, the enzymes induced by the matrix, 
gut pH, microbial presence, fermentation status and transit time can all influence the 
uptake of compounds (290) in sorghum with the potential to improve metabolic 
syndrome and other health parameters. The digestion process altered bioavailability of 
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hydroxycinnamic acids (441) and the differing digestion from a rat model to human 
model will result in different outcomes.  
Identification and quantification of the bioactive compounds present in the whole grain 
sorghum used in this study would add considerable weight to the study. Knowledge of 
the individual components would provide a link between these compounds and the 
research outcomes. Given the vast differences in sorghum composition due to genetic 
and environmental factors, this would provide a baseline for further research. In the 
absence of this information, the effects cannot be well correlated with these 
components.  
High carbohydrate commercial cereal made of wheat, barley, maize and oats, eaten in 
conjunction with grape seed extract, reduced post-prandial plasma concentrations of 
dimeric and trimeric procyanidins; however, the concentrations of the monomeric 
forms, catechin and epicatechin, were increased when compared with sole 
consumption of grape seed extract (442). The high corn starch diet used in this study 
might have a similar effect, reducing uptake of bioactive compounds present in 
sorghum, particularly complex procyanidins however increasing the uptake of 
monomeric forms. Flavanols had higher post-prandial concentrations when consumed 
in the presence of both complex and simple carbohydrates (443). 
Presence of milk proteins as in the condensed milk of the HCHF diet may also change 
bioavailability. Milk proteins do not alter uptake of catechins or epicatechins (444, 
445). However, the presence of milk can affect the excretion profile over time of 
epicatechin and its conjugates, in addition to altering the position of conjugates 
moieties, particularly sulphates (446). This study used whole milk so the interaction 
of fat and carbohydrates may also play a role. Protein-rich foods did not improve or 
hinder catechin or epicatechin flavanol uptake (443). The development of a well-
designed meal with a combination of foods may optimise uptake of sorghum 
components, specifically the procyanidin groups.  
Increasing the percent of sorghum supplemented may have a more pronounced effect, 
and this is explored in subsequent chapters.   
Longitudinal changes in attitudes and culture toward food have become more 
important in a society where food is cheap, accessible and choice is relatively 
unlimited. Examples of changing positive attitudes to cereal foods include chia, 
quinoa, teff and spelt. Sorghum may follow the same path with the correct evidence to 
back its health benefits, as has been shown here, particularly for reduction of 
cholesterol concentrations.   
Addition of 5% in the diet in rats, equivalent to approximately 30g intake per day in 
humans, may not be sufficient to produce changes in some aspects of metabolic 
syndrome. The average wheat consumption in Australia is 87.7kg per annum per 
person, equating to approximately 240g per day (447). Replacement of refined wheat 
products with unrefined sorghum may result in greater benefits than the low level of 
supplementation in this study. This may be achieved by replacing wheat-based cereals, 
pasta, breads and bakery products with sorghum substitutes. Higher sorghum doses are 
studied in Chapter 4.  
3.5 Conclusion  
Supplementation of sorghum to diet at a level of 5% may be a very simple way to 
reduce the metabolic syndrome risk especially for correction of cholesterol 
concentrations, improved liver structure and glucose tolerance. These impacts could 
be translated to humans. It should be noted that there are multiple varieties of sorghum 
which differ in tannin, flavonoid and polyphenol content which are some of the 
functional components of sorghum. Overall, sorghum consumption showed very few 
negative effects, and had a positive impact on plasma lipid status, glucose tolerance 
and liver physiology. Furthering these trials to humans will give a more applicable 
understanding on the possible role of sorghum in human nutrition and as a functional 
food.  
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Chapter 4 - 20% Red and black sorghum flour in a rat model of metabolic 
syndrome 
4.1 Introduction 
Sorghum and its components have garnered interest for health promotion, due to the 
composition of both their macro- and micronutrients. Cereal grain products are a large 
part of the diet, and intakes are expected to remain relatively constant over the next 10 
years (447). Calorie consumption globally is increasing (447), which leads to 
metabolic sydrome (448). There is significant resistance to changing dietary habits that 
lead to obesity and metabolic syndrome, due to price, time and desire (449). On 
average, Australians consume approximately 240g of wheat per person per day (447). 
Can incorporating sorghum flour into the diet as a replacement for wheat flour present 
an easy and manageable way to alter the risk of metabolic sydrome? 
Sorghum contains multiple components which show potential to reduce the risk of, or 
improve, the symptoms of metabolic syndrome. This is partly due to its phenolic 
composition (272, 450, 451) and the potential of consumption of the unique sorghum 
polysaccharides (106). Most studies have investigated isolated components of 
sorghum, but a few have supported the theory of sorghum as a wholegrain to improve 
paramenters of metabolic syndrome.  
Studies in overweight cats showed that sorghum-based diets reduced post-prandial 
glucose concentrations, and may be preventative for type 2 diabetes (452). A portion 
of this may be attributed to the methanol-extractable portion (185) or ethanol-
extractable portion which include phenolic acids, 3-deoxyanthocyanidins, flavones, 
flavanones, catechins and tannins (207). Wholegrain sorghum flour muffins resulted 
in lower post-prandial glucose fluctuations than wheat muffins, attributed to high 
concentrations of resistant starches (206).  
Decreased cholesterol concentrations in a rat model of diet-induced metabolic 
syndrome were shown in Chapter 3 of this thesis. Improved serum lipid status is 
supported by other animal studies, however only with conusmption of sorghum 
extracts (181-185). Sorghum improved lipid status in human trials with the 
consumption of 100g per day (187). Effects on central adiposity are expected to be 
minimal (186), however long term sorghum consumption improved satiety responses 
(222) which may reduce calorie consumption. Little research exists on the 
cardiovascular effects of sorghum consumption, but wholegrain cereal consumption 
was inversely correlated with cardiovascular disease (397).  
The interactions between sorghum and the gastrointestinal tract and the effects of 
sorghum on metabolic syndrome have not been widely studied and need to be 
investigated. The addition of sorghum, which includes resistant starches, unique 
proteins and a combination of bioactive compounds could have similar beneficial 
effects to other cereal grains such as oats (450). Despite this, some evidence suggests 
that sorghum may cause problems. Dextran sodium sulphate-induced colitis injury in 
rat models was exacerbated in black and Sumac sorghum bran-supplemented studies 
compared with those supplemented with cellulose (453). The same study also showed 
lower gut microbial population diversity in animals consuming sorghum brans which 
contained high concentrations of tannins (453). Sorghum cereal consumption altered 
colonic microflora and improved biomarkers associated with cardiovascular disease 
such as gamma-glutamyl transferase (454). Circulating endotoxins such as 
lipopolysaccharides, which originate in the gut, have been linked to the development 
of metabolic syndrome (237, 455, 456). Improvements in metabolic syndrome with 
wholegrain intake may be due to reduced gastrointestinal permeability and reduced 
TLR4 (toll-like receptor 4) mediated inflammation (218). Wholegrains improve colon-
mediated inflammation and reduce post-prandial glucose concentrations (457). 
Wholegrain barley improves inflammation and markers of metabolic syndrome by 
changes in the colon (458).  
Red and black sorghum flours are two types which are commercially available for use. 
Although both are from the species Sorghum bicolor, they differ in colour and also in 
the composition of polyphenols. The unque combination of phenolics and their 
concentrations has led to the speculation that sorghum has nutraceutical properties. 
The 3-deoxyanthocyanidin pigments which result in the colours in sorghum are 
luteolinidin (orange to brown) and apigeninidin (orange to dark red). Other pigments 
include 5-methoxyapigeninidin (dark red), 7-methoxyapigeninidin, apigeniniden 5-
glycoside, 7-methoxyapigeniniden 5-glucoside, 5-methoxyluteolinidin, 7-
methoxyluteolinidin, and 5-methoxyluteolinidin 7-glucoside, apigenin, luteolin, 
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eriodictyol, eriodictyol 5-glycoside, kaempferol 3-rutinoside-7-glucuronide, 
naringenin (white), taxifolin (pale yellow (459)), taxifolin 7-glucoside, apiforol, 
luteoforol, catechin and procyanidin B1 (451). Black sorghum colour is due to higher 
concentrations of 3-deoxyanthocyanidins in the pericarp than red or tan lines, but also 
higher concentrations of flavanols and flavones (165). Colours can be affected by light, 
oxygen, solvent, present of oxidants and pH (460). Condensed tannins also contribute 
to the red or brown colouring in sorghum, and these are higher in red varieties (165).  
Sorghum flour is the most likely way for sorghum to be incorporated into the diet, due 
to increased reliance on packaged and processed food products (461). While 
wholegrains are beneficial for health, processing wholegrains alter the bioaccessibility 
and bioavailability, and therefore biological responses to the grain (88, 160, 272). The 
macronutrient composition in wholegrain sorghum and sorghum flour may appear 
similar at the outset but the milling process changes the structure of starch granules. 
Longer milling times generally result in reduced starches which are resistant to 
hydrolysis, and higher starch granule damage (462). Both of these properties increase 
digestibility of starch (463) by reducing the amount of resistant starches. Phenolic 
compounds are bound to starch granules and proteins, both covalently and by adhesive 
forces. The milling makes these components more available (159, 160) and as starches 
and proteins are digested they can release not only differing amounts of the complexed 
compounds, but also cause their release in different parts of the gastrointestinal tract 
(272).  
In this chapter, two different types of sorghum flour were tested in a rat model of diet-
induced metabolic syndrome to determine whether sorghum flour has benficial or 
detrimental effects on  physiology with specific reference to parameters of metabolic 
syndrome. I propose that the unique combination of phenolics in red and black 
sorghum will improve metabolic syndrome. I also suggest that part of the mechanism 
will be alteration of the colon environment which will influence circulating 
lipoplysachharides, which are known activators of TLR4-mediated inflammation 
which contributes to metabolic syndrome (Figure 4.41).    
 Figure 4.41: Sorghum’s potential for improving metabolic syndrome.  
4.2 Materials & Methods 
4.2.1 Ethics  
Approval for experimentation with 20% sorghum was granted under AEC approval 
number 15REA005 valid from 20th June 2015 to the 20th June 2018 by the Animal 
Ethics Committee of the University of Southern Queensland. All rats were treated and 
housed as per the NHMRC (National Health and Medical Research Council) 2014 
guidelines for the ethical treatment of animals. 
4.2.2 Rat Diet and Experimental Structure  
Seventy-two Male Wistar rats were randomly divided into 6 experimental groups of 
n=12. The groups were mCS (modified corn starch diet), mHCHF (modified high 
carbohydrate, high fat diet), mCRed (modified corn starch diet + 20% w/w red 
sorghum flour), mHRed (modified high carbohydrate, high fat diet + 20% w/w red 
sorghum flour), mCBlack (modified corn starch diet + 20% w/w black sorghum flour) 
and mHBlack (modified high carbohydrate, high fat diet + 20% w/w black sorghum 
flour). Partially de-branned red sorghum flour was donated by Maralong Milling Co 
(Toowoomba, Qld, Australia), and wholegrain black sorghum flour was purchased 
from Nu Life™ Market (Scott City, Kansas, USA).  
111 
 
For the first 8 weeks of the protocol, all mCS, mCRed and mCBlack rats received the 
control mCS diet and all mHCHF, mHRed and mHBlack rats received the control 
mHCHF diet as described in method 2.2. At eight weeks, the mCRed, mHRed, 
mCBlack and mHBlack groups were transferred to the treatment diet as indicated and 
remained on these diets until protocol completion.   
An additional 3.85 kJ/mL energy was added to calculations for the mHCHF, mHRed 
and mHBlack diets in fructose water.  
At 16 weeks, prior to termination, oral glucose tolerance (method 2.3), body 
composition (method 2.4) and systolic blood pressure (method 2.5) were determined. 
Rats had urine collected as per chapter 2.10.1. All rats were starved for 2 hours prior 
to termination. Rats were euthanised as per method 2.6.1. At termination, rats 
underwent serum collection (method 2.6.2), plasma collection (method 2.6.3), vascular 
reactivity (method 2.6.5), ileum and colon contractility (method 2.6.6), organ weights 
(method 2.6.7) and histological tissue collection (method 2.8.1). 10 rats per group 
underwent isolated heart perfusion (method 2.6.4), with the remaining two hearts 
preserved in formalin for histological analysis as per method 2.8.1. Plasma 
biochemistry was assessed on 8 rats per group for liver enzyme activity (method 2.7.1), 
and plasma lipid profile (method 2.7.2.). Collected serum was analysed for presence 
of endotoxins as per method 2.9. Liver and distal colon sections were assessed for 
expression of TLR4 (method 2.11.3). Distal colon sections were also assessed for 
occludin and claudin expression using methods 2.11.4. Urine samples collected prior 
to termination were prepared (method 2.10.2) and analysed as per method 2.10.3. 
Histological tissue samples were processed automatically (method 2.8.3) and 
sectioned (method 2.8.3). Liver, ileum, colon, pancreas and left ventricle were stained 
with haematoxylin and eosin (method 2.8.5.1). Separate sections of left ventricle were 
stained with picrosirius red (method 2.8.5.2). Microscopy and imaging were 
performed as per method 2.8.6.1, 2.8.6.2, 2.8.6.3 and 2.8.6.4. 
Statistical tests were performed with one-way ANOVA. Where a one-way ANOVA 
reported a significant difference between the means, these results are indicated as a 
significant difference at p<0.05, where lower-case letters differ. Further testing was 
carried out when a two-way ANOVA indicated a significant effect of sorghum or 
interaction. In this case, Student’s t-test was performed between the following 
comparisons: mCS-mHCHF, mCS-mCRed, mCS-mCBlack, mCS-mHRed, mCS-
mHBlack, mHCHF-mCRed, mHCHF-mCBlack, mHCHF-mHRed, and mHCHF-
mHBlack.  
The following null hypotheses were tested: 
1. There is no difference between the mCS and mHCHF diet on the parameter in 
question. 
2. There is no effect of sorghum addition to the base diet, i.e. the addition of 
sorghum to the mCS diet does not alter the outcome, or the addition of sorghum 
flour to the mHCHF diet does not alter the outcome.  
3. The addition of sorghum to the HCHF does not normalise an outcome to the 
CS control. 
4. The addition of sorghum to the CS diet does not change the outcome to be 
comparable to the HCHF control.   
4.3 Results  
4.3.1 Black and red sorghum flour composition 
Acidified methanol extracts of red and black sorghum flour show differing profiles. 
HPLC with detection at 210nm (Figure 4.42) indicated that the hydrophilic compounds 
were relatively similar between the two. However, red sorghum showed small peaks 
between 10.5 and 11.5 minutes which were not present in black sorghum flour extracts. 
Similarly, there were a number of peaks present between 13.5 and 14 minutes which 
were present in black sorghum flour extracts but not in red sorghum flour extracts.  
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Figure 4.42: 210nm UV detection of HPLC of acidified methanol extracts of red 
sorghum flour (top) and black sorghum flour (bottom). 210nm detection detects 
primarily hydrophilic compounds.  
Detection of anthocyanins were detected at 510nm. This wavelength will also detect 
3-deoxyanthocyanins and their glycosides. There was a marked difference in the 
compounds in red and black sorghum (Figure 4.43). The peaks at 7.5, 7.0, 6.1 and 5.8 
minutes were much higher in the red sorghum extract than that of the black sorghum. 
Several peaks were present between 13.0 and 15 minutes in black sorghum extract that 
were not detected in the red sorghum.  
 
Figure 4.43: 510nm UV detection of HPLC extracts of red sorghum flour (top) and 
black sorghum flour (bottom). 510nm detection primarily indicates anthocyanin 
presence.  
The 330nm profile (Figure 4.44) primarily indicates phenolic acids. This wavelength 
is also suitable for detection of flavones (153). These differ considerably between the 
red and black sorghum extracts. In black sorghum, the majority of phenolic acids 
eluted between 13.5 minutes and 14 minutes. These 3 peaks were absent, or present at 
very low amounts, in the red sorghum extract. There are two clusters of compounds in 
red sorghum extracts, four peaks between 10.5 and 11 minutes, and two between 12.3 
and 12.8 minutes, which are not present in the black sorghum extract.  
 
Figure 4.44: 330nm UV detection of HPLC separated acidified methanol extracts of 
red sorghum flour (top) and black sorghum flour (bottom). 330nm detection primarily 
indicates presence of phenolic acids.  
Despite both types of sorghum having compounds which are potentially bioactive, the 
composition of these extracts differs markedly and therefore their effect on the body 
may differ. Macronutrient profiles of the two flours are shown in Table 4.16.  
Table 4.16: Macronutrient profiles of red and black sorghum flour used in the dietary 
protocols.  
 
NR indicates not reported. 
Maralong Milling Red 
Sorghum Flour
NuLife Black Sorghum 
Flour
Energy (kJ)  1500 1463
Protein (g)  9.9 7.5
Fat, Total (g)  2.5 3.75
- Saturated (g)  0.4 0
 - Monounsaturated (g)  0.8 0
- Polyunsaturated (g)  1.2 NR
- Trans (g)  <0.01 NR
Fibre - Dietary (g)  5.8 5
Carbohydrates 70.7 (g)  70.7 77.5
- sugars (g)  <0.01 0
Sodium (mg)  <5mg 0
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4.3.2 Physiology and metabolism indicators  
The addition of red and black sorghum flour to the diet at 20% increased the caloric 
value of the mHCHF diet from 14.65 kJ/g to 17.65 kJ/g and 17.78 kJ/g, respectively. 
Addition to the mCS diet increased caloric value from 9.94 kJ/g to 12.94 kJ/g and 
13.08 kJ/g, respectively. At 8 weeks, all mCS groups showed a similar body weight, 
similarly in all mHCHF groups. The mHCHF, mHRed and mHBlack groups showed 
higher body weight than all other groups. At 16 weeks, the mCBlack and mCRed 
groups had higher body weight than mCS (Figure 4.45). The addition of 20% red 
sorghum flour did not affect body weight in the mHCHF diet, despite the increased 
calorie density of the food.  
 
 
Figure 4.45: Body weight changes over 16 weeks of the dietary protocol. ↑ indicates 
start of intervention with 20% red or black sorghum flours. Differing lower-case letters 
indicate a significant difference at 16 weeks (p<0.05) and differing upper case letters 
indicate a difference at 8 weeks (p<0.05).  
0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6
0
2 0 0
4 0 0
6 0 0
W e e k
B
o
d
y
 w
e
ig
h
t 
(g
)
m CS
mHCHF
mCRed
mHRed
m C B la ck
m HB la ck
­
a
b
c
d
A
B
Table 4.17: Physiological parameters of rats fed mCS, mCRed, mCBlack, mHCHF, mHRed, and mHBlack diets.  
 
Differing lower-case superscript letters indicate significant difference at p<0.05 determined by one-way ANOVA.  
 
Parameter Diet Intervention Interaction
Food intake (g/day) Week 0-8 36.6 ± 0.5 a 37.8 ± 1.0  a 37.0 ± 0.8 a 30.7 ± 1.1 b 27.5 ± 0.6  b 27.7 0.6 b 0.2391 0.0201 < 0.0001
Food Intake (g/day) Week 8-16 34.5 ± 0.7 a 26.8 ± 1.0  c 26.9 ± 0.5  c 31.7 ± 0.7 b 23.4 ± 0.6  c 22.7 ± 0.6  c < 0.0001 0.5844 < 0.0001
Water intake (g/day) Week 0-8 34.9 ± 2.7 a 24.3 ± 1.9  b 32.1 ± 1.5 a 21.6 ± 1.1 b 21.8 ± 1.3  b 21.4 ± 1.1 b 0.0568 0.6315 0.5989
Water Intake (g/day) Week 8-16 31.2 ± 3.4 a 21.1 ± 1.5  b 31.7 ± 2.3 a 22.3 ± 1.1 b 22.9 ± 1.3  b 25.7 ± 0.9 b 0.0052 0.0016 0.0142
Energy intake (kj/day) Week 0-8 363.9 ± 5.0 a 375.6 ± 9.7 a 368.0 ± 7.9  a 532.4 ± 16.9  c 486.6 ± 11.0  b 405.4 ± 8.9  ab < 0.0001 < 0.0001 < 0.0001
Energy intake (kj/day) Week 8-16 343.0 ± 7.2 a 346.3 ± 13.5  a 352.1 ± 6.6 a 550.4 ± 11.6 c 501.3 ± 9.1  b 404.7 ± 10.6  b < 0.0001 < 0.0001 < 0.0001
Feed efficiency (mg gained. kJ-1) Week 0-8 -2.0 ± 0.3 a -1.7 ± 0.3  a -1.6 ± 0.5  a 2.7 ± 0.3 b 2.2 ± 0.2  b 2.4 ± 0.2  b 0.917 0.454 < 0.0001
Feed efficiency (mg gained. kJ-1) Week 8-16 -0.2 ± 0.2 a 1.7 ± 0.2  b 3.8 ± 0.7  b 2.7 ± 0.2  b 3.1 ± 0.2  b 3.8 ± 0.3  b < 0.0001 0.0006 < 0.0001
Sorghum flour intake (g/day) 0.0 ± 0.0  a 5.4 ± 0.2 b 5.4 ± 0.1 b 0.0 ± 0.0  a 4.7 ± 0.1 c 4.5 ± 0.1 c < 0.0001 0.0022 < 0.0001
Bone mineral density (g/cm2) 0.17 ± 3E-3 a 0.18 ± 3E-3 a 0.16 ± 3E-3 a 0.18 ± 2E-3 b 0.18 ± 3E-3 b 0.18 ± 2E-3 ab 0.0003 0.7474 < 0.0001
Bone mineral content (g by DXA) 9.75 ± 0.31 c 11.39 ± 0.37  c 12.56 ± 0.54  b 15.28 ± 0.41  a 15.07 ± 0.74  a 15.87 ± 0.71  a 0.0027 0.1181 < 0.0001
Total body fat mass (g by DXA) 42.2 ± 6.5 a 59.1 ± 11.9 a 88.6 ± 14.6 a 170.2 ± 10.4 b 151.1 ± 18.2 b 168.8 ± 21.0 b 0.0188 0.3008 0.0065
Total body lean mass (g by DXA) 248.2 ± 3.9 a 274.0 ± 5.5 b 291.1 ± 14.6 c 308.4 ± 8.2 c 327.0 ± 8.5 c 315.6 ± 7.1 c 0.0015 0.0742 < 0.0001
Lean:Fat mass ratio 7.4 ± 1.0 a 5.6 ± 0.8 a 4.0 ± 0.7 b 1.9 ± 0.1 b 2.4 ± 0.4 b 2.2 ± 0.4 b 0.012 0.0037 < 0.0001
Retroperitoneal fat (mg/mm tibial length) 150.3 ± 12.3 a 163.3 ± 16.7 a 153.8 ± 21.2 a 394.2 ± 34.4 b 363.8 ± 23.7 b 352.2 ± 49.0 b 0.8035 0.6789 < 0.0001
Epididymal fat (mg/mm tibial length) 67.1 ± 6.8 a 88.0 ± 9.7 ab 91.0 ± 13.0 ab 143.3 ± 16.0 b 176.7 ± 13.2 b 197.3 ± 25.4 b 0.0411 0.6214 < 0.0001
Omental fat (mg/mm tibial length) 97.7 ± 6.6 a 111.2 ± 11.8 a 95.9 ± 10.3 a 209.9 ± 10.9 b 203.7 ± 15.0 b 186.9 ± 23.1 b 0.5045 0.7129 < 0.0001
Total abdominal fat pad (mg/mm tibial length) 315.1 ± 22.7 a 362.5 ± 35.8 a 340.7 ± 42.6 a 747.4 ± 58.3 b 744.2 ± 49.7 b 736.4 ± 94.3 b 0.9227 0.8974 < 0.0001
Total abdominal fat pad (mg/mm tibial length) 315.1 ± 22.7 a 340.7 ± 42.6 a 744.2 ± 49.7 b 362.5 ± 35.8 a 747.4 ± 58.3 b 736.4 ± 94.3 b 0.9227 0.8974 < 0.0001
mHBlackmCS mCRed mCBlack mHCHF mHRed
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Feed efficiency was higher in the mHCHF than mCS at 8 and 16 weeks. Sorghum did 
not affect feed efficiency in the HCHF diet. In the mCS diet, red and black sorghum 
increased feed efficiency (Table 4.17). Feed intake was lower in the mHCHF than 
mCS in the first 8 weeks. Food intake was decreased from controls in the mCRed, 
mCBlack, mHRed, and mHBlack. The addition of red or black sorghum flour to the 
mCS diet resulted in the largest decrease in food intake, with similar decreases between 
sorghum types. Energy intake was higher in the mHCHF than mCS in the first and 
second 8 week periods. Energy intake was not changed by adding sorghum flour to the 
mCS diet, but addition to the mHCHF diet reduced energy intake (Table 4.17).  
Despite the decrease of food volume intake with sorghum supplementation in both 
diets, energy intake did not necessarily reduce, due to increased calorie density of food. 
For the same energy intake, there was a higher feed efficiency in the mCRed and 
mCBlack groups (Table 4.17). mCRed group gained 33±5g over weeks 8-16, and 
mCBlack gained 67.8±7g. For the same energy intake, the mCS group lost an average 
of 3±3g. This change was from both lean and fat mass increase, as indicated by 
increased lean mass as shown in Table 4.17. Lean mass changes were not associated 
with changes in myofibril diameter (Figure 4.46). 
Fat mass was increased in the mHCHF group compared with the mCS group. 
Supplementation with sorghum flour did not affect fat mass in the mHCHF diet. Lean 
mass was increased with the addition of black and red sorghum flour to the mCS diet, 
but neither intervention had an effect in the mHCHF diet (Table 4.17).  
The ratio of lean:fat mass was higher in mCS than mHCHF groups. The mCBlack 
group showed a reduced lean:fat mass ratio from the mCS control. The addition of 
sorghum flour to the mHCHF diet did not alter lean:fat mass ratio from 1.89±0.11 
(Figure 4.46). 
 
 Figure 4.46: Lean:fat mass ratio at 16 weeks (left) and skeletal muscle myofibril width 
(right). Differing lower-case letters indicate significant differences at p<0.05 
determined by one-way ANOVA.  
Total abdominal fat pad weights, normalised to tibial length did not differ between the 
mCS control and the mCRed and mCBlack groups. Fat pad mass was increased in all 
high fat, high carbohydrate diets from mCS. Addition of sorghum flour did not alter 
the total fat pad mass in either diet as indicated in Table 4.17.  
Bone mineral density was higher in the mHCHF group compared with the mCS group, 
as was bone mineral content. Bone mineral content was higher in all high 
carbohydrate, high fat based diets (mHCHF, mHRed, mHBlack) compared with the 
corn starch diets. This is likely a reflection of the elevated bone mineral density and 
higher overall body size and comparative bone content. Two-way ANOVA indicated 
that both diet and supplementation were factors contributing to bone mineral content, 
with p values of <0.0001 and 0.0027 respectively.  
4.3.3 Blood glucose regulation, dyslipidaemia and lipopolysaccharides 
After 8 weeks of feeding, the glucose TAUC was increased from the mCS control in 
the mHCHF and mHRed groups. Data shown in Table 4.18 indicate that the mHBlack 
group did not develop changes in TAUC expected for metabolic syndrome, with no 
difference from the mCS control. Additionally, the mCBlack group had lower fasting 
blood glucose concentrations than the mCS controls, and mHBlack showed fasting 
glucose concentrations similar to mCS. As this occurred prior to intervention, it cannot 
be attributed to sorghum and suggests an issue with the group of rats used for those 
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two interventions purchased from ARC, or another environmental problem. For this 
reason, changes from 8 weeks to 16 weeks were assessed, in addition to changes from 
the control groups. Red sorghum flour changes appear reliable, as these rats developed 
the expected metabolic changes, comparable to the control rats by 8 weeks. Changes 
in fasting glucose concentrations from 8 weeks to 16 weeks showed that mCS, 
mHCHF and mCBlack groups had an increased fasting glucose concentration at 16 
weeks compared with their 8 week tests (Figure 4.47). The mHBlack group showed 
more impaired glucose tolerance at 16 weeks, than at 8 weeks, while no others changed 
significantly from their 8 week values.    
 
Figure 4.47: Changes in glucose TAUC (area under curve), and fasting glucose blood 
concentrations between the 8-week test, and 16 week tests. Differing lower-case letters 
indicate significantly different change from control, determined by one-way ANOVA 
at p<0.05. * indicates significantly different change from 8-week glucose TAUC, at 
p<0.05 determined by non-parametric T-test.  
Average islet area did not differ between the mHCHF and mCS control groups. The 
only differences noted were between the mCS and the mHBlack or mHRed groups, 
which both had lower pancreatic islet size than the mCS control. The cell count did 
not differ between the mCS and mHCHF groups. mHRed group had lower cell counts 
per islet than both the mCS and mHCHF control groups. Islet density was higher in 
the mHCHF than mCS. Red or black sorghum flour increased density in the mCS diet. 
The only group which did not differ from the mCS control was the mHRed group, 
however it did not differ from mHCHF (Figure 4.48). 
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Figure 4.48: Pancreatic islet 
cell area, cells per islet and cell 
density. No differences were 
detected by one-way ANOVA. 
Differences detected by pair-
wise t-tests (Mann-Whitney) 
are indicated by capped lines.   
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Table 4.18: Blood glucose and plasma lipids of rats fed mCS, mCRed, mCBlack, mHCHF, mHRed, and mHBlack diets.  
Differing lower-case letters indicate significant differences at p<0.05 determined by one-way ANOVA. 
Parameter Intervention Diet Interaction
Fasting Blood glucose (mM) 8 week 3.3 ± 0.2 a 4.4 ± 0.2  b 3.5 ± 0.1  a 4.4 ± 0.1  b 5.3 ± 0.2  c 4.3 ± 0.1  b 0.5512 < 0.0001 < 0.0001
 TAUC Blood Glucose 8 week 695 ± 20 a 732 ± 29 a 640 ± 27 a 838 ± 19 b 863 ± 17 b 727 ± 14 a 0.4127 < 0.0001 < 0.0001
Fasting Blood glucose (mM) 16 week 4.0 ± 0.2 a 4.6 ± 0.2
 a
b 4.0 ± 0.2
 a 4.9 ± 0.1  b 5.4 ± 0.1  b 4.6 ± 0.2  ab < 0.0001 < 0.0001 < 0.0001
 TAUC Blood Glucose 16 week 724 ± 20 a 740 ± 27 ab 676 ± 16 a 841 ± 28 b 866 ± 48 ab 785 ± 18 ab 0.9447 0.024 < 0.0001
Plasma total cholesterol (mM) 1.71 ± 0.11 a 1.71 ± 0.10 a 1.78 ± 0.118 a 1.66 ± 0.13 a 1.70 ± 0.06 a 1.65 ± 0.10 a 0.3099 0.7525 0.0596
Plasma triacylglycerides (mM) 0.48 ± 0.04 a 0.64 ± 0.06  a 1.09 ± 0.133  ab 1.80 ± 0.36 b 1.49 ± 0.42 ab 2.44 ± 0.44  b 0.0599 < 0.0001 < 0.0001
Plasma non-esterified fatty acids (mM) 1.75 ± 0.17 a 2.44 ± 0.16  a 2.81 ± 0.198 a 4.78 ± 0.17  b 3.68 ± 0.61  b 4.49 ± 0.44  b < 0.0001 0.0003 < 0.0001
mHRed mHBlackmCS mCBlackmCRed mHCHF
Cholesterol concentrations did not differ between the mCS and mHCHF groups, nor 
any other groups as indicated in Table 4.18. Plasma triglyceride concentrations were 
elevated in the mHCHF group from the mCS control. The addition of red sorghum 
flour to the mCS diet did not alter triglyceride concentrations, however the mCBlack 
group showed triglyceride concentrations comparable to both mCS and mHCHF. 
Triglyceride concentrations in the mHRed group were comparable to mCS and 
mHCHF. There was a large variability in the concentrations within the mHRed group 
ranging from 3.51 to 0.51 mM, therefore results should be interpreted with caution. 
Black sorghum flour did not reduce the triglycerides concentrations in the mHBlack 
group. Plasma NEFA concentrations were increased in mHCHF from the mCS. 
Addition of sorghum flour did not alter NEFA concentrations in either diet or group 
(Table 4.18).    
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Figure 4.49: Serum LPS 
concentrations. Top row indicates 
the division of rats into progeny or 
time groups. Bottom row indicates 
the combined results.  Differing 
lower-case letters indicate a 
significant difference at p<0.05 
determined by one-way ANOVA.  
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Serum LPS concentrations did not differ with addition of sorghum flour, red or black. 
It appears that there were differences between the red sorghum flour supplementation 
and black sorghum flour supplementation. As these interventions were carried out at 
different times, it is not clear whether changes were due to the sorghum itself or 
another time-based factor such as progeny differences in rats. The results shown in 
Figure 4.49 have been interpreted with caution. There were differences in control 
groups which were carried out at different times. For controls carried out at the same 
time as the red sorghum flour intervention, the mCS group had a serum LPS 
concentration 4 times higher than that of the mCS controls carried at the same time as 
the black sorghum flour intervention.  
4.3.4 Liver and cardiovascular structure and function  
Normalised liver wet weight was higher in the mHCHF, mHBlack and mHRed groups 
than the mCS, mCBlack and mCRed groups. Addition of sorghum did not affect liver 
weight. Histology indicated that there was ballooning and fat deposition in the 
mHCHF livers, shown in Figure 4.50. There was a reduction in the ballooning and fat 
deposition in the mHRed group, which appeared comparable to mCS. In the mHBlack 
group, there was a reduction in markers of steatosis but these were not normalised to 
mCS.   
 
 
 
 
 
 
  
  
  
Figure 4.50: Haematoxylin and eosin staining of liver sections (10µm) under 20x 
magnification. mCS (A), mHCHF (B), mCRed (C), mHRed (D), mCBlack (E), 
mHBlack (F). “INF” indicates inflammatory cell, “FV” indicates fat vacuole. 
Plasma AST activities were higher in the mCS group compared with the mHCHF 
group. Addition of sorghum to either diet only resulted in a change in the mCBlack 
group, where AST activity was comparable to mHCHF. Plasma ALT activities were 
not altered by diet or intervention. The AST/ALT ratio was lower in mHCHF than 
mCS. All other groups were statistically comparable to the mCS and mHCHF. This 
indicated a possible increase in mCS sorghum flour supplemented rats and a possible 
A B 
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reduction in the mHRed and mHBlack rats, supported by significant interaction effect. 
Creatine kinase activities did not change between groups. Lactate dehydrogenase 
activity was higher in the mCS group than all other groups, as indicated in Table 4.19.  
 
 
 Table 4.19: Cardiovascular and liver structure and function parameters of rats fed mCS, mCRed, mCBlack, mHCHF, mHRed, and 
mHBlack diets.  
Differing lower-case letters indicate significant differences for a given parameter at p<0.05 determined by one-way ANOVA. 
Abbreviations are as follows: ALT (alanine transferase), AST (aspartate transferase), CK (creatine kinase), LD (lactate dehydrogenase). 
 
 
Parameter Intervention Diet Interaction
Systolic Blood Pressure 16 week (mmHg) 135 ± 0.5 a 140 ± 1.8 a 132 ± 1.7 a 139 ± 0.6 a 133 ± 2.3 a 143 ± 4.7 a 0.1329 0.5739 < 0.0001
Left ventricle + septum (mg/mm tibial length) 17.61 ± 0.91 a 18.21 ± 0.58 a 17.07 ± 1.65 a 23.89 ± 0.97 b 20.14 ± 0.62 ab 22.86 ± 1.26 b 0.087 0.3361 < 0.0001
Right ventricle (mg/mm tibial length) 4.64 ± 0.37 a 4.30 ± 0.22 a 3.77 ± 0.43 a 6.35 ± 0.36 b 4.90 ± 0.36 ab 5.24 ± 0.35 ab 0.3719 0.0096 0.001
Liver wet weight (mg/mm tibial length) 184.10 ± 6.65 a 216.30 ± 10.98  a 209.70 ± 20.01  a 340.60 ± 9.05 b 309.80 ± 8.61  b 300.70 ± 27.94 b 0.0851 0.8693 < 0.0001
Diastolic stiffness constant (κ)  24.9 ± 0.30  a 25.6 ± 0.30 ab 29.8 ± 1.0 c 27.50 ± 0.40  b 26.9 ± 0.30  ab 26.6 ± 0.20 ab 0.0014 0.6076 < 0.0001
Plasma ALT activity (U/L) 31.7 ± 2.2  a 30.1 ± 2.0  a 26.4 ± 1.8  a 32.4 ± 5.3  a 25.4 ± 1.1  a 25.8 ± 1.3 a 0.0116 < 0.0001 0.0414
Plasma AST activity (U'L) 93.3 ± 6.2  a 89.6 ± 8.4  a 64.5 ± 3.4 b 65.3 ± 4.3  b 70.6 ± 3.1  b 68.1 ± 3.5  b < 0.0001 < 0.0001 < 0.0001
Plasma ALT/AST Ratio 3.0 ± 0.4 a 3.0 ± 0.2 ab 2.5 ± 0.1 ab 2.1 ± 0.3 b 2.8 ± 0.1 ab 2.7 ± 0.2 ab < 0.0001 0.0004 0.0001
Plasma CK activity (U/L) 99.5 ± 11.6 a 104.1 ± 10.5 a 88.1 ± 12.2 a 117.8 ± 25.6 a 87.0 ± 17.9 a 121.0 ± 15.1 a 0.0005 0.09 0.0241
Plasma LD activity (U/L) 273.8 ± 29.2 a 188.4 ± 19.9 b 170.4 ± 16.0 b 218.0 ± 62.7 b 186.3 ± 15.3 b 166.4 ± 11.5 b 0.0195 < 0.0001 0.0188
mHBlackmCS mCRed mCBlack mHCHF mHRed
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GLUT2 expression did not differ between the mCS and mHCHF groups, nor any 
intervention groups, Figure 4.51.  
 
Figure 4.51: GLUT2 expression in liver determined by semi-quantitative ELISA. No 
significant differences were noted at p<0.05 determined by one-way ANOVA.  
Liver TLR4 expression did not differ between the mCS and mHCHF. Sorghum 
addition to the diet did not change expression in either diet.  
 
Figure 4.52: Liver TLR4 expression determined by semi-quantitative ELISA. No 
significant difference between CS and HCHF, using a one-way ANOVA, p<0. 05 
determined by one-way ANOVA. 
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Normalised left ventricle + septum weight was increased in the mHCHF group from 
the mCS control. Addition of sorghum partially reduced weight in the mHRed group 
to comparable to the mCS control (Table 4.19). Intervention had no effect in any other 
group. Right ventricle weight was higher in the mHCHF group than mCS. The mHRed 
and mHBlack groups showed a partial reduction in right ventricular weight with no 
difference from mCS, however not different from mHCHF. Diastolic stiffness was 
increased in the mHCHF from mCS. Diastolic stiffness of mHRed and mHBlack was 
comparable to both the mCS and mHCHF. The mCBlack group had a higher diastolic 
stiffness (κ) than all other groups (Table 4.19).  
 
 
Figure 4.53: Picrosirius red staining indicating the % type I and type III collagen 
deposition in the left ventricle. No significant difference was found at p<0.05 
determined by one-way ANOVA.  
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Figure 4. 54:  Picrosirius red stained left ventricle sections, 20x magnification. Bright 
red striations indicate deposition of collagen (Type I and Type III fibres). mCS (A), 
mHCHF (B), mCRed (C), mHRed (D), mCBlack (E), mHBlack (F).  
 
A B 
C D 
E F 
 Thoracic aortic force of contraction with exposure to noradrenaline was greater in the 
mHCHF group, than mCS. The mHBlack group had higher reactivity than all other 
groups. There was no significant difference between the mCS group and the mHRed 
or mHBlack group, yet there was also no significant change from the mHCHF group. 
Response to sodium nitroprusside did not differ between any group for any 
concentration as shown in Figure 4.55.  
Responses to acetylcholine did not differ between the mCS and mHCHF groups. All 
treatment groups had a reduced force of contraction.   
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of isolated vessel in response to 
noradr naline, sodium nitroprusside or 
acetylcholine. Differences in 
maximum force of contraction are 
indicated by differing lower-case 
letters determined by one-way 
ANOVA, p<0.05.  
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4.3.5 Gastrointestinal function 
No changes in maximum ileal force of contraction to acetylcholine were noted between 
any diets, as is indicated in Figure 4.56. The minimal concentration required for 
contraction did not differ between the mCS and mHCHF groups. The minimum 
concentration required to elicit a response was lower in the mHRed and mHBlack 
groups than in the mHCHF control. The TAUC of the curves indicated the overall 
responsiveness of the ileum. These values did not differ between any groups.  
 
            
There were no differences in maximal colonic contraction to acetylcholine in the mCS 
and mHCHF diets. No differences in minimum concentration of acetylcholine required 
for contraction, or total dose-response area under curve were found between groups. 
The overall p value for one-way ANOVA of minimum concentration of acetylcholine 
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Figure 4.56: Force of contraction of 
isolated ileum sections in response to 
acetylcholine exposure (a) total area 
under curve (b) and minimum 
concentration required for contraction 
(c). Significant differences by one-
way ANOVA are indicated by 
differing lower-case letters. 
Differences detected by pair-wise t-
tests are indicated by capped lines.   
 
required for response was 0.0464, therefore the null hypothesis cannot be rejected in 
this case.  
Further investigation using t-tests indicated that addition of black sorghum flour to the 
mHCHF diet lowered the minimum concentration required for a response, to a level 
that was comparable with the mCS group. Minimum acetylcholine concentration 
required for a response was reduced in mCRed from mCS (Figure 4.57).  
   
                 
Colon TLR4 expression did not differ between any experimental or control groups, 
Figure 4.58. 
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Figure 4.57: Dose-response curves 
of force of contraction of isolated 
proximal colon sections in response 
to acetylcholine exposure (left). 
Difference by one-way ANOVA 
(p<0.05) is shown by differing 
lower-case letters. Significant t-test 
differences are indicated by capped 
lines.   
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Figure 4.58: Colon TLR4 expression as determined by semi-quantitative ELISA. No 
significant differences were noted at p<0.05 determined by one-way ANOVA.  
Colon claudin expression did not differ between mHCHF and mCS model after 16 
weeks, Figure 4.59. No differences were evident after supplementing with either black 
or red sorghum flour.  
 
Figure 4.59: Claudin expression as determined by semi-quantitative ELISA. No 
significant differences were noted at p<0.05 determined by one-way ANOVA.    
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Colon occludin expression was higher in mCS compared with mHCHF group after 16 
weeks. 20% red sorghum flour in the mCS diet did not alter occludin expression from 
mCS. In both the mHRed and mHBlack groups, addition of sorghum did not result in 
a difference from mHCHF, nor did it differ from mCS. Results are shown in Figure 
4.60. 
 
Figure 4.60: Colon occludin expression. Differing lower-case letters indicate 
significant difference, determined by paired t-tests against the mCS and mHCHF 
control at p<0.05 determined by one-way ANOVA.  
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Figure 4.61: Lactulose:mannitol ratio of percent recovery. Differing lower-case letters 
indicate significant differences by one-way ANOVA at p<0.05.  
The lactulose:mannitol ratio based on total percent recovery or orally gavaged sugars 
was higher in the mHCHF group compared with the mCS group. Addition of sorghum 
flour to the mCS diet did not alter the ratio of recovered sugars. Addition of either 20% 
black or red sorghum flour to the mHCHF diet did not alter the ratio of recovery from 
the mHCHF group. It also did not differ from the mCS control.  
Percent recovery of individual sugars only differed between mCS and mHCHF for D-
mannitol and sucralose in the 8-20 hour time-period. For both compounds, the percent 
recovery was higher in mHCHF than mCS. Results discussed are for the 8-20 hour 
time period. Mannitol recovery was not affected by sorghum in the mCS diet. Both 
mHBlack and mHRed showed no statistical difference from mCS or mHCHF. 
Sucralose percent recovery in mCBlack, mHBlack and mHRed did not differ from 
either the mCS or mHCHF controls.  Results are shown in Table 4.20.  
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Table 4.20: Percent recovery of orally gavaged sugars from urine over a 20-hour period.  
 
Time (hours) mCS mHCHF mCRed mHRed mCBlack mHBlack 
Sucrose 0-3  0.05 ± 0.02 a 0.05 ± 0.01 a 0.17 ± 0.04 a 0.07 ± 0.02 a 0.05 ± 0.02 a 0.04 ± 0.02 a 
 
3-8 0.20 ± 0.07 a 0.18 ± 0.03 a 0.32 ± 0.07 a 0.11 ± 0.02 a 0.17 ± 0.02 a 0.19 ± 0.07 a 
 
8-20 0.26 ± 0.06 a 0.24 ± 0.09 ab 0.05 ± 0.02 b 0.34 ± 0.05 ab 0.42 ± 0.09 ab 0.32 ± 0.07 ab 
Lactulose 0-3  0.31 ± 0.14 a 0.21 ± 0.08 a 0.54 ± 0.16 a 0.61 ± 0.32 a 0.25 ± 0.10 a 0.10 ± 0.06 a 
 
3-8 1.29 ± 0.72 a 1.26 ± 0.32 a 0.80 ± 0.20 a 0.90 ± 0.14 a 0.88 ± 0.14 a 1.19 ± 0.20 a 
 
8-20 0.90 ± 0.30 a 1.20 ± 0.40 ab 0.20 ± 0.07 ab 1.53 ± 0.24 ab 2.66 ± 1.24 b 1.63 ± 0.16 ab 
Mannitol 0-3  0.44 ± 0.14 a 0.58 ± 0.16 a 1.26 ± 0.27 a 0.63 ± 0.34 a 0.33 ± 0.15 a 0.39 ± 0.25 a 
 
3-8 1.28 ± 0.32 a 2.51 ± 0.67 a 2.36 ± 0.63 a 1.06 ± 0.50 a 1.81 ± 0.28 a 2.65 ± 0.40 a 
 
8-20 1.51 ± 0.47 a 4.07 ± 0.87 b 0.53 ± 0.17 a 2.98 ± 0.34 ab 2.03 ± 0.62 a 2.70 ± 0.50 ab 
Sucralose 0-3  0.54 ± 0.22 a 0.70 ± 0.23 a 1.31 ± 0.40 a 0.80 ± 0.54 a 0.39 ± 0.26 a 0.29 ± 0.29 a 
 
3-8 3.08 ± 1.07 a 2.86 ± 0.59 a 2.36 ± 0.96 a 1.40 ± 0.45 a 1.80 ± 0.31 a 1.71 ± 0.46 a 
 
8-20 1.80 ± 0.56 a 4.27 ± 0.90 b 0.27 ± 0.17 a 2.08 ± 1.36 ab 3.39 ± 1.16 ab 3.73 ± 0.97 ab 
Differing superscript lower-case letters indicate a significant difference at p<0.05 determined by one-way ANOVA.
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4.4 Discussion 
This study quantified the responses following supplementation of 20% red or black 
sorghum flour into the diet of rats to alter metabolic syndrome. Overall, red and black 
sorghum altered metabolic syndrome minimally. There were different effects of red or 
black sorghum flour. More changes occurred with sorghum addition to the mCS diet, 
than to the mHCHF diet. These implications are also discussed. Red sorghum in a corn 
starch-based diet increased feed efficiency, increased lean mass, increased epididymal 
fat, increased body weight, reduced feed intake, increased pancreatic b-cell density, 
reduced vascular responses to acetylcholine ex vivo and decreased urinary recovery of 
sucrose given orally. Changes caused by black sorghum in a corn starch-based diet 
were increased feed efficiency, increased lean mass, increased epididymal fat, 
increased body weight, reduced feed intake, increased pancreatic b-cell density, 
increased cholesterol, increased left ventricular diastolic stiffness, reduced vascular 
responses to acetylcholine ex vivo and increased urinary recover of lactulose given 
orally. Red sorghum flour in the mHCHF diet improved liver morphology, reduced 
vascular responses to acetylcholine and noradrenaline, reduced minimum 
concentration of acetylcholine needed to induce ileum contraction. It also showed 
indications of reduced cholesterol, reduced right ventricular weight, reduced diastolic 
stiffness, increased colon occluding expression, and reduced mannitol and sucralose 
recovery in urine after an oral challenge. Black sorghum addition to the mHCHF diet 
resulted in reduced b-cell density in islets, improved liver structure, reduced vascular 
reactivity to acetylcholine and noradrenaline exposure, increased sensitivity to 
acetylcholine in the ileum and colon, and reduced mannitol recovery in urine after an 
oral challenge, indicating improved small intestinal integrity.  
Body composition and dietary intake   
The reduced food intake caused by adding sorghum flour to the mHCHF diet shows 
that there is a satiety effect of sorghum that is not simply caused by increased energy 
density. In humans, increased concentrations of post-prandial satiety hormones, GLP-
1 (glucagon like peptide-1), PYY (peptide YY/peptide-tyrosine-tyrosine) and GIP 
(gastric inhibitory peptide) occurred after consumption of sorghum-based foods (222). 
The same study suggested higher subjective satiety than with wheat consumption. 
Resistant starches present in sorghum increased satiety in other studies (464). This 
may be in part due to delayed gastric emptying (465). The increased protein, energy 
density and carbohydrates are all likely contributors to the change in food volume 
consumption. Further, the presence of tannins, 3-deoxyanthocyanidins and phenolic 
acids slow the digestion, primarily of starch (56, 103). Extruded whole white or red 
sorghum consumption by rats showed satiety effects (466).   
The reduced feed intake, improved feed efficiency and increased lean mass following 
sorghum consumption in the mCS diet suggests that the mCS diet may have been 
protein-deficient. “Low protein diets” in Wistar rats contain protein contents of 10% 
(467) or 9% (468-470), and some as low as 6% (471-473). The percent protein in the 
diet was only 1.58%; the supplemented diets had protein contents of approximately 
5%. In the mHCHF rats, the diet had a protein content of 4.31%, and the mHBlack and 
mHRed rats were consuming diets with 7.3% protein. Protein in the diet is the primary 
driver of food consumption (474). In this case, the increased energy and protein 
content of the mCS and mHCHF diets when sorghum flour was added is likely to have 
caused the reduction in food consumption.  
Low protein diets result in lower cross-sectional area of muscle fibres, and reduction 
in body weight (471). These results suggest that sorghum is a suitable nutritional 
source of protein and calories in protein-deficient diets. Furthermore, higher protein 
diets were more effective in reduction of bodyweight and correcting metabolic 
syndrome than low protein counterparts (224, 475-477).  
Changes in body composition can be explained, in part, by increased calorie intake 
and increased protein intake. Protein-deficient diets led to reduced muscle synthesis, 
and with the addition of protein to a suitable level, repair can occur. This is typically 
simultaneous with some fat gain, as was seen in this study. Rats given diets with 6.4% 
protein showed no body weight gain, and when changed to a diet of 18% after 28 days 
showed large increases in body weight and overall body protein content (lean mass) 
(478). Other studies showed similar results where switching from protein-
malnourished (8% protein diet) to a high-protein (22%) diet led to considerable weight 
gain (479). That study also reported that, if malnutrition occurs post-weaning, 
adipocyte differentiation is reduced and may not recover with refeeding (479). Others 
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note the importance of leucine intake in protein malnutrition recovery (480), and this 
has been suggested as a treatment of obesity and metabolic syndrome (475).  
The amino acid profile of sorghum is favourable for leucine intake. Leucine is the 
second highest amino acid by weight in sorghum, after glutamic acid (481). Although 
it can vary by type and treatment (482), the typical amount of leucine is 0.643g of 
leucine per 100g of raw flour (32). The amount of leucine required to stimulate muscle 
synthesis does not appear to be exceptionally high. There was a linear trend to 
increased protein synthesis in rat skeletal muscle with doses of leucine from 0.068g/kg 
to 1.35g/kg body weight (483). A 20% sorghum supplement in the diet is 
approximately equivalent to 0.045g leucine intake per day, based on 0.643g leucine 
per 100g of flour, and intake of 35g per day. For a rat of 300g, this is approximately 
0.15g of leucine per kilogram per day. From this data, it appears that leucine derived 
from sorghum may be a driver of increased lean mass, even though diets were still 
“low protein” in the mCS and sorghum-supplemented mCS models. The assessment 
of myofibril diameter showed no differences between rats, yet the DXA results showed 
increased muscle mass. The increase can thus be attributed to increased myofibril 
number rather than size. This outcome is particularly beneficial as there was an inverse 
correlation between skeletal muscle mass and metabolic syndrome in a Korean cohort 
(484, 485), and in the general population (486-488).   
Pre-diabetes 
An improvement in the glucose tolerance with the addition of sorghum was expected 
due to the increased concentration of phenolic acids, flavanols and anthocyanidins. In 
chapter 3, there was normalisation of glucose tolerance with 5% whole sorghum. The 
higher dose of sorghum was expected to improve glucose tolerance. No improvements 
in fasting glucose concentrations nor glucose tolerance tests were found in this study. 
These outcomes are comparable to what was seen in supplementing decorticated 
sorghum flour or sorghum bran into an obesogenic diet of rats (489). That study 
showed that only whole sorghum flour without decortication corrected glucose 
tolerance in a high-fat diet, despite having a lower phenolic content (489). This 
outcome suggests that the effects on glucose tolerance when consuming sorghum flour 
are due to another component, possibly the starch, lipid or protein. Short-term 
ingestion of whole sorghum flour muffins lowered insulin fluxes more than a wheat-
based counterpart and marginally reduced fluctuations in glucose (206), and whole 
sorghum resulted in a smaller increase in plasma glucose than with rice and wheat 
foodstuffs (204). Methanol extracts of sorghum reduced fasting glucose in a mouse 
model of diet-induced obesity (185). Ethanol extracts of sorghum showed insulin-
independent normalisation of glucose responses in diabetic rats (207). 
The different outcomes suggest that the matrix by which sorghum is delivered in the 
diet, not the amount, is important as supported by Moraes, et al. (489). Whole sorghum 
has a greater effect at a lower dose than sorghum flour. Particle size of flour does not 
affect glucose responses in wholemeal flours (490). Wholegrains and wholemeal 
flours, although similar in a macronutrient sense, have very different effects on blood 
sugar and post-prandial responses, whereby wholegrains are more slowly digested and 
show lower insulin responses (491). The structure and digestibility differ largely, 
although macronutrients do not generally differ markedly between the wholegrain and 
the wholemeal flour (492).  
Dyslipidaemia  
Blood lipid profiles were expected to differ between the mCS and mHCHF groups 
(353). For cholesterol, no difference was noted between any groups. This was 
unexpected as typically diets with high levels of beef tallow resulted in high circulating 
cholesterol concentrations (353). Diet-induced obesity in rats showed differences in 
HDL and LDL concentrations, even when total cholesterol did not differ, but sorghum 
flour had no effect (489). I could not link sorghum flour consumption to changes in 
serum cholesterol, however LDL and HDL were not assessed separately. Sorghum 
extracts decreased plasma cholesterol concentrations in hamster models (183, 184), 
while in hyperlipidaemic rats increased total cholesterol (392). Unrefined sorghum 
consumed at a rate of 100g per day in human studies improved serum lipid profiles 
(187). 
The outcomes with respect to triglycerides reflected the outcomes of another sorghum 
flour study, where no change in triglycerides was found (489). Sorghum extract 
reduced plasma triglycerides in mice (185) and rats (181). Resistant starches may 
reduce the concentrations of serum triglycerides in rat models (493). Phenolic 
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compounds including gallic acid, vanillic acid, coumaric acid, caffeic acid, ferulic 
acid, chlorogenic acid and naringenin reduced triglyceride synthesis in vitro, while 
protocatechuic acid, hydroxybenzoic acid and syringic acid were ineffective  (494).  
Cardiovascular changes 
Very few changes occurred with respect to cardiovascular parameters. The lack of 
differences between the two control diets was of concern. The raised systolic blood 
pressure, above the expected healthy 120mmHg, in all groups may be caused by the 
low protein in the mCS, mCBlack and mCRed groups. Rats maintained on a low 
protein (8%) diet after in utero protein restriction showed increased blood pressure 
(495). A few studies have linked undernutrition to hypertension in children and 
adolescent humans (496). Post-weaning protein malnutrition in male Wistar rats has 
been linked to increased systolic and diastolic blood pressure, with contributions from 
increased superoxide production, and increased nitric oxide release (497).  
As this model appears to have insufficient protein, the lack of change in systolic blood 
pressure cannot be directly related to metabolic syndrome. I cannot make reasonable 
assumptions about the effects of sorghum on hypertension in metabolic syndrome. Red 
or black sorghum flour at 20% supplemented to the diet did not correct hypertension, 
although the cause in this study remains unclear. Additionally, I observed no change 
in diastolic stiffness, which is consistent with the lack of changes in systolic blood 
pressure. Evidence of sorghum’s direct effect on blood pressure is scarce. Wholegrain 
consumption reduced blood pressure in adult individuals (498-500). 
It was expected that an obesogenic diet would impair endothelium-dependent 
vasoconstriction (353) and that overweight rats would have lower reactivity to 
acetylcholine. This has been shown on studies of high-fat diet-induced obesity in mice 
(501) and rats (353). In our model this did not occur. This is similar to the increased 
vasoconstriction sensitivity to noradrenaline in diabetic dogs (502), and diabetes has 
been linked to hypertension in rats (503). Therefore, the marked increase in response 
with black sorghum flour to noradrenaline is potentially detrimental, as sensitivity to 
vasoconstrictors may be a contributor to the development of hypertension, possibly 
caused by a diabetic state (504).  
The reduced vasodilation to acetylcholine in all sorghum-treated groups is of concern. 
Impaired vasodilation indicates vascular dysfunction and is associated with type 2 
diabetes (505, 506), hypercholesterolaemia (507) and hypertension (508). No research 
on the effects of sorghum flour on vasodilatation and vasoconstriction sensitivity have 
been published. Our outcomes suggest that sorghum flour does not improve these 
symptoms of metabolic syndrome.  
Impaired vasodilatation is associated with high concentrations of circulating free fatty 
acids, such as occurs in dyslipidaemia of metabolic syndrome (509), which is 
consistent with the lack of changes seen in plasma lipids. Wholegrain cereals can 
improve endothelial-dependent vasodilation (510). Flavonoids reduced blood pressure 
in rat models and ex vivo vascular reactivity to acetylcholine (230). As both sorghum 
flours were produced for human consumption and subject to quality testing, we assume 
that there was no effect of mycotoxins which commonly cause vasoconstriction (511).  
Liver changes 
Supplementing with sorghum flour showed that there are benefits to liver function and 
to structure. Plasma AST and ALT activities are increased in liver disease, as is LDH 
to a lesser extent. The increased AST in the “healthy diet” is concerning and makes 
interpretation of sorghum’s effects difficult. Median reference values for male Wistar 
rats are 33 U/l and 66 U/l for ALT and AST respectively (512). The “healthy” controls 
had AST activities in the upper range of normal, while the mHCHF had “healthier” 
activities comparable to the median reference range. Sorghum did not affect these 
enzymes in the obesogenic diet, but black sorghum flour reduced and likely improved 
AST activity in the corn starch diet. Similarly, lactate dehydrogenase activity appeared 
improved with sorghum consumption in the mCS diet. The elevated activities of lactate 
dehydrogenase and AST show higher liver damage in the mCS model, yet 
histopathology data indicates that steatosis was more pronounced in the mHCHF 
model.  
Low protein diets in Wistar rats can result in increased amino acid transferase activity, 
and increased lactate dehydrogenase activity (513). The suggested mechanism is an 
adaptive increase in nitrogen efficiency to minimise loss (513). Other studies of low 
protein diets also indicate that there may be increased AST with low protein intake, in 
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studies where protein was 4.13% of the total diet. Additionally, the raised ratio of 
AST:ALT can be indicative of hepatocellular damage. ALT is considered more 
specific to liver damage than AST, therefore this change may not simply be a reflection 
of the liver damage. 
 Values of approximately 204U/L lactate dehydrogenase indicate a healthy liver 
function in rat models (512). All sorghum-supplemented groups showed a lactate 
dehydrogenase activity comparable to the mHCHF group, which is comparable to the 
CS diet in other studies (353), which suggests poor liver function in the healthy control 
which is improved by sorghum consumption.  
Despite the apparently healthy liver enzymes, histological analyses indicated cellular 
ballooning and fat deposition in hepatocytes due to a high fat diet, which improved 
with sorghum flour, but the damage was not completely absent. Chronic consumption 
of diets high in fatty acids can lead to fat deposition and dysregulation of liver function 
as seen in metabolic syndrome (514). A low protein diet of 4.13% exacerbated 
development of fatty liver in high simple carbohydrate models (515). The improved 
liver structure was consistent with other studies using 51% sorghum in a high fat diet 
(412).  
Expression of TLR4 and GLUT2 in the liver were unchanged by diet or intervention 
in this study. The expression of GLUT2 in the liver was increased in metabolic 
syndrome and diabetes (310, 322, 516). In type 1 diabetes, there was increased TLR4 
expression in monocytes (517). Insulin-resistant individuals showed higher TLR4 
expression in muscle tissue (518). As the liver plays such a major role in peripheral 
glucose control, as does muscle tissue, similar changes might occur in the liver and be 
involved in progression or reversal of metabolic syndrome. This was not the case in 
our model.  
Gastrointestinal changes 
Effects on the gastrointestinal tract were variable. Most changes that were noted could 
be attributed to sorghum, rather than the type of diet it was added to. Very few 
differences were evident between the mCS and mHCHF controls in ileum and colon 
reactivity. The diet can affect different parts of the gastrointestinal tract in different 
ways. High fat diets lead to increased gastric emptying (176, 519), while some research 
showed slowed gastric emptying (520). Most studies suggest that high-fat diets 
resulted in increased upper gastrointestinal motility (179) and delayed transit in the 
colon (179, 521). Reduced cholinergic (acetylcholine-stimulated) contraction was 
associated with slow colonic transit (522).  
More research needs to be conducted as there are problems associated with both weak 
and strong contractions of the gastrointestinal tract. The optimal gastrointestinal 
contraction rate or force has not been fully studied. The controls in this research were 
subject to very low fibre intake. The increased contractions may have been due to the 
low fibre content. It was noted that the faecal pellets of the mCS and mHCHF rats 
were much harder and less prevalent in cages than those which received either type of 
sorghum flour. It is difficult to say whether the changes caused by sorghum were 
“good” or “bad”.   
Isolated sorghum compounds caused relaxation of pig ileum ex vivo (420). In mice, 
increasing sorghum leaf extract concentration in the diet increased transit time and 
reduced intestinal motility and doses of 200mg/kg or more showed anti-diarrhoeal 
activities (421). Sorghum extracts dose-dependently increased relaxation in the rabbit 
jejunum and rat stomach (421). Likewise, methanol extracts of red sorghum seeds 
showed anti-diarrhoeal activity and prolonged gastrointestinal transit time (523).  
The expression of occludin in the colon was altered by the diet, however no changes 
in TLR4 or claudin-1 expression were noted. Claudin and occludin were chosen 
because they share similar properties with respect to their cellular location but have 
very different roles (compared with other tight junction proteins), as shown in Figure 
4.62.  
Given that expression of claudin did not change, I can assume that structurally, the 
tight junctions are still intact. However, the key change is more likely to be the 
regulation of the function of these tight junctions. Depletion of occludin resulted in 
increased selective macromolecule movement across the epithelial barrier, without 
altering the overall permeability or epithelial resistance (524). One of the molecules 
studied was mannitol, which had increased flux where occludin was silenced (524). 
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This is consistent with the increased mannitol recovery in the intestinal permeability 
tests.  
The improvement (reduction) of intestinal permeability in the sorghum treated rats was 
promising for gastrointestinal health, although permeability was not completely 
normalised. The increased urinary mannitol recovery in the obesogenic diet indicates 
that malabsorption is occurring, and this is improved with the addition of sorghum. 
Because the sorghum consuming groups did not differ from either control for 
lactulose/mannitol ratio, we cannot reject the hypothesis that sorghum flour improved 
the GI tract integrity in the small intestine. Dextran sodium sulphate-induced colitis in 
a rat model was exacerbated by black and Sumac sorghum bran compared with 
cellulose (453), while sorghum lipids reduced intestinal stress and damage (525). 
  
 
Figure 4.62: Cellular location of tight-junction proteins (526).    
Other considerations 
While this study compared black and red sorghum flour, it should be noted that “black” 
and “red” varieties can show major differences within a group with respect to the 
content of phenolic acids, procyanidins, 3-deoxyanthocyanidins, anthocyanins, 
flavones and flavanones. Not all sources of “red” or “black” sorghum will give the 
same effects. While this research is a starting point to promote sorghum as a food 
source, this information must be taken into consideration. Even within “red” sorghum 
varieties, there can be marked differences in the composition. The 3-
deoxyanthocyanidins, luteolinidin, apigeniniden, 5-methoxyluteolinidin and 7-
methoxyluteolinidin, can vary from undetectable to 282.6, 166.2, 120.6 and 104.9µg/g 
(153). The concentrations of flavones such as luteolin and apigenin can also differ 
considerably from undetectable to 182.2 and 203.7µg/g similar to the flavanones such 
as eriodictyol and naringenin which can vary from undetectable to 12.9 and 48.4µg/g 
(153). The coloured compounds are often biologically active, hence changes in these 
compounds may confer different health benefits (527). Other compounds including 
tannins and phenolic acids also vary depending on whether the source is “red” or 
“black” and also markedly differ within the “red” group of sorghum types (528). In 
Australia, a number of “red” grain sorghum varieities are grown. Depending on 
seasonal conditions and the genotype, these will vary in their composition (529).  
When comparing black and red sorghum, the true genetic makeup of the plants and 
breeds that were used in the process is unclear. There are a number of known genes 
that affect the plant pericarp colour (153). At least two genes control pericarp colour, 
two affect the testa colour, and 2 affect secondary colour which includes the kernel, 
sheath and glume (153). These genes  may be present in a number of combinations, 
depending on the variety, and will affect the secondary plant metabolites that affect 
colour, phenolic contant and therefore biological activty.  
Identification and quantification of the bioactive compounds present in the sorghum 
flours used in this study would further the understanding of how sorghum composition 
affects health outcomes. This would also provide a baseline for future comparative 
studies.  
Additionally, even though macronutrient profiles of the two sorghums were similar, 
other studies have shown that the concentrations of resistant starches can differ in 
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addition to the way they interact in the rat (530), and their health effects (489). The 
preparation of sorghum will alter its ability to affect metabolic syndrome context, and 
for human consumption. Major differences in biological effects of products from a 
single grain source can be due to processing. Hydrolysable starch and glycaemic index 
vary considerably, since decortication increases hydrolysable starch, as does making a 
bread, and the hydrolysable starch is more easily digested (531). One of the most 
significant differences between the whole sorghum and the sorghum flour, although 
these are marketed as “wholemeal”, is that there is a large reduction in resistant starch, 
both soluble and insoluble fibre, and in phenolic compounds (531). Most of these 
components are present in the bran layer, and the degree of decortication will 
inevitably change their concentrations (531). Processing sorghum alters the starch 
granule structure, reducing resistant starch amounts.  
4.5 Conclusion 
There are differing effect of red and black sorghum flour on metabolic syndrome. Red 
sorghum flour improved appearance of the liver remarkably, while black sorghum 
flour showed moderate improvements. No changes were noted in blood lipids with 
either flour. Both red and black sorghum flour were efficient in helping gain lean mass 
and improve feed efficiency in a low protein, high complex carbohydrate diet. 
Occludin expression in the colon appeared more susceptible to changes with sorghum 
consumption than claudin, however this did not translate to reduced concentrations of 
circulating lipopolysaccharides.  
Red or black sorghum flour has shown benefits with its consumption, however there 
was indications that it may alter vascular reactivity in a way that could be detrimental. 
Following this project, human trials will provide more accurate information on its 
effects. Studying sorghum replacements for wheat flour-based diets should be 
considered, as incorporation into human diets will likely be by replacement rather than 
addition as in this study. Overall the changes were minimal, but should not be 
discounted as sorghum can be integrated into a whole diet approach to improving 
metabolic syndrome.  
  
Chapter 5 – 20% wet cake sorghum in a dietary model of metabolic syndrome 
5.1 Introduction 
Wet cake sorghum (WS), also called dry distillers grain sorghum, is the by-product of 
ethanol production. It is produced on a commercial scale and has typically been used 
for livestock feed. The interest in this sorghum product for human health and especially 
metabolic syndrome is due to concentrated compounds that have been identified as 
having nutraceutical benefits. As an example, the concentration of policosanols, long 
chain alcohols (CH3-(CH2)n-CH2OH n=24-34) derived from plant waxes, are 3 times 
higher in WS than in grain sorghum (123). The two major long chain policosanols in 
WS with approximately 90% of the total content are the C30:0 and C28:0 alcohols 
(131). Treatment of hamsters with WS lipid extracts resulted in reduced plasma and 
liver cholesterol concentrations (182, 183). Further, plant sterols are approximately 4 
times more concentrated in WS than in sorghum grains (123). Plant sterols reduced 
plasma concentrations of LDL cholesterol and triglycerides (532). Conversely, 
tocopherols are decreased in WS to 0.2mg/g of lipid (126) compared with 4mg/g of 
lipid from whole sorghum grains (182). 
The fermentation process concentrates phenolic acids to approximately 3 times higher 
than the raw grain equivalent (533), although some studies suggest phenolic acids are 
present at around half the amount in whole sorghum, and tannins are also lower at 
around 80% of that found in whole sorghum (534). Phenolic acids are recognised as 
having potential to reduce plasma lipids, weight (535) and inflammation (140), and are 
hypoglycaemic (216, 536). Sorghum distillery waste also contains increased 
concentrations of flavonoids and anthocyanins compared with the raw sorghum 
starting product (537). While flavonoid glycoside concentrations decrease, flavonoid 
aglycones increase, bound phenolic acids and flavonoids are released, and depending 
on the specific fermentation process, new metabolites are generated (150). Increased 
intake of dietary flavonoids is associated with reduced risk of developing type-2 
diabetes (538), reduced arterial stiffness (539) and reduced systemic inflammation 
(540) which are all pathologies of metabolic syndrome.  
Recent studies on the sorghum waste from biorefinery sources showed that the 
fermentation process resulted in peptides that have antimicrobial activity, and that the 
waste contains phenolics with anti-inflammatory properties including ferulic acid, 
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cinnamic acid, 4-hydroxybenzioc acid, taxifolin, protocatechuic acid and p-coumaric 
acid (541). Anti-microbial activity is also noted in other studies which has implications 
for gastrointestinal function (542).  
Sorghum contains a unique profile of proteins, most notably kafirin proteins. These 
have been studied as an oral delivery model for tannins (43), and catechins (543). Their 
resistance to digestion prevents the breakdown of encapsulated compounds within the 
kafirin micro-particles, allowing for effective delivery of nutraceuticals to the intestine 
(40, 43) (543). The proteins themselves have not been widely studied in relation to 
their potential health benefits, although kafirin fractions can inhibit ACE (angiotensin 
converting enzyme), which may reduce hypertension and cardiovascular disease risk 
(544).  
These features suggest that sorghum waste from bioethanol production is a possibly 
untapped resource for nutraceuticals or functional foods. The potential of this sorghum 
waste product is explored in a rat model of metabolic syndrome and its implications 
for human health are discussed.   
5.2 Materials and Methods   
5.2.1 Ethics  
Approval for experimentation with 20% sorghum was granted under AEC approval 
number 15REA005 valid from 20th June 2015-20th June 2018 by the Animal Ethics 
Committee of the University of Southern Queensland. All rats were treated and housed 
as per the NHMRC (National Health and Medical Research Council) 2014 guidelines 
for the ethical treatment of animals. 
5.2.2 Rat Diet and Experimental Structure  
Forty-eight male Wistar rats were randomly divided into 4 experimental groups of 
n=12; mCS (corn starch diet), mHCHF (high carbohydrate, high fat diet), mCWS (corn 
starch diet + 20% w/w dehydrated wet cake sorghum), mHWS (high carbohydrate, 
high fat diet + 20% w/w dehydrated wet cake sorghum). Wet cake sorghum was kindly 
donated by the United Dalby Bio-refinery (United Petroleum).   
For the first 8 weeks of the protocol, all mCS and mCWS rats received the control 
mCS diet and all mHCHF and mHWS rats received the control mHCHF diet as 
described in Methods method 2.2. Energy and nutrient profile of the wet cake sorghum 
(WS) was tested by Agrifood Technology (Werribee, Victoria), NATA (National 
Australian Testing Authority) accreditation number 2726. Energy was determined by 
Atwater metabolizable energy, protein by method TP/026 (Agrifood test method), fibre 
by method TP/098, carbohydrate by method TP/110 and fat by method TP/050.   
At eight weeks, the mCWS and mHWS groups were transferred to the treatment diet 
as indicated and remained on these diets until protocol completion. Macronutrient and 
energy profiles of the diets are outlined in Table 5.1. An additional 3.85 kJ/mL energy 
was added to calculations for the mHCHF and mHWS diets in fructose water (8). 
Table 5.21: Macronutrient profiles of diets, per 100g. 
 
mCS mHCHF mCWS mHWS 
Energy (kJ)  992.5 1495.9 2269.5 2772.8 
Protein (g)  1.8 5.1 30.6 33.9 
Fat, Total (g)  0.5 11.2 9.4 20.0 
Fibre - Dietary (g)  0.5 0.0 7.0 6.5 
Carbohydrates (g)  54.2 41.9 91.2 78.9 
 
At 16 weeks, prior to termination, oral glucose tolerance (method 2.3), body 
composition (method 2.4) and systolic blood pressure (method 2.5) were determined. 
Urine was collected as described in method 2.10.1. All rats were starved for 2 hours 
prior to termination. Rats were euthanised as described in method 2.6.1. At 
termination, rats underwent serum collection (method 2.6.2), plasma collection 
(method 2.6.3), vascular reactivity (method 2.6.5), ileum and colon contractility 
(method 2.6.6), organ weights (method 2.6.7) and histological tissue collection 
(method 2.8.1). 10 rats per group underwent isolated heart perfusion (method 2.6.4), 
with the remaining two hearts preserved in formalin for histological analysis as 
described in method 2.8.1. Plasma biochemistry was assessed on 8 rats per group for 
liver enzyme activity (method 2.7.1) and plasma lipid profile (method 2.7.2.). 
Collected serum was analysed for the presence of endotoxins as described in method 
2.9. Liver sections were assessed for expression of GLUT2 and TLR4 (method 2.11.3). 
Distal colon sections were also assessed for occludin and claudin expression as 
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described in method 2.11.4, in addition to TLR4. Urine samples collected prior to 
termination were prepared (method 2.10.2) and analysed (method 2.10.3). 
Histological tissue samples were processed automatically and sectioned (method 
2.8.3). Liver, ileum, colon, pancreas and left ventricle were stained with haematoxylin 
and eosin (method 2.8.5.1). Separate sections of left ventricle were stained with 
picrosirius red (method 2.8.5.2). Microscopy and imaging were performed as 
described in methods 2.8.6.1, 2.8.6.2, 2.8.6.3 and 2.8.6.4. 
5.2.3 Statistical analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad Software, 
California). Data was analysed using a one-way ANOVA or two-way ANOVA were 
indicated. A test for normality was undertaken using a D’agostino-Pearson test for 
normality (GraphPad Prism). For analyses where distribution was determined to be 
normal, one-way ANOVA was used (Tukey’s multiple comparison). Where groups 
were determined not to be of a normal distribution, a non-parametric test was applied. 
Removal of outliers was based on a Tukey boxplot identification of outliers.  
In all cases, the null hypotheses were tested: 
1. There is no difference between the mCS or mHCHF diet on the parameter in 
question. 
2. There is no effect of wet cake sorghum addition on the outcomes of the mCS 
or mHCHF, respectively.  
3. Addition of WS to the mHCHF diet does not result in a change which results 
in comparable outcomes to mCS. 
4. Addition of WS to the mCS diet does not result in a change which results in 
comparable outcomes to mHCHF. 
 
 
5.3 Results 
5.3.1 Phytochemical composition  
Extraction profiles of WS supplement are shown. For comparison puposes, profiles of 
whole red sorghum extract have been included. The red sorghum is not the source from 
which the WS was produced, as it is made on an industrial scale. It is provided as a 
guide to indicate that there is alteration in the compounds and their relative abundance 
which occur during processing.  
HPLC with detection at 210nm (Figure 4.42) indicates hydrophilic compounds. There 
was a change in the real-time abundances of compounds in the WS compred to the 
whole red sorghum. The peak at 19.5 minutes was increased in the WS, while the peaks 
between 20.0 and 22.0 minutes were lower than those in the whole red sorghum. There 
was also increased relative sizes of peaks between 1.0 and 2.0 minutes in the WS 
comapred to the whole red sorghum extract.  
 
Figure 5.63: 210nm UV detection of HPLC of acidified methanol extract of WS (top) 
and local whole red sorghum (bottom). 210nm detection detects primarily hydrophilic 
compounds.  
 
510nm detection is optimal for anthocyanin detection (Figure 4.43). Most peaks seen 
in the whole red sorghum extract were absent in the WS extract profile.  
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Figure 5.64: 510nm UV detection of acidified methanol extracts separated by HPLC 
of WS. 510nm detection primarily indicates anthocyanin presence.  
 
The 330nm profile (Figure 4.44) primarily indicates phenolic acids. This wavelength 
is also suitable for detection of flavones (153). Most of the peaks present in the whole 
red sorghum extract were absent from the WS extract. Only the peak at 1.0 minutes 
was larger in the WS profile.  
  
 
Figure 5.65: 330nm UV detection of HPLC separated acidified methanol extracts of 
WS. 330nm detection primarily indicates presence of phenolic acids.  
 
 
 
5.3.2 Feed intake, energy intake and body composition 
All rats began the protocol with the same body weight. At 8 weeks, mHCHF had a 
higher weight than mCS. There was a lower weight at 8 weeks with the mHWS group 
prior to intervention, compared to mHCHF, however final body weight did not differ 
between these groups (Figure 5.66). There was an increase in body weight in the 
mCWS group compared with the un-supplemented mCS from weeks 8-16. 
Figure 5.66: Weekly bodyweight gain.  
An increase in fat mass was evident in the mCWS group compared with mCS (Table 
5.22). No change in fat mass occurred in the mHWS group against the mHCHF 
control. Abdominal fat pad mass was higher in the mHCHF group than the mCS 
control. Addition of WS did not alter abdominal fat pad mass (Table 5.22). 
The lean mass of mHCHF was higher than that of the mCS group at 16 weeks. Addition 
of WS resulted in increased lean mass in both diets from their respective controls. An 
increase in lean mass of 35% in the mCWS and 11.4% in the mHWS was measured, 
when compared with the CS and HCHF controls respectively (Table 5.22). Bone 
mineral density was higher in the mHCHF group compared with the mCS group. WS 
addition to the mHCHF diet reduced bone mineral density. Bone mineral content was 
again higher in the mHCHF group than the mCS control. Addition of WS to the mCS 
diet resulted in an increased bone mineral content. Addition of WS to the mHCHF diet 
did not affect bone mineral content.  
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Table 5.22: Body composition of rats fed on mCS, mCWS, mHCHF, and mHWS protocols.  
 
Values are expressed as mean ± SEM. Differing lower-case letters indicate a significant difference between groups for a parameter determined by 
one-way ANOVA at p<0.05. 
Parameter Interaction Intervention Diet
Total body fat mass 16 weeks (g) 43.63 ± 6.25 a 87.17 ± 11 b 166 ± 12.26 c 155.7 ± 10.8 c < 0.0001 < 0.0001 0.0456
Total body lean mass 16 weeks (g) 247.2 ± 4.3 a 333.8 ± 6.3 b 307.6 ± 8.205 b 342.6 ± 13.2 c 0.0033 < 0.0001 0.0002
Lean:Fat mass ratio 16 weeks 7.10 ± 1.0 b 4.31 ± 0.6 a 1.98 ± 0.167 a 2.33 ± 0.3 a 0.0267 0.0807 < 0.0001
Bone mineral density (g/cm2) 0.167 ± 2E-3 a 0.167 ± 2E-3 a 0.181 ± 2E-3 b 0.172 ± 4E-3 a 0.0897 0.0651 0.0005
Bone mineral content (g by DXA) 9.755 ± 0.3 a 13.03 ± 0.5 b 15.15 ± 0.49 c 15.31 ± 0.42 c 0.001 0.0004 < 0.0001
Retroperitoneal fat (mg/mm tibial length) 140.4 ± 12.5 a 201 ± 14 a 380.7 ± 33.92 b 331.9 ± 20.1 b 0.0157 0.7813 < 0.0001
Epididymal fat (mg/mm tibial length) 69.16 ± 6.73 a 103 ± 12 a 156 ± 13.06 b 185.6 ± 16.6 b 0.8678 0.0152 < 0.0001
Omental fat (mg/mm tibial length) 106.4 ± 8.51 a 122 ± 13 a 206.6 ± 12.23 b 186.2 ± 16.8 b 0.1648 0.8652 < 0.0001
Total abdominal fat pad (mg/mm tibial 
length)
316 ± 23 a 426.1 ± 29 a 743.3 ± 55.6 b 703.8 ± 48.7 b 0.0766 0.3967 < 0.0001
mCS mCWS mHCHF mHWS
Feed intake for the first 8 weeks was not different between the mCS and mCWS 
groups. The mHCHF groups ate less food than mCS while the mHWS group ate less 
than mHCHF. It was expected that the mHWS and mHCHF groups would eat the same 
amount of food prior to intervention. For this reason, changes in intake from the 8 
week point are a better indicator of feed intake changes (Figure 5.67). Addition of WS 
reduced weight of food intake in both diets. Energy intake was increased in the mHWS 
and mCWS groups (Figure 5.67).  
 
Figure 5.67: Change in feed intake and energy intake. Differing lower-case letters 
indicate a significant difference between groups, while asterisks indicate a significant 
change between the 0-8-week period and the 8-16-week period. All data were 
distributed normally and all analyses were determined using a parametric one-way 
ANOVA, at significance <0.05.  
 
Feed efficiency was higher in the mHCHF than mCS in weeks 0-8 and 8-16. Addition 
of WS to the mCS diet or mHWS diet increased feed efficiency (Figure 5.68).   
 
mC
S
mC
WS
mH
CH
F
mH
WS
-10
-5
0
5
D
 in
 fe
ed
 in
ta
ke
 (g
/d
ay
)
ab
a
c*
b*
mC
S
mC
WS
mH
CH
F
mH
WS
-100
-50
0
50
100
D
 e
ne
rg
y 
in
ta
ke
 (k
j/d
ay
)
ab
a
b
c*
157 
 
 
Figure 5.68: Feed efficiency 0-8 weeks (hollow bars) and 8-16 weeks (solid colour). 
Differing lower-case letters indicate significant difference between groups for the first 
8 weeks. Differing upper case letter indicate a significant difference between groups 
for the second 8 weeks of the protocol. * indicates a significant difference within a 
group between the first 8 weeks and the second 8 weeks of the protocol. All analyses 
were determined by one-way ANOVA.   
Protein intake in weeks 8-16 was higher in the mHCHF control from the mCS control. 
Both the mCWS and mHWS groups had higher protein intake in the second 8 weeks 
than all controls (Figure 5.69).  
 
Figure 5.69: Protein intake weeks 8-16. Differing lower-case letters indicate a 
significant difference at p<0.05 determined by one-way ANOVA.  
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5.3.3 Glucose control and blood lipid profile  
Non-esterified fatty acids and triglycerides were higher in the mHCHF and mHWS 
groups compared with the mCS control. Addition of wet cake to either diet did not 
alter circulating plasma NEFA or triglycerides (Table 5.23). No changes in cholesterol 
were found with either diet or intervention.  
After 8 and 16 weeks of dietary treatment, mHCHF showed impaired glucose tolerance 
indicated by higher TAUC than the mCS control. The mHWS group showed improved 
glucose tolerance, normalised to within the range of the mCS control (Table 5.23).  
Fasting plasma glucose concentrations at 8 weeks were increased in mHCHF 
compared with mCS. The mCWS and mHWS groups did not differ from the mCS 
control (Table 5.23). At 16 weeks, the mHCHF group again had higher fasting glucose 
concentrations compared with mCS. The mCWS group was comparable to mCS and 
the mHWS was not significantly different from either the mHCHF and mCS groups.  
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Table 5.23: Blood lipids and glucose tolerance.  
 
Differing lower-case letters indicate significant difference at p<0.05 determined by one-way ANOVA. Fasting blood glucose was measured in 
mM, TAUC (total area under the curve) is unitless. 
Parameter Interaction Intervention Diet
Fasting blood glucose 8 week 3.5 ± 0.25 a 3.3 ± 0.25 a 4.4 ± 0.13 b 3.6 ± 0.179 a 0.1621 0.0248 0.0044
 TAUC blood glucose 8 week 688.8 ± 23.5 a 724 ± 22.6 a 861.4 ± 25.5 b 810 ± 34.77 b 0.1194 0.7775 < 0.0001
Fasting blood glucose 16 week 4.0 ± 0.21 a 3.8 ± 0.14 a 4.7 ± 0.11 b 4.5 ± 0.13 ab 0.8499 0.1253 < 0.0001
 TAUC blood glucose 16 week 728.3 ± 20.3 a 761 ± 22.4 a 916.4 ± 46.3 b 791 ± 31.25 a 0.0314 < 0.0001 < 0.0001
Plasma total cholesterol (mM) 1.65 ± 0.08 a 1.79 ± 0.1 a 1.69 ± 0.09 a 1.72 ± 0.065 a 0.5244 0.3287 0.9039
Plasma triacylglycerides (mM) 0.58 ± 0.06 a 0.98 ± 0.09 a 1.77 ± 0.2 b 2.42 ± 0.3216 b 0.4977 0.0076 < 0.0001
Plasma non-esterified fatty acids 
(mM) 1.96 ± 0.16
a 2.73 ± 0.19 a 4.83 ± 0.19 b 4.54 ± 0.395 b 0.0305 0.3115 < 0.0001
mCS mCWS mHCHF mHWS
Histology sections of the pancreas showed that the cell density per islet was lower in 
the mCS groups than in all other groups.  
 
Serum lipopolysaccharide concentrations did not differ between any group as 
indicated in Figure 5.71.  
 
 
 
Figure 5.71: Serum lipopolysaccharide concentrations determined by horseradish 
peroxidase activity. No significant differences were found at p<0.05 determined by 
one-way ANOVA.  
5.3.4 Cardiovascular and liver structure and function 
Liver wet weight was increased in the mHCHF from mCS. Addition of WS to the mCS 
diet caused increased liver wet weight. No change resulted from addition to the 
mHCHF diet (Table 5.24). Histology of livers revealed ballooning and fat deposits in 
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Figure 5.70: Pancreatic islet 
density. Differing lower-case letters 
indicate a significant difference at 
p<0.05 determined by one-way 
ANOVA.  
161 
 
the mHCHF, which were absent in the mCS rats. In the mHWS rats, these features 
were all but absent (Figure 5.72).  
  
  
Figure 5.72: Haematoxylin and eosin stain of liver section at magnification 20x. 
Arrows show indicative cellular ballooning and fat vacuoles (FV) and inflammatory 
cells (INF). mCS,(A), mHCHF (B),mCWS (C), mHWS (D). 
 
Plasma ALT activity did not differ between any groups. AST activities were lower in 
the mHCHF than the mCS group. The mCWS and mHWS AST activities were 
between the two controls, not differing from either (Table 5.4). ALT/AST ratio was 
lower in the mHCHF group than the mCS. mCWS and mHWS were comparable to 
both groups. Lactate dehydrogenase was higher in the mCWS model compared with 
all other groups. Creatinine kinase did not differ between any groups (Table 5.24).   
A B 
C D 
Inf 
FV 
Table 5.24: Cardiovascular and liver structure and function parameters of rats fed on mCS, mCWS, mHCHF, and mHWS protocols.  
 
Differing superscript lower-case letters indicate a significant difference at p<0.05 determined by one-way ANOVA.  
 
 
 
Parameter Interaction Intervention Diet
Systolic blood pressure (mmHg) 134.2 ± 1.6 a 138.8 ± 2.1 a 128.0 ± 2.5 a 127.6 ± 1.4 a 0.2158 0.295 0.0004
Left ventricle + septum (mg/mm tibial 
length)
18.1 ± 1.1 a 23.1 ± 1.5 b 23.0 ± 1.1 b 22.5 ± 0.7 b 0.0172 0.051 0.0573
Right ventricle (mg/mm tibial length) 12.4 ± 1.0 a 16.7 ± 0.8 b 18.2 ± 0.8 b 17.5 ± 0.5 b 0.0034 0.0273 <0.0001
Liver (mg/mm tibial length) 183.5 ± 6.2 a 241.2 ± 6.6 b 316.8 ± 14.8 c 307.2 ± 6.8 c 0.0008 0.0141 < 0.0001
Diastolic stiffness constant (κ) 24.9 ± 0.3 a 25.9 ± 1.7 a 27.5 ± 0.4 a 25.6 ± 0.3 a 0.0754 0.5563 0.1732
Plasma ALT activity (U/L) 29.3 ± 1.4 a 28.5 ± 2.7 a 28.0 ± 2.6 a 25.1 ± 2.2 a 0.6439 0.4313 0.3165
Plasma AST activity (U/L) 93.3 ± 6.2 a 70.8 ± 5.9 ab 65.3 ± 4.3 b 74.3 ± 5.6 ab 0.0095 0.2465 0.0399
Plasma AST/ALT ratio 3.2 ± 0.2 b 2.5 ± 0.1 ab 2.5 ± 0.2 a 3.0 ± 0.2 ab 0.0045 0.7153 0.5397
Lactate dehydrogenase (U/L) 273.8 ± 29.2 b 124.3 ± 8.8 a 159.0 ± 27.2 a 159.1 ± 15.1 a 0.001 0.001 0.0552
Creatine kinase (U/L) 99.5 ± 11.6 a 139.4 ± 30.8 a 117.8 ± 25.6 a 114.6 ± 19.0 a 0.3906 0.4638 0.8962
mCS mCWS mHCHF mHWS
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Liver TLR4 expression did not differ between the mCS and mHCHF controls. 
Addition of 20% intervention in the mHCHF diet resulted in decreased expression of 
TLR4 in the liver from the mHCHF control. The addition of 20% intervention to the 
mCS diet did not alter expression. Liver GLUT2 expression did not differ between the 
mCS and mHCHF controls. The mCWS group had lower GLUT2 expression in the 
liver than the mCS control. No change was found in the mHCHF diet group, Figure 
5.73.  
 
Figure 5.73: Liver TLR4 and GLUT expression determined by semi-quantitative 
ELISA. Differing lower-case letters indicate significant difference at p<0.05 
determined by one-way ANOVA. AU indicates absorption units.   
 
Normalised right ventricular weights and left ventricular weights were higher in the 
mHCHF, mHWS and mCWS groups, compared to the mCS, at termination. Diastolic 
stiffness was not changed by diet or intervention. Systolic blood pressure was 
unchanged by addition of WS, and did not differ between mCS and mHCHF.  
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 Figure 5.74: Ex vivo thoracic aortic reactivity in response to acetylcholine, sodium 
nitroprusside and noradrenaline. Differing lower-case letters indicate a significant 
difference in final maximal force of contraction, p<0.05 determined by one-way 
ANOVA.  
 
Maximum force of relaxation upon acetylcholine exposure did not differ between the 
mCS and mHCHF groups. Maximum force of relaxation was lower in the mHWS and 
mCWS groups than both control groups (Figure 5.74). Different forces of contraction 
were observed at concentrations of 1x10-6M acetylcholine and above. The minimum 
concentration required to elicit a response did not differ between any groups. Maximal 
force of contraction with sodium nitroprusside exposure did not differ between any 
groups (Figure 5.74). The minimum concentration required to induce relaxation did 
not differ between any groups.  
The maximum force of contraction in response to noradrenaline was higher in the 
mHCHF group than the mCS group. Both the mHWS and mCWS groups were 
increased from the mCS control, however not the mHCHF control, Figure 5.74. The 
minimum concertation required to induce contraction did not differ between the mCS 
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and mHCHF control groups. The mHWS groups showed contraction at a lower 
concentration of noradrenaline than the mHCHF control. 
  
  
Figure 5.75: Type I and III collagen stained by picrosirius red, determined at % of total 
cross-sectional area. Differing lower-case letters indicated significant difference as 
determined by one-way ANOVA, at p<0.05. mCS,(A), mHCHF (B),mCWS (C), 
mHWS (D). 
 
Collagen cross-sectional areas were higher in the mHCHF group than the mCS group. 
The mHWS group had lower collagen than the mHCHF control, comparable to the 
mCS group, Figure 5.75.   
 
5.3.5 Gastrointestinal function 
No statistical differences were noted in the maximal force of contraction of the ileum 
between groups. Concentration-contraction comparisons showed no difference in 
contraction between any groups at any individual concentration. No differences in total 
area under the curve were noted between any groups, nor was the minimum 
concentration required for contraction.  
 
There was no difference in the minimum concentration of acetylcholine required to 
induce contraction between the mCS and mHCHF groups in the colon. The 
concentrations required in the mHWS and mCWS groups were higher than both 
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controls. Maximal force of contraction did not differ between the mCS and mHCHF 
controls. At concentrations of 1x10-7M acetylcholine and above, force of contraction 
was lower in the mCWS and mHWS than both controls (Figure 5.76).   
  
Figure 5.76: Reactivity of isolated ileum and proximal colon sections to acetylcholine. 
Differing lower-case letters indicate significant difference in maximal force of 
contraction determined by one-way ANOVA.  
 
Colon TLR4 or claudin-1 expression did not differ between any treatments as shown 
in Figure 5.77. There was higher occludin expression in the proximal colon of mHCHF 
rats compared with mCS. Addition of 20% WS to mCS diet increased occludin 
expression and addition to the mHCHF reduced occludin expression.   
 
Figure 5.77: Colon occludin, claudin-1 and TLR4 expression. Differing lower-case 
letters indicate a significant difference at p<0.05 determined by one-way ANOVA.  
 
Recovery of sucrose, lactulose and sucralose did not differ between any group, for a 
given time period. Recovery of mannitol did not differ between any groups for the 0-
3 hour time period or the 3-8 hour time period. In the 8-20 hour time period, there was 
a higher recovery of mannitol in the mHCHF group than the mCS group. The mCWS 
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recovery did not differ from the mCS control. The recovery in the mHWS was 
comparable to both the mCS and mHCHF groups (Table 5.25)  
Table 5.25: Total percent recovery of sugars from urine.  
 
Differing lower-case letters indicate a significant difference at p<0.05 determined by one-way ANOVA between groups for a given time point. 
Time 
(hours) Interaction Time Treatment
Sucrose 0-3 0.05 ± 0.02 a 0.04 ± 0.03 a 0.05 ± 0.01 a 0.04 ± 0.02 a 0.9734 < 0.0001 0.8848
3-8 0.20 ± 0.07 a 0.11 ± 0.03 a 0.18 ± 0.03 a 0.11 ± 0.05 a
8-20 0.26 ± 0.06 a 0.26 ± 0.05 a 0.24 ± 0.09 a 0.26 ± 0.10 a
Lactulose 0-3 0.31 ± 0.14 a 0.25 ± 0.19 a 0.21 ± 0.08 a 0.34 ± 0.10 a 0.5639 0.0142 0.2600
3-8 1.29 ± 0.72 a 0.54 ± 0.15 a 1.26 ± 0.32 a 0.90 ± 0.23 a
8-20 0.90 ± 0.30 a 0.45 ± 0.23 a 1.20 ± 0.40 a 2.02 ± 0.59 a
Mannitol 0-3 0.44 ± 0.14 a 0.51 ± 0.27 a 0.58 ± 0.16 a 0.51 ± 0.17 a 0.2940 < 0.0001 0.0007
3-8 1.28 ± 0.32 a 1.03 ± 0.39 a 2.51 ± 0.67 a 2.77 ± 0.81 a
8-20 1.51 ± 0.47 a 1.59 ± 0.29 a 4.07 ± 0.87 b 2.94 ± 0.94 ab
Sucralose 0-3 0.49 ± 0.21 a 0.59 ± 0.25 a 0.70 ± 0.23 a 0.89 ± 0.24 a 0.7212 0.0001 0.3046
3-8 3.08 ± 0.95 a 1.13 ± 0.34 a 2.86 ± 0.59 a 3.11 ± 1.15 a
8-20 2.53 ± 0.89 a 2.80 ± 1.22 a 4.27 ± 0.90 a 3.68 ± 0.96 a
mCS mCWS mHCHF mHWS
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Total % recovery over the 24 hour period only differed for mannitol recovery, Figure 
5.78. The lactulose/mannitol ratio was higher in mCS than mHCHF. The mCWS had 
a lower lactulose/mannitol ratio of recovery compared to mCS. No change from the 
mHCHF control was seen in mHWS (Figure 5.78).  
  
Figure 5.78: Total mannitol recovery and lactulose/mannitol recovery ratio over a 20 
hour period. Differing lower-case letters indicate difference at p<0.05 determined by 
one-way ANOVA. 
 
5.4 Discussion 
It was hypothesised that supplementation in the mHCHF diet with WS would reverse 
the symptoms associated with metabolic syndrome. Not all parameters were reversed, 
however several beneficial outcomes were noted.  
Physiology and metabolism 
Supplementation resulted in decreased food intake in the mHCHF diet. The reduced 
intake can be explained by the increased protein and energy densities in the diet. 
Protein intake is suggested to be the major driver of food intake (474), and higher 
satiety with protein intake is well documented (545-547). With addition of WS, there 
was a large increase in protein intake in both diets. The initial mCS diet and mHCHF 
diets are considered to be low in protein when compared with other studies of rat 
models (467-470).  
Many studies have linked reduced calorie consumption with improvements in 
metabolic syndrome (548, 549). Therefore, this is especially promising in the mHCHF 
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model which aimed to mimic metabolic syndrome. High protein, calorie-reduced diets 
have a wide scientific grounding in improving metabolic syndrome (477, 550-552). In 
the mCS model, WS consumption increased protein intake and energy intake. In mice, 
long-term dietary studies of low protein, high carbohydrate intakes indicated good 
cardio-metabolic health, but with a higher risk of fatty liver, low lean mass and high 
triglyceride concentrations (474).  
Notably, the feed efficiency in the rats which received WS was increased. In the 
mHWS group, the increased feed efficiency resulted in an increased lean mass, with 
no apparent change in total body fat mass. In the mCWS diet, the increased efficiency 
resulted in both lean mass and fat mass increase. Similar results have been seen in 
other studies. In a cat model, high protein diets resulted in a lean mass increase of 
4.2%, with no additional exercise (553). Inverse correlations have been established 
between lean mass and metabolic syndrome (484-486, 488). Sorghum distillery waste 
products increased lean mass in feedlot cattle however less efficiently than a corn 
equivalent (554). In finishing, distillery waste reduced fat free mass (555). Little 
research has been done on its consumption outside the livestock production field.  
Increases in lean mass are driven by protein intake, but also essential amino acid intake 
(556). Increased leucine intake, even without increased protein intake, resulted in 
improved muscle mass (483). This has been theorised to be due to inhibition of muscle 
breakdown (myopathy) rather than increased muscle synthesis (557). Sorghum is high 
in leucine, and after processing, leucine can represent 9.59% of total crude protein, 
and up to 2.55% of total dry mass (558).  
There is evidence to suggest that epicatechin is a myostatin inhibitor, which may 
prevent skeletal muscle breakdown (559). WS is known to contain catechin and 
epicatechin (160). The inhibition of myostatin by epigallocatechin-3-gallate in tea 
results in inhibition of ubiquitin-mediated protein breakdown, and increased anabolic 
factors (560). The increased lean mass is also likely to be a contributing factor in the 
improved glucose tolerance.  
Glucose Tolerance  
The improved glucose tolerance in the mHWS group was a significant outcome in this 
study. Sorghum grain extracts improve diabetes by increasing insulin sensitivity in 
mice fed a high fat diet (185) and have anti-diabetic effects in rats (207, 208). 
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However, this appears to be the first study that has shown whole spent sorghum from 
distilleries can have an anti-diabetic effect.  
Peripheral glucose clearance dysfunction is one of the contributing factors to the 
development of impaired glucose tolerance (561, 562). Muscle fibre area correlated 
with the latter stage of the glucose tolerance test (52) with a correlation of 0.39 between 
muscle fibre area and glucose tolerance (53). Not all studies agreed, with lean mass 
amount not related to glucose tolerance in overweight or obese individuals (54). Our 
results indicate no correlation between lean mass and oral glucose tolerance. Many 
suggest it is the function of the muscle, rather than the total mass, that dictates skeletal 
muscle influence on glucose tolerance. This has been linked to mitochondrial 
dysfunction (563), GLUT4 dysfunction (561) and insulin-like growth factor-1 (564). 
Procyanidins improved peripheral glucose clearance by correcting GLUT4 
translocation (565). Procyanidins are present in sorghum and its distillery waste 
products (160). Isolated sorghum fractions rich in phenolics showed antidiabetic 
effects in rats and mice (185, 207, 208, 214) 
Liver GLUT2 is involved in control of blood glucose (281). In hyperthyroid rats, 
impaired glucose tolerance is associated with an increase in GLUT2 expression in the 
liver (566). Cellular models of fatty liver were associated with increased GLUT2 
mRNA expression and glucose output and gluconeogenesis, rather than increased 
uptake (322). GLUT2 increases are usually associated with impaired glucose 
tolerance, and correction was seen in improved glucose tolerance (282, 313, 315, 318). 
In this study, there was a reduction in the GLUT2 expression in mHWS rats which 
also showed improved glucose tolerance. However, in the corn starch diet, the reduced 
expression was not coupled with changes in glucose tolerance. There is also a lack of 
difference between the controls with respect to GLUT2 expression, with vastly 
different glucose tolerances. Although GLUT2 is involved, explaining the complexity 
is beyond the scope of this research. The effect of WS on its expression and the 
mechanism by which it occurs are not clear.  
Observations in the pancreas showed that there was no change in islet density 
accompanying the improved mHWS glucose tolerance. Although progression of 
diabetes results in reduced β-cell density (567), it has also been shown to be positively 
correlated with weight in non-diabetic patients (568, 569). The increased body weights 
of all these three groups compared to the mCS control may underlie the increased β-
cell density in these rats, and not appear to be directly correlated to glucose tolerance. 
Irrespective of the mechanism, the improvement in glucose tolerance is in line with 
other studies using sorghum extracts where glucose tolerance was improved (208, 
570). This study furthers the work by showing that not only isolated extracts can 
improve glucose tolerance, but a commercial waste product can do the same as a novel 
food. 
Dyslipidaemia 
No changes were noted in the plasma triglyceride, cholesterol or non-esterified fatty 
acid concentrations. Therefore, sorghum distillery waste does not improve the 
dyslipidaemia of metabolic syndrome. Other studies indicated that extracts of WS alter 
plasma lipid profiles, particularly lowering both HDL and LDL concentrations (183). 
The wax component reduced cholesterol concentration in hamster models (571). These 
changes may only be noted in certain extracts rather than the whole fraction. 
Approximately 86% of the lipids present in WS are triacylglycerides (126), so 
although dietary intake of triglycerides was increased, this did not lead to increased 
circulating triglycerides.  
Previous studies showed that the fatty acid composition of sorghum distillery waste 
was 53.96-56.53% linoleic acid, 25.25−27.15% oleic acid, 13.25−16.41% palmitic 
acid, 1.80−2.34% stearic acid and 1.15−1.40% linolenic acids (572). Although these 
unsaturated fats have been associated with improved lipid profiles, this was not seen 
in this study. As with cholesterol, plasma triglyceride concentrations and their link to 
metabolic syndrome are also dependent on the composition whereby unsaturated fatty 
acids, especially linoleic and oleic acids, are inversely related to metabolic syndrome, 
and saturated C14 and C16 fatty acids are positively correlated with metabolic 
syndrome development (573). The intake did not alter plasma lipids, but the dietary 
lipids may have been the functional compounds which affected other parameters, 
especially since WS fats comprised 8.8% of the daily diet.  
Liver 
The mCWS and mHWS showed increased liver weight, which was not associated with 
observations of steatosis or liver inflammation as indicated by histology. There exists 
a linear relationship in the body size and organ weight (574). The same increase was 
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noted in left ventricular weight and right ventricular weight of rats consuming WS. 
Although these values are normalised to tibial length prior to statistical analysis, the 
tibial length is set prior to intervention and is not a reflection of changes in lean mass 
or overall body size. Lean mass is indeed correlated with higher liver size and total 
body weight (575). Similarly lean mass is correlated with ventricular weight, whereas 
height or skeletal size is less indicative (576).  
Due to the low protein content of the mCS diet, using it as a “healthy” control for liver 
studies is not ideal. The elevated plasma AST activity in the mCS may be an indication 
of liver damage, but it can also indicate poor nutrition or low protein intake (513). 
Other studies of low protein diets using maize meal at 4% protein reported AST 
increases after just 5 days (513). This would usually be accompanied by an increase in 
ALT activity but this was not noted, and an increase in lactate dehydrogenase, which 
was. Median reference values for male Wistar rats are 33 U/l and 66 U/l for ALT and 
AST respectively (512). Normal ranges for male Wistar rats are 23-50U/l ALT and 
49-98U/l AST (512). All rats, irrespective of diet or intervention, had ALT values in 
the lower range. The mCS rats showed AST activities increased to the upper range of 
normal, while the mHCHF had “healthier” activities comparable to the median 
reference range.  
Similarly, using this as a control for lactate dehydrogenase may not be optimal. Typical 
reference ranges for male Wistar rats for lactate dehydrogenase are between 83-298 
U/l (512). The rats in this study all had values in the upper range, well above the 
median 114 U/l value for male Wistar rats (512). All rats that were given an 
intervention, irrespective of base diet, were closer to the median value than the 
controls. The addition of 20% WS to the mCS diet markedly reduced the lactate 
dehydrogenase activity. Again, this is possibly due to the low protein content of the 
diets. Protein energy malnutrition in humans is associated with low lactate 
dehydrogenase activity compared to normal protein and energy intake (577).  
Despite the lack of change in liver enzyme activity caused by addition of WS to an 
obesogenic diet, there was improved histology of the liver. The mHCHF group showed 
steatosis and fat vacuoles, while these were absent in the mHWS group. Aqueous 
extracts of Sorghum bicolor improve liver microstructure in rats (413). Sorghum 
bicolor leaf sheath ethanol extract induced hepatocyte ballooning, however only at 
very high doses of over 2000mg/kg per day and prolonged exposure (578). The lack 
of changes to liver enzyme activity are similar to the outcomes seen with rats ingesting 
sorghum flour (253, 489). Aqueous sorghum extracts dose-dependently increased ALT 
and AST activities in rats on a normal diet (579). Methanol extracts of sorghum seed 
showed no effect on the liver enzyme activity, ALT or AST, but these were also 
unchanged by a high fat diet (185). 
Due to the lack of difference between the mCS and mHCHF for TLR4 expression in 
the liver, it is difficult to suggest which changes occur with metabolic syndrome, 
although WS decreased TLR4 expression in the high-fat diet. The implications of this 
are not clear, and whether the reduction in TLR4 affected other parameters is not clear, 
but warrants further research. There was no correlation between LPS concentrations 
and liver TLR4 expression.  
TLR4 is a known mediator of hepatic injury in high fat diets, but its research has been 
focussed on activation and knockouts which have revealed its involvement in 
metabolic syndrome (219, 370, 580, 581). TLR4 expression was increased in muscle 
from insulin-resistant patients (518). TLR4 expression was increased in monocytes 
exposed to oxidised LDL cholesterol (582), which is a risk factor for metabolic 
syndrome (583). No studies have shown that sorghum altered liver TLR4 expression.  
Cardiovascular health 
There was no improvement in left ventricular diastolic stiffness or systolic blood 
pressure with WS consumption. The reduction in collagen deposition may have 
preceded larger physiological changes such as reductions in diastolic stiffness. There 
is some evidence to suggest that procyanidins reduced the proliferation of cardiac 
fibroblasts (584) which are the primary cell type responsible for collagen synthesis in 
the heart (585).   
Increased vascular contraction in response to noradrenaline with WS consumption 
may indicate hypersensitivity. Increased sensitivity to noradrenaline can lead to 
increased blood pressure (586). It was expected that the mHCHF group would have 
lower reactivity than the mCS controls, as has been shown in studies of high fat, diet-
induced obesity in mice (501) and rats (353). In this case, all intervention groups 
showed poorer relaxation when exposed to acetylcholine, which may be detrimental 
to blood pressure control, as may be the increased contraction to noradrenaline. 
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Increased vasoconstriction sensitivity to noradrenaline occurs in diabetic dogs (502) 
and is linked to hypertension in rats (503).  
Gastrointestinal health 
Generally, reduced gastrointestinal motility is associated with increased satiety in the 
small intestine, and in the colon with poorer expulsion of faecal pellets (587). 
Increased sectional contractility resulted in delayed emptying (84). There are still 
significant knowledge gaps in the role of gastrointestinal contraction and metabolic 
syndrome. However, this study suggested that there was reduced sectional contractile 
force with WS consumption which may either reduce risks of constipation, or improve 
colonic clearing.  
This is indeed an area that requires more research. This study indicates that altering 
the diet by adding WS sorghum will change the gastrointestinal function with respect 
to contraction, but its implications are only speculative. Although it is observational 
and data were not collected quantitatively, it was noted that the stool of mCWS rats 
was softer, bulkier and appeared to be passed more frequently than the mCS control. 
Isolated sorghum compounds caused relaxation of pig ileum ex vivo (420). In mice, 
increasing sorghum leaf extract concentration in the diet increased transit time and 
reduced intestinal motility and doses of 200mg/kg or more showed anti-diarrhoeal 
activities (421). Sorghum extracts dose-dependently increased relaxation in the rabbit 
jejunum and rat stomach (421). Likewise, methanol extracts of red sorghum seeds 
showed anti-diarrhoeal activity and prolonged gastrointestinal transit time (523).  
There were no improvements in the gastrointestinal permeability with WS 
consumption. A high fat diet increased gastrointestinal permeability in many rat 
studies (175, 219, 588, 589). Diet did not affect stomach permeability or colon 
permeability but the small intestine was affected as indicated by the mannitol recovery. 
The recovery of mannitol is an indicator of transcellular permeability or absorption, 
while lactulose is an indicator of paracellular absorption (590). These respectively 
indicate villi absorptive capacity and intestinal permeability (591). There was a large 
increase in mannitol recovery in the mHCHF group, which was unchanged by WS. 
The uptake is proportional to absorptive capacity (591), and the subsequent excretion 
shows poor absorption in the high fat diet. One study of red and white sorghum showed 
that colon crypt depth was reduced in the proximal colon with sorghum consumption 
(466) and, in fat rats, crypt depth is also decreased and coupled with poor 
gastrointestinal absorption of sugars (592).  
The expression of tight junctions was not studied in the small intestine, which would 
add weight to this comparison. The expectation based on literature was that changes 
would occur primarily in the large intestine. Ultimately, addition of WS did not greatly 
alter colon permeability, nor did there appear to be changes in serum LPS 
concentrations as was hypothesised.  
Metabolic endotoxaemia 
No significant differences in serum LPS concentrations existed between any control 
or treatment groups. LPS can induce symptoms of metabolic syndrome (238) and 
others suggest it is a direct cause of diet-induced metabolic syndrome (175, 237). 
While LPS may play a role in the progression of metabolic syndrome by initiating 
TLR4-mediated inflammation in the pancreas, colon, liver, heart and other tissues 
(370), this research does not support these changes as being the key factors. It must be 
considered that there is a complex interaction of multiple factors. LPS is produced by 
gastrointestinal Gram-negative bacteria (593). Poor gastrointestinal integrity will 
allow cells and cell components into the blood stream that cause inflammatory 
responses (237). Other factors will affect the concentrations of LPS, including the 
microbial composition of the colon (593), detoxification of LPS by intestinal alkaline 
phosphatase (594), the expression of TLR4 in tissues which is able to be activated 
(595) and the concentration of serum lipopolysaccharide binding protein (596). A more 
comprehensive study investigating all of these components will be beneficial. The 
complexity has not been fully studied, and the high concentration of circulating plasma 
free fatty acids which mimic LPS cannot be discounted (433, 434).  
There are many cellular components that result in inflammation of bacterial origin and 
these must not be discounted in the process of metabolic syndrome progression. TLR2 
is critical in the development of metabolic syndrome (597). TLR5 has a protective 
effect against metabolic syndrome development, where TLR5-deficient mice develop 
metabolic syndrome (598), rather than being protected as in TLR4-deficient mice 
(219). All inflammatory mediators which react to environmental signals are likely to 
play some role in progression of the disease. There is evidence to show that circulating 
free fatty acids and other lipids can stimulate TLR4 and TLR2, and exacerbate 
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inflammation (599). In dyslipidaemia, high concentrations of circulating fatty acid 
components are surmised to be the cause of excessive inflammation and cellular 
dysfunction, rather than LPS itself (370). TLR3, typically associated with detection of 
exogenous double stranded RNA (600), was involved in the progression of type 2 
diabetes, where TLR3-deficient mice were resistant to development of whole body 
insulin sensitivity and somewhat protected from dyslipidaemia (601).  
In this study, I approached the expression of TLR4, but I was unable to quantify all 
the factors which link TLR4 concentrations and the inflammatory process which 
contribute to metabolic syndrome. A single dietary intervention of WS is not sufficient 
to change the concentrations of circulating LPS, and changes in colonic permeability 
did not appear to be involved. Approaching only one inflammatory mediator may have 
been too simplistic.  
5.5 Other considerations and limitations 
Identification and quantification of the bioactive compounds present in the distillers 
grain sorghum used in this study would add considerable weight to the knowledge and 
outcomes. Determination of the individual components would provide a link between 
these compounds and the research outcomes. There can be vast differences in sorghum 
composition due to genetic and environmental factors, and in processing of the grain 
for ethanol production. This will affect the composition of batches used in other 
research, and the research outcomes. Knowledge of the bioactives would provide a 
baseline for further research. In the absence of this information, comparison to future 
studies will be limited.   
5.6 Conclusions 
WS sorghum has shown some positive changes in a model of diet-induced metabolic 
syndrome. One aspect which has become clear is that there is a strong interaction 
between the diet and the supplement. It appears insufficient to use a single supplement 
to reverse the symptoms and a focus needs to be made on the whole diet. The most 
relevant change was the improvement of glucose tolerance, even in a diet high in fat 
and simple sugars. I could not elucidate the mechanisms that were at play, as changes 
in GLUT2 in the liver and pancreatic histology revealed little.   
The link between gastrointestinal permeability, inflammation and LPS has not been 
shown in this dietary model. It is most likely that these changes were minor at the 
molecular level, which did not result in statistical changes, or that the changes are a 
much smaller component of overall diet-induced metabolic syndrome, which is a very 
complex disease.   
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Chapter 6 – Phloretin in a rat model of metabolic syndrome 
6.1 Introduction 
Glucose transport inhibitors have gained much interest with the theoretical application 
to the management or amelioration of diabetic progression (602). Many sugar 
transporters are present, however recent interest has emphasised sodium-dependent 
glucose transporters 1 and 2 (SGLT1, SGLT2) and Glucose Transporter 2 (GLUT2). 
Several SGLT2 inhibitors are already on the market including dapagliflozin, 
canagliflozin and empagliflozin (603).  
SGLT1 transports glucose and galactose and is present in the intestine tract, kidney, 
heart, brain, testis and prostate. SGLT2 is also responsible for glucose and galactose 
transport, however in the kidney, brain, liver, thyroid, muscle and heart (280). GLUT2 
is present in the gastrointestinal tract, pancreas, liver, brain and other parts of the 
nervous system (281). It is not only responsible for sugar transport of glucose, 
galactose and fructose (282), but hepatoportal glucose sensing, pancreatic sensing, 
taste preference and thermoregulation (281).  
Several studies have shown potential for SGLT and GLUT inhibitors to ameliorate 
diabetes (331, 333, 604, 605). Phloretin produces anti-inflammatory responses (349, 
350). As many of the signs of metabolic syndrome are initiated by and associated with 
an inflammatory mechanism (606-608), phloretin has the potential to suppress the 
inflammatory status of the disease. When exposed to phloretin concentrations greater 
than 10µM, LPS-induced macrophages had reduced translocation of TNF-α (tumour 
necrosis factor alpha), PGE-2 (prostaglandin E2), iNOS (inducible nitrogen oxide 
synthase), COX-2 (cyclooxygenase-2) and NFκ-B (nuclear factor kappa-B) (Chang et 
al., 2012). Phloretin improved glucose homeostasis (336, 609), reduced glycation 
which is responsible for diabetic complications (339), was hepatoprotective (341) and 
improved lipid metabolism (337).  
As the targets for phloretin are expressed in multiple tissues, there could be wide-
reaching effects including altered glucose uptake in the GI tract, kidneys, altered 
GLUT2 mediated peripheral uptake and release in the liver, and potentially alterations 
in the sensing of glucose in the pancreas. In addition, SGLT-mediated glucose re-
uptake in the kidney and other tissues may be altered.  
Many studies have looked at the cellular responses to phloretin by exposure in cell or 
tissue culture (339, 343, 349, 351, 610). Very few studies have been conducted to 
assess the overall physiological changes with ingestion in diet-induced metabolic 
syndrome. Only one study appears to have combined all of these effects and researched 
oral ingestion of phloretin in a model of metabolic syndrome, a recently published 
work by Alsanea, et al. (340).  
Metabolic syndrome is hypothesised to be both contributed to by gastrointestinal 
function and as causing gastrointestinal dysfunction (177, 377, 611). Increased 
permeability of the gastrointestinal tract is linked to high plasma insulin and low HDL 
cholesterol concentrations (589). The increased permeability has been associated with 
higher inflammation, resulting from mild endotoxaemia, particularly activation of the 
TLR4 innate immune receptor (219). TLR4 activation increases the risk of 
development of fatty liver (612), hepatic dysfunction (613), vascular inflammation and 
insulin resistance (345). Diet can influence expression of tight junction proteins, 
responsible for maintaining the gastrointestinal integrity. High fat diets increase small 
intestinal permeability (424). Lipopolysaccharides reduce tight junction proteins 
(614), which have origins in the gut induced by a high fat diet (611). Flavonoids 
studied to date that show improved tight junction barrier protein function in the 
gastrointestinal tract are epigallocatechin gallate, genistein, myricetin and quercetin 
(615). Phloretin has not been studied in a gastrointestinal model.  
6.2 Materials & Methods 
6.2.1 Phloretin analysis 
Approximately 1mg of phloretin was dissolved in 10mL of 100% methanol. The 
sample was analysed using an Agilent 1260 HPLC-MS system. The system consisted 
of an Agilent 1260 Degassing Unit, 1260 ALS Infinity Autosampler, 1260 TPP 
quaternary Pump, 260 DAD (Diode Array Detector), connected to an Agilent 6120 
Quadrupole LC/MS (Liquid chromatography/ mass spectrometry) (Agilent, Santa 
Clara, California). 
 
The sample was run isocratically in 90% water, 10% methanol at 0.400mL/min on an 
Agilent, with a 10µL injection volume. The system was run at 20°C on a 
150x10.00mm 5µm Phenomenex Luna 5u C18(2) column (Phenomenex, Lane Cove, 
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New South Wales). The mass spectrum was analysed using APCI (atmospheric 
pressure chemical ionisation), in the negative mode. Gas temperature and vaporiser 
were maintained at 300°C, with a drying gas flow of 9.0L/min, corona current of 
20µA, and a nebuliser pressure of 40 pounds per square inch, gage. The mass spectrum 
peak width was set to 0.1 minutes. 
 
The compound was confirmed to be >99% by peak area, eluting at 0.768 minutes. The 
mass spectrum confirmed the identity of phloretin with an expected molecular weight 
of 274.26g/mol. The negative ion mode generated two major peaks at 273.1 (intensity 
100, parent peak) and 274.1 (intensity 15.1) as shown in Figure 6.1. 
 
 
Figure 6.79: Mass spectrum of phloretin. 
6.2.2 Rats and diets  
Forty-eight male Wistar rats were purchased from ARC (Animal Research Centre, 
Perth, Western Australia) and divided into 6 experimental groups of n=12. 
Experimental groups were CS (corn starch diet), HCHF (high carbohydrate, high fat 
diet), CPh50 (corn starch diet + 50mg/kg/day phloretin), HPh50 (high carbohydrate, 
high fat diet + 50mg/kg/day phloretin), CPh200 (corn starch diet + 200 mg/kg/day 
phloretin), HPh200 (high carbohydrate, high fat diet + 200mg/kg/day phloretin). 
For the first 8 weeks of the protocol, CS, CPh50, and CPh200 rats received the CS diet 
and HCHF, HPh50 and HPh200 rats the HCHF diet as described in method 2.2. At 
eight weeks, treatment groups were changed to their respective intervention diets of 
CS (corn starch), CPh50 (CS containing 0.1% w/w phloretin), CPh200 (CS + 0.4% 
w/w phloretin), HCHF (high carbohydrate, high fat), HPh50 (HCHF + 0.1% w/w 
phloretin), and HPh200 (HCHF + 0.4% w/w phloretin). Phloretin was considered to 
have no metabolisable energy. 
At 0, 8, and 16 weeks, prior to termination, oral glucose tolerance (method 2.3), body 
composition (method 2.4) and systolic blood pressure (method 2.5) were determined. 
Rats were starved for 2 hours prior to termination. Rats were euthanised as per method 
2.6.1. At termination, rats underwent plasma collection (method 2.6.3), vascular 
reactivity (method 2.6.5), ileum and colon contractility (method 2.6.6), organ weights 
(method 2.6.7) and histological tissue collection (method 2.6.1). 10 rats per group 
underwent isolated heart perfusion (method 2.6.4), with the remaining two hearts 
preserved in formalin for histological analysis as per method 2.6.1. Plasma samples 
were assessed on 8 rats per group for liver enzyme activity (method 2.7.1) and plasma 
lipid profile (method 2.7.2.). Collected serum was analysed for presence of endotoxins 
as per method 2.9. Liver sections were assessed for expression GLUT2 and TLR4 
(method 2.11.3). Distal colon sections were also assessed for occludin and claudin-1 
expression using the method described in method 2.11.4, and for TLR4 expression. 
Histological tissue samples were processed manually (method 2.8.2) and sectioned 
(method 2.8.3). Liver, ileum, colon, pancreas and left ventricle were stained with 
hematoxylin and eosin (method 2.8.5.1). Separate sections of left ventricle were 
stained with picrosirius red (method 2.8.5.2). Microscopy and imaging were 
performed as per method 2.8.6.1, 2.8.6.2, 2.8.6.3 and 2.8.6.4. Statistical analysis was 
performed on pancreatic islet cell count and density.  
6.3 Results 
6.3.1 Physiological parameters 
Phloretin daily intake, and equivalent human dose is shown in Table 6.1. Calculations 
have been based on scaling equations by Bachmann, et al. (616) for a 70kg adult 
human.  
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Table 6.26: Phloretin daily intake of rats and equivalent human doses. Calculations are 
based on the average rat bodyweight at 16 weeks.  
 
 CS CPh50 CPh200 HCHF HPh50 HPh200 
Rat phloretin intake (mg) 0 61 ± 0.3 131 ± 0.6 0 26 ± 0.1 100 ± 0.3 
Rat bodyweight (g) 379 ± 1.9 397 ± 1.7 378 ± 2.0 505 ± 1.6 543 ± 3.6 511 ± 4.0 
Dose (mg/kg) 0 93.4 347 0 47 183 
Equivalent human dose (mg) 0 1167 4270 0 657 2543 
Equivalent human dose (mg/kg) 0 17 61 0 9 36 
 
Treatment with phloretin did not change body weight gain as indicated in Figure 6.2. 
Food intake and energy intake did not differ in the first 8 weeks of intervention within 
a dietary group (Table 6.27). HCHF rats consumed a lower weight of food than the CS 
groups, however showed higher energy intake (Table 6.2). After intervention, the 
HCHF, HPh50 and HPh200 rats showed similar food and energy consumption. 
Similarly, energy intake did not differ between the CS fed rats and CPh50 or CPh200 
rats.  
 
Figure 6.80: Weekly body weight.  
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Feed efficiency increased in all HCHF rats in the first 8 weeks of feeding. Feed 
efficiency with phloretin addition was not different from respective diet controls. 
However, HPh200 feed efficiency was comparable to CS controls, and CPh50 feed 
efficiency was similar to HCHF diet.  
Total body fat mass was affected by both diet and by intervention. Total body fat mass 
(body composition by DXA) was increased in the HPh50 rats compared to the HCHF 
group. Addition of phloretin at 200mg/kg/day in the HPh200 rats did not result in any 
fat mass changes by DXA compared with the HCHF rats. 
Addition of phloretin was shown to have an impact on lean body mass, which was 
increased when a dose of 200mg/kg/day were administered, and decreased at a dose 
of 50mg/kg/day in the CS diet. The only change was a difference between the CPh200 
and CPh50 groups, however neither differed from respective controls (Table 6.27). 
The ratio of lean:fat mass was increased in the CPh200 rats compared with the CS rats. 
Lean:fat mass ratio was unchanged by adding phloretin to the HCHF diet.  
Both diet and phloretin supplementation had an impact on individual abdominal fat 
pads and total abdominal fat pads, as determined by two-way ANOVA, shown in Table 
6.1. Despite this, statistically significant changes from the respective controls were not 
evident, based on a one-way ANOVA. The significance of the intervention effect was 
due to the consistent trend of higher abdominal fat pad mass in the 50mg/kg/day dose, 
and consistently lower trend of abdominal fat pad mass in rats consuming 
200mg/kg/day. 
Bone mineral content (BMC) was increased in all HCHF rats compared with CS 
control, CPh50 and CPh200 rats. There was no difference between HCHF and HPh200 
fed rats; however, the HPh50 rats had a significantly higher BMC than HCHF. Bone 
mineral density (BMD) was higher in the HCHF fed groups. Addition of phloretin did 
not alter BMD. 
185 
 
Table 6.27: Physiological and metabolic parameters of CS, CPH50, CPh200, HCHF, HPh50, and HPh200 fed rats. 
 
Differing superscript letters indicate significant difference at p<0.05 as determined by one-way ANOVA. Interaction, intervention, and diet were 
tested for significant contributions to variation using a two-way ANOVA, with p values reported far right.    
Parameter Interaction Intervention Diet
Food intake (g/day) Week 0-8 36.6 ± 1.1 a 36.8 ± 0.9 a 39.7 ± 1.3 a 24.4 ± 0.3 b 26.3 ± 0.8 b 24.4 ± 0.4 b 0.0244 0.1883 < 0.0001
Food Intake (g/day) Week 8-16 36.2 ± 0.8 ab 37.1 ± 0.6 a 32.8 ± 0.9 b 24.2 ± 0.6 c 25.7 ± 0.9 c 24.9 ± 0.7 c 0.0238 0.0068 < 0.0001
Energy intake (kJ/day) Week 0-8 410.6 ± 12.1 b 412.9 ± 10.1 b 445.8 ± 14.2 b 514.2 ± 5.6 a 548.7 ± 15.4 a 530.0 ± 10.8 a 0.099 0.0951 < 0.0001
Energy intake (kJ/day) Week 8-16 406.6 ± 9.1 b 416.1 ± 6.4 b 368.5 ± 10.5 b 523.7 ± 10.9 a 553.9 ± 17.4 a 539.6 ± 14.8 a 0.0882 0.0411 < 0.0001
Feed efficiency (g gained. kJ-1) Week 0-8 0.22 ± 0.24 b 0.31 ± 0.13 b 0.77 ± 0.24 b 3.09 ± 0.13 a 3.59 ± 0.22 a 3.32 ± 0.25 a 0.2148 0.1488 < 0.0001
Feed efficiency (g gained. kJ-1) Week 8-16 1.57 ± 0.12 2.03 ± 0.20 0.95 ± 0.38 2.72 ± 0.15 3.06 ± 0.17 2.29 ± 0.25 0.7852 0.0005 < 0.0001
Bone mineral density (g/cm2) 0.176 ± 0.003 ab 0.179 ± 0.003 ab 0.174 ± 0.002 b 0.183 ± 0.002 ab 0.189 ± 0.004 a 0.182 ± 0.003 ab 0.8616 0.1494 0.0021
Bone mineral content (g by DXA) 11.16 ± 0.35 c 12.52 ± 0.40 c 11.23 ± 0.32 c 15.40 ± 0.38 b 17.96 ± 0.48 a 15.35 ± 0.39 b 0.1835 < 0.0001 < 0.0001
Total body fat mass (g by DXA) 85.3 ± 7.5 cd 117.5 ± 11.4 c 58.3 ± 4.6 d 202.8 ± 9.0 b 262.4 ± 14.8 a 201.7 ± 16.7 b 0.4387 < 0.0001 < 0.0001
Total body lean mass (g by DXA) 284.8 ± 6.8 ab 265.2 ± 8.2 b 315.1 ± 6.6 a 286.8 ± 4.5 ab 274.5 ± 10.5 ab 294.7 ± 19.0 ab 0.4039 0.0133 0.7471
Lean:Mat mass ratio 3.32 ± 0.46 b 3.02 ± 0.56 a 5.11 ± 0.63 ab 1.51 ± 0.09 c 1.03 ± 0.09 a 1.72 ± 0.27 ab 0.1238 0.0053 0.7471
Retroperitoneal fat (mg/mm tibial length) 164.40 ± 15.16 b 182.10 ± 14.33 b 128.50 ± 7.60 b 383.40 ± 40.54 a 449.70 ± 23.67 a 363.10 ± 30.54 a 0.6017 0.0208 < 0.0001
Epididymal fat (mg/mm tibial length) 91.85 ± 8.19 b 104.60 ± 8.18 b 84.05 ± 2.25 b 194.80 ± 18.07 a 219.00 ± 10.25 a 164.80 ± 21.88 a 0.4267 0.0212 < 0.0001
Omental fat (mg/mm tibial length) 97.65 ± 12.91 b 123.40 ± 8.21 b 88.38 ± 6.00 b 206.30 ± 14.86 a 240.40 ± 16.54 a 195.00 ± 14.23 a 0.9084 0.0062 < 0.0001
Total abdominal fat pad (mg/mm tibial length) 338.9 ± 28.5 c 410.0 ± 27.5 c 300.9 ± 11.5 c 784.5 ± 56.5 ab 909.1 ± 39.0 a 723.0 ± 55.3 b 0.6043 0.0014 < 0.0001
HPh200CS CPh50 CPh200 HCHF HPh50
6.3.2 Plasma lipids and glucose control 
At 8 weeks of dietary feeding, prior to phloretin intervention, the HCHF, HPh50 and 
HPh200 rats showed increased fasting blood glucose concentrations as indicated in 
Table 6.28. The CPh200 group also had raised fasting blood glucose concentrations. 
Glucose area under the curve was raised in the HCHF diets at 8 weeks.  
At 16 weeks, the HCHF, HPh50 and HPh200 groups had elevated fasting glucose 
compared to the CS. Supplementation at 50mg/kg/day did not alter the fasting blood 
glucose or glucose tolerance in either the CS or HCHF diet. Supplementation at 
200mg/kg/day reduced the TAUC in the CPh200 fed rats from the CS control. The 
HPh200 group showed glucose tolerance normalised to that of the CS control (Table 
6.28). The HPh200 glucose tolerance curves show that fasting glucose was not altered 
from the HCHF model, however peak glucose concentration was reduced, and from 
60 minutes onward the curve was comparable to that of the CS control.  
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Table 6.28: Blood glucose control and plasma lipids of CS, CPH50, CPh200, HCHF, HPh50, and HPh200 fed rats.  
 
Differing superscript letters indicate significant difference at p<0.05 as determined by one-way ANOVA. Interaction, intervention, and 
diet were tested for significant contributions to variation using a two-way ANOVA, with p values reported far right.    
 
Parameter Interaction Intervention Diet
Fasting blood glucose (mM) 8 week 3.0 ± 0.1 b 3.2 ± 0.2 b 3.8 ± 0.2 a 4.4 ± 0.3 a 4.2 ± 0.1 a 4.2 ± 0.1 a 0.0239 0.1609 < 0.0001
 TAUC blood glucose 8 week 686.7 ± 26.5 a 689.4 ± 26.8 a 692.8 ± 20.3 a 724.0 ± 46.8 ab 786.1 ± 22.1 ab 816.1 ± 26.1 b 0.2998 0.2144 0.0004
Fasting blood glucose (mM)16 week 3.5 ± 0.2 b 3.7 ± 0.2 b 3.7 ± 0.2 b 5.0 ± 0.3 a 5.1 ± 0.2 a 4.5 ± 0.1 a < 0.0001 < 0.0001 < 0.0001
 TAUC blood glucose 16 week 723.0 ± 22.4 bc 775.9 ± 29.7 b 635.9 ± 17.8 c 919.1 ± 36.8 a 922.4 ± 34.0 a 724.0 ± 21.5 b 0.1364 < 0.0001 < 0.0001
Plasma total cholesterol (mM/L) 1.66 ± 0.30 a 1.67 ± 0.33 a 2.08 ± 0.29 b 1.62 ± 0.15 a 1.85 ± 0.36 a 2 ± 0.24 b 0.3615 0.0003 0.8255
Plasma triacylglycerides (mM/L) 0.45 ± 0.21 ab 0.39 ± 0.11 a 0.46 ± 0.26 ab 0.98 ± 0.55 c 0.7 ± 0.65 b 1.24 ± 0.43 c 0.2268 0.0946 < 0.0001
Plasma non-esterified fatty acids (mM/L)1.31 ± 0.43 a 1.42 ± 0.41 a 1.83 ± 0.95 a 3.6 ± 1.60 b 2.96 ± 2.42 ab 4.23 ± 1.22 b 0.5957 0.1826 < 0.0001
HPh200CS CPh50 CPh200 HCHF HPh50
    
   
Figure 6.81: Haematoxylin & eosin stain of pancreatic islets at 10x magnification. CS 
(A), CPh50 (B), CPh200 (C), HCHF (D), HPh50 (E), HPh200 (F).  
 
Pancreatic islet cell density was not changed by diet or phloretin intervention. No 
indication of b-cell death was noted in any section, as shown in Figure 6.81.  
Total cholesterol concentration did not differ between the HCHF and CS control 
groups. Both the CPh200 and HPh200 groups showed increased total plasma 
cholesterol concentrations compared to all other groups (Table 6.28).   
Plasma triacylglycerides (TAG) were more than doubled in the HCHF diet compared 
with the CS. No change was evident with phloretin ingestion (Table 6.28). 
Plasma NEFA (non-esterified fatty acids) were 2.75 times higher in the HCHF model 
compared with the CS. No statistical changes were associated with phloretin addition 
in the CS diet. The HPh50 group had NEFA concentrations comparable to the CS 
control, but had not changed sufficiently to be different from the HCHF control, as 
shown in Table 6.3. The HPh200 group did not show the same decrease, indicating 
that there may be dose-dependent effects. 
6.3.3 Cardiovascular and hepatic structure and function 
Normalised left ventricular weight did not differ between any groups (Table 6.29). 
Normalised liver wet weight was increased in HCHF compared to CS diets, and was 
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not altered by phloretin consumption. The diastolic stiffness (κ) was not altered in any 
group.  
Table 6.29: Cardiovascular and hepatic structure and function of CS, CPH50, CPh200, HCHF, HPh50, and HPh200 fed rats. 
 
Differing superscript letters indicate significant difference at p<0.05 as determined by one-way ANOVA. Interaction, intervention, and 
diet were tested for significant contributions to variation using a two-way ANOVA, with p values reported far right.    
 
Parameter Interaction Intervention Diet
Left ventricle + septum (mg/mm tibial length) 18.55 ± 0.95 ab 18.96 ± 1.04 ab 18.10 ± 0.50 a 21.83 ± 1.02 b 21.55 ± 0.56 b 19.99 ± 0.71 ab 0.6953 0.2536 0.0003
Right ventricle (mg/mm tibial length) 4.09 ± 0.28 ab 4.30 ± 0.44 ab 3.87 ± 0.22 b 4.97 ± 0.27 ab 5.16 ± 0.26 a 4.90 ± 0.24 ab 0.9502 0.4999 0.0003
Systolic blood pressure (mmHg) 154.4 ± 1.2 a 124.1 ± 1.1 c 121.4 ± 0.5 c 135.6 ± 3.5 b 136.5 ± 1.9 b 135.4 ± 1.3 b < 0.0001 < 0.0001 0.114
Liver (mg/mm tibial length) 204.40 ± 6.83 b 198.70 ± 5.41 b 215.80 ± 8.17 b 305.00 ± 8.65 a 292.40 ± 6.52 a 291.10 ± 14.20 a 0.3361 0.5296 < 0.0001
Diastolic stiffness constant (κ) 26.45 ± 2.193 a 30.94 ± 1.595 b 31.51 ± 1.134 bc 32.8 ± 1.34 ab 27.08 ± 2.301 ab 26.66 ± 0.6361 ab 0.0097 0.8256 0.1523
Plasma ALT activity (U/L) 33.25 ± 11.57 a 28.18 ± 7.236 a 30.22 ± 7.085 a 28.7 ± 10.6 a 29.18 ± 20.33 a 31.67 ± 7.599 a 0.692 0.7952 0.826
Plasma AST activity (U/L) 83 ± 20.78 a 66.82 ± 15.85 b 67.67 ± 13.38 ab 62.3 ± 14.67 b 63.91 ± 23.61 b 60.56 ± 10.48 b 0.2566 0.2625 0.0284
HPh200CS CPh50 CPh200 HCHF HPh50
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The deposition of collagen was not altered by treatment with phloretin (Figure 6.82). 
Deposition of collagen was increased in the HCHF (6.4%) group compared to the CS 
control (4.8%). Both the CPh50 (14.1%) and CPh200 (9.6%) groups showed increased 
collagen deposition compared to the CS control. In the HPh200 (6.5%) group, collagen 
was comparable to the HCHF control.  
 
 
Figure 6.82: Picrosirius red staining indicating deposition of collagen type I and III 
fibres in the left ventricle. Shown at 20x magnification. CS (A); CPh50 (B), CPh200 
(C), HCHF (D); HPh50 (E); HPh200 (F).  
 
HCHF rats had a severely blunted relaxant response to acetylcholine in isolated 
thoracic aortic rings compared with the CS control. HPh50 and HPh200 rats did not 
display this. Maximal responses were normalised to the CS control in the HPh50 
group. Both the CPh200 and HPh200 rats had comparable responsiveness, which 
exceeded the CS control, as indicated in Figure 6.5. 
Aortic responsiveness to noradrenaline did not differ between CS and HCHF groups. 
Maximal responses to noradrenaline were markedly increased in the CPh200 group, 
compared to all other groups, which did not differ, as shown in Figure 6.83. Maximal 
responses to sodium nitroprusside were higher in the CS, CPh200 and HPh50 groups 
than the HCHF, CPh50 and HPh200 groups.  
A B C 
D E F 
             
   
Figure 6.83: Thoracic aortic responses to acetylcholine, sodium nitroprusside and 
noradrenaline of control and phloretin-treated rats. Lower-case letters indicate a 
significant difference in final force of contraction (mN) at p<0.05 determined by one-
way ANOVA. 
 
Plasma alanine aminotransferase (ALT) activity was not affected by diet or 
intervention. Plasma aspartate aminotransferase (AST) activity was higher in the CS 
control compared with the HCHF. Phloretin did not change AST activity at either dose 
in the HCHF model, in the CPh50 group AST was lower than the CS control, 
comparable to the HCHF control Table 6.4. 
Hepatocyte ballooning and fat deposition were evident in the HCHF model, and not in 
the CS model. This appeared unchanged with phloretin addition as shown in Figure 
6.6. 
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Figure 6.84; Haematoxylin and eosin stains of liver indicating ballooning and fat 
deposition, at 20x magnification. CS (A); CPh50 (B); CPh200 (C); HCHF (D); HPh50 
(E); HPh200 (F). Scale bars indicate 200µm. 
 
GLUT2 and TLR4 expression in the liver were unchanged by diet or intervention, 
Figure 6.85.  
 
 
Figure 6.85: Liver GLUT2 expression (left) and liver TLR4 expression (right).  
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 6.3.4 Gastrointestinal parameters 
Colonic and ileal reactivity did not differ with dietary groups. Rats on the HPh200 diet 
had a higher final ileal force of contraction than the CS control, and all other groups 
as shown in Figure 6.86. No other groups differed. No changes in colonic responses 
were noted between any groups.  
 
Figure 6.86: Colon (top) and ileum (bottom) reactivity to acetylcholine. Differing 
lower-case letters indicate a different final maximal force of contraction, determined 
by one-way ANOVA, p<0.05. Where no letters are indicated, no difference was 
calculated. 
 
TLR4 expression in the colon did not differ between any groups, Figure 6.87. 
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Figure 6.87: Liver TLR4 expression determined by semi-quantitative ELISA. No 
significant difference was seen between any groups.  
Claudin-1 expression was elevated in the HCHF group. The CPh50 and CPh200 
groups had increased expression from the CS control. Occludin expression was 
unchanged by diet or intervention, Figure 6.88. 
  
Figure 6.88: Claudin-1 expression in the colon (left) and occludin (right) expression 
in the colon determined by semi-quantitative ELISA. Differing lower-case letters 
indicate a significant difference at p<0.05.  
 
6.4 Discussion 
The aim of this study was to determine whether phloretin was able to ameliorate the 
physiological and biochemical changes that occur with metabolic syndrome including 
cardiovascular remodelling, impaired glucose tolerance, adipose tissue presence and 
dyslipidaemia. Further, the study aimed to determine some of the molecular 
mechanisms by which phloretin may affect metabolic syndrome including alteration 
of gastrointestinal integrity reflected in changes in occludin and claudin-1 expression, 
and expression of TLR4. 
It was predicted that phloretin would have the largest impact on glucose tolerance due 
to its known activity in inhibiting SGLT-1 and GLUT2. Phloretin was also surmised to 
be highly anti-inflammatory based on in vitro studies, which could reverse or prevent 
progression of metabolic syndrome. Using body weight scaling equations (616), the 
equivalent human dose for the HPh200 group is 2543mg per day, for an adult of 70kg. 
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When compared with other studies that use a similar animal model, this high dose is 
probably excessive, expensive and not more effective than other supplements. Overall, 
the most promising indication for phloretin intake appears to be improved glucose 
tolerance.  
Body composition 
Phloretin did not result in fat loss where obesity is caused by a high fat diet. This is 
consistent with the data from Alsanea, et al. (340), who used intraperitoneal injections 
in mice. Given the different direction of change in fat mass, lean:fat mass ratio, and 
abdominal fat pad mass with the two phloretin doses, it is surmised that there is a dose-
dependent and dietary interaction. The effect on adiposity may be from altered uptake 
of sugars and fats, altered gene expression, or changes in metabolic pathways, as the 
energy intake was unaltered. Lipid accumulation and adipocyte differentiation 
increased with phloretin exposure in in vitro studies using 3T3L-1 adipocytes, and 
markers of lipid accumulation were increased (609). Adipogenic regulator expression 
increased on exposure to phloretin at 50µM with increased 3T3L-1 adipocyte 
differentiation (610). Skeletal muscle palmitate uptake in cell culture was inhibited by 
phloretin in the presence of 300mmol phloretin (617). Other studies suggest that 
phloretin inhibited lipid accumulation and reduced the expression of adipogenic 
transcription factors (351).  
Given that the outcomes of fat accumulation differed in magnitude and direction with 
differing doses, phloretin may be adipogenic or anti-adipogenic depending on the dose. 
It is also noted that the true dose in the HCHF and CS supplemented diets differ, despite 
the same dose in food. For this reason, comparison between the interaction with the 
CS diet and phloretin, and the HCHF diet and phloretin may be affected largely by the 
dose, rather than simply interaction with the other dietary components.  
Energy and food consumption 
Phloretin did not affect appetite in high fat diets but reduced food volume intake by 
approximately 11% in a low-fat diet. To date, very little research has been reported on 
sugar inhibitors affecting appetite. However, Kuhre, et al. (618) showed that inhibition 
of GLUT2 by phloretin resulted in suppression of neurotensin release, which is 
surmised to be responsible for glucose-stimulated appetite regulation. Inactivation of 
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glucose sensors in GLUT2-null mice resulted in over-consumption (619). 
Administration of 2-deoxyglucose, also a GLUT2 inhibitor, resulted in hypoglycaemia 
and stimulated food consumption (620). These results contrast with the food intake 
results in this study. Consumption of a GLUT2-inhibiting compound in the diet did not 
lead to impaired glucose-controlled feeding.  
 
Pre-diabetes 
Phloretin corrected post prandial glucose tolerance but not fasting glucose. There 
appeared to be no damaging effects of phloretin to glucose tolerance in a normal, 
healthy diet. The results here are somewhat consistent with other studies. Treatment of 
obese mice with phloretin by intraperitoneal injection led to reduced insulin 
concentrations in a rat model of obesity (340). In cell culture models, phloretin 
improved insulin sensitivity (610). The phloretin glycoside, phloridzin, improved non-
fasted glucose concentrations in streptozotocin-diabetic rats at concentrations less than 
40mg/kg/day (337). Reduced blood glucose concentrations have been shown with 
phloretin intake simultaneous to glucose ingestion (621).   
The improvement seen could not be attributed to normalisation of β-cell mass. In 
animal models of obesity, preceding type 2 diabetes mellitus, there is an increase in 
the b-cell mass (622), whereas after development of type 2 diabetes mellitus there is a 
distinct decrease in b-cell mass (623). The restoration of glucose tolerance must be due 
to improved function of the islets, improved peripheral glucose clearance or action of 
glucose regulating hormones.  
Plant-derived flavonoids including marinin and okanin at a dose of 20mg/kg/day 
restored pancreatic function in diabetic Wistar rats (624). In pre-diabetic rats, there 
was a loss of GLUT2 from the pancreatic b-cells (302, 303, 625). GLUT2 expression 
in the pancreas reduced with non-insulin dependent diabetic progression (625) (626). 
Inhibition of GLUT2 can prevent loss of expression in pancreatic β-cells in rat models 
of streptozotocin-induced diabetes, exhibiting potential for phloretin (300). In other 
studies, GLUT2 inhibition was protective and preventative in the progression of 
insulin resistance and pre-diabetes (627, 628). This was not studied in our research as 
humans do not have GLUT2 as their primary glucose sensor in the pancreas (299), 
limiting the indications for phloretin in human trials.  
Peripheral glucose clearance can be improved by normalisation of GLUT2 expression 
in the liver. The expression of GLUT2 in the liver was unchanged in this study. This 
is in contradiction to other models of diabetes. In other models, an increase in GLUT2 
expression occurred in glucose-impaired hyperthyroid rats (566). Cell models of fatty 
liver showed increased GLUT2 mRNA expression, glucose output and 
gluconeogenesis, rather than uptake (322). In an 60 day model of diabetes, Wistar rats 
had increased GLUT2 mRNA in the liver and increased protein expression (629).  
The composition of sugars and complex carbohydrates is likely to be of importance in 
the situations where sugar transporters are targeted as therapeutic agents. The ability 
of GLUT2 to transport fructose (630) may be one of the contributing factors that have 
caused differing effects in the HCHF and CS diets in this study. Other sugar 
transporters may have a compensatory role when another is inhibited. GLUT2 and 
GLUT5 work in conjunction to transport fructose, and GLUT5 contributes most of the 
fructose transport at the brush border (631). GLUT5 increased under high fructose 
feeding in GLUT2 null mice, therefore this may have a compensatory action (632). 
Fructose uptake can be reduced by GLUT2 inactivity (632) but cannot be fully 
stopped. This is likely to explain the lack of weight loss in the high fructose HCHF 
diet, even though it was expected.    
Dyslipidaemia 
At high doses, phloretin increased plasma total cholesterol concentrations. The 
increased total cholesterol concentration suggests an increased risk of atherosclerosis 
associated with the metabolic syndrome. Low HDL concentrations are a risk factor 
and diagnostic tool for metabolic syndrome (173). As LDL and HDL were not tested 
separately, we cannot definitively suggest that phloretin will increase the 
predisposition of cardiovascular risk due to high total cholesterol. A more significant 
factor is reduced HDL, and increased LDL cholesterol. Shu, et al. (609) showed 
reduced cholesterol concentrations at low doses of phloretin. Alsanea, et al. (340) 
showed no change in plasma lipids, despite reduced fat deposits in the liver, similar to 
what was seen in our study. Apple polyphenols, which include phloretin, resulted in 
an improved plasma cholesterol profile, through altering the ratio of LDL:HDL (633). 
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In vitro studies have shown that phloretin and GLUT2 inhibition may increase 
cholesterol secretion rates in intestinal TC7 cells, however  it was suggested that this 
was a non-significant increase (634). In contrast, apple polyphenols were shown by 
Vidal, et al. (635) to reduce cholesterol esterification and secretion by TC7 cells, by 
the related phloretin metabolite phloretin-2-glucoside. Uptake of cholesterol was 
inhibited by phloretin in vitro (636), which is not supported by this research. If 
phloretin is able to prevent oxidation of cholesterol molecules, this will reduce the 
cardiovascular risk (637). 
Cardiovascular health and liver health 
Phloretin restored efficacy of acetylcholine in eliciting vasodilation in the HCHF diet 
at both doses, but this was not correlated with improved systolic blood pressure. This 
may be due to the anti-inflammatory effects with phloretin resulting in reduced aortic 
stiffness. TNFα antagonists also have these effects (638). Phloretin suppressed changes 
in endothelial cells when exposed to TNFα (343). In rabbit isolated vessels, phloretin 
induced vascular relaxation at concentrations as low as 5µM by an endothelium-
independent mechanism (639). The same study showed that genestin had similar 
effects and was transferrable to in vivo human trials. Presence of phloretin impaired 
noradrenaline contractile responses in isolated rabbit vascular sections, and was again 
suggested to be endothelium-independent, and promote vaso-relaxation (640). There 
was no reduction in diastolic stiffness or collagen deposition with phloretin 
consumption. Phloretin does not show promise for cardiovascular health in a model of 
metabolic syndrome when all factors are accounted for.  
The addition of phloretin to the CS diet resulted in reduced plasma AST activity yet 
the change was not associated with changes in the histology of the liver or liver size. 
Although no changes in liver enzymes occurred in the high fat diet with phloretin, 
there was an improvement in the liver histology. Estrogenic studies show no changes 
in liver enzyme activity with phloretin doses up to 100mg/kg (641). Phloretin delivered 
by intraperitoneal injection at a dose of 10mg/kg twice weekly reversed fat 
accumulation and cellular ballooning of hepatocytes in a high-fat diet, mouse model 
(340). 
 
Gastrointestinal function 
Gastrointestinal effects of phloretin include increased colonic and ileal reactivity on 
exposure to acetylcholine. Within the gastrointestinal tract, there is an ideal contraction 
strength and frequency which can be altered by multiple disorders. In obese leptin-
deficient mice, responses to cholecystokinin were diminished, but responses to 
acetylcholine were unchanged (642). This may explain the lack of difference between 
the CS and HCHF diets. Other research indicated increased small intestinal 
contractility and lowered distal contractility (179). The increase in ileal contractility 
with phloretin addition, specifically in a high fat diet, may lead to increased smooth 
muscle contraction, and should be considered a potential contraindication in those with 
pre-existing gastrointestinal disorders. Phloretin phosphate at 40µg/mL decreased 
contraction in isolated guinea pig ileum (643).  
Gastrointestinal integrity is gaining traction as a contributing factor to overall health, 
particularly with respect to inflammatory disease such as obesity and metabolic 
syndrome. In this study, we demonstrated that the HCHF model unexpectedly showed 
increased claudin expression. The complex of tight junction proteins also contains ZO-
1 (zonula occludin-1) and junctional adhesion molecules (644). ZO-1 was not studied, 
and occludin was not altered. These results appear to contradict other studies that 
suggest high fat feeding reduces expression of tight junction proteins (237) and in 
genetically obese and diabetic mice (177, 423).  
Increased expression of occludin has been linked to improved gut integrity. Similar to 
the outcome seen in phloretin ingestion, grapeseed extract containing polyphenols 
increased colonic occludin expression (645). Although the outcomes in control rats 
were unexpected, there is a promising indication that phloretin can improve 
gastrointestinal integrity.  
Limitations 
A number of shortcomings are evident in this study. Due to the complexity of the 
system, it was not possible to explore all mechanisms involved in phloretin’s 
improvement of glucose tolerance. Several other aspects such as changes in cholesterol 
oxidation, oxidative state, GLUT2 and TLR4 expression in more tissues, and the 
densities of SGLT-1 and other sugar transporters were not assessed. In addition to 
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determining the pancreatic islet density, it would have been ideal to assess a suite of 
inflammatory markers that alter insulin release, and determining insulin concentrations 
in conjunction with blood glucose concentrations. It would also prove beneficial to 
assess GLUT-4 and 5 expression in muscle tissue, as there appeared to be a much 
improved peripheral glucose clearance in phloretin-supplemented rats.  
6.5 Conclusions 
The research provides evidence that phloretin has a therapeutic role with respect to the 
glucose tolerance aspect of metabolic syndrome, but this is no greater than other more 
cost-effective examples. There is some evidence to suggest that it may cause 
gastrointestinal discomfort at high doses, as indicated by the increased ileal 
contractions. Although phloretin does not seem to be harmful in this rat model of 
obesity, it does have some contraindications which require consideration. While 
phloretin impacts glucose uptake and results in lower peak blood glucose 
concentrations, long-term ingestion with meals does not reduce calorie consumption 
in ad libitum models, nor does it ameliorate weight gain, cardiovascular changes or 
lipid dysregulation associated with metabolic syndrome.  
  
Chapter 7 – Conclusions 
7.1 Conclusions and future directions of sorghum in diets 
7.1.1 Summary of key findings and their implications 
Sorghum as an addition to diets to improve metabolic syndrome has shown potential 
in this research as it alters a range of parameters of metabolic syndrome. A key take-
away message from the research was that sorghum’s impacts were varied, based on 
the type of intervention.   
Whole sorghum showed significant promise for reduction of total cholesterol in a 
similar way that oats have been touted as a dietary component to improve cholesterol 
concentrations, and also normalisation of post-prandial glucose. Incorporating 
sorghum into diets is a simple and feasible way for people to improve cholesterol 
concentrations at a dose of just 30g per day. Continuing research with clinical trials to 
further this, and confirm the effects in humans, will be important to promote sorghum 
products for the consumer market, and reduce the risk of developing  type 2 diabetes 
and cholesterol-related complications.   
Black sorghum flour and red sorghum flour improved metabolic parameters in a 
normal diet, although few changes in high fat-high carbohydrate diets that induce 
metabolic syndrome. This should not be a deterrent for the consumption of sorghum, 
as there were indications that sorghum flour can help prevent the changes that lead to 
metabolic syndrome. A wholegrain flour will have greater functional properties.   
Wet cake sorghum consumption resulted in improvements in glucose tolerance, 
improved liver histology, increased lean mass, and reduced liver GLUT2 and TLR4 
expression. Few studies have looked at sorghum products or sorghum-based diets and 
their effects on metabolic syndrome, and wet cake has not been studied in a human 
context for health. This presents an important possibility for future research. This 
research provides a foundation to indicate that this waste product of sorghum 
fermentation for ethanol production can be used as a functional food product. Sorghum 
wet cake has been added to chocolate chip cookies, sugar cookies, molasses cookies, 
bread (646), and spaghetti (647) with no sensory aversion by consumers. These studies 
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are old, and the idea has not taken off. We may see these fortified food products on the 
market with added health information backing their use.  
Addition in the diet also showed increased lean mass which is of interest for fields 
other than metabolic syndrome. This could be looked at as an alternate nutrition source 
in countries where protein is expensive or has low availability, as well as in ageing 
patients. Further, this is likely to influence nutrition studies where efficient sources of 
protein are of high interest and components which inhibit muscle breakdown such as 
catechins, or components which promote muscle growth, are also of interest.   
7.1.2 Limitations and considerations for future research 
There are limitations to this research, especially considering the physiological 
differences between rat models of metabolic syndrome and transferring to human 
consumption. Further, the development of metabolic syndrome was less pronounced 
in the modified high-carbohydrate, high-fat diet with minimal changes in liver 
enzymes, diastolic stiffness and cholesterol concentrations. There were inconsistent 
changes in the expression of GLUT2, TLR4, occludin and claudin between the two 
diets. This suggests other components may be contributors or that one progresses the 
molecular changes more quickly. Further, the control diets differed in their 
macronutrient composition and the rats fed the modified corn starch diet showed 
indications of liver damage and muscle wasting, possibly due to the low protein or 
energy content of the diet.  
Rat models are inherently complex systems, as are humans. Assessing a single system 
such as the progression from gastrointestinal tract to tight junctions to intestinal 
permeability to endotoxaemia and finally to metabolic syndrome is important to 
understand its contribution and involvement, but does not give a full picture of the 
processes involved. Because of the complexity of the system, monitoring a wider range 
of biomarkers as a pilot study might show the weighted average of contributions of the 
biochemical pathways which lead to metabolic syndrome. Statistically, we did not see 
changes in many anatomical, pathological or biochemical features of metabolic 
syndrome. The application of statistics is key in moving forward with metabolic 
research. Continual improvement of statistics applied to clinical and animal trial needs 
to be prioritised. In this study, simply adding more “groups” to the mix altered the 
outcome when assessing the difference between the corn starch and high-carbohydrate, 
high-fat diets, hence the application of t-tests in the 20% sorghum flour study. Sliding 
dichotomy models have been proposed (648) to show progressive changes rather than 
absolute “yes” or “no” statistical changes. Re-assessing this data with new statistical 
methods will most likely reveal new information.  
The situation is further complicated by the presence of responders and non-responders 
in the population (649). Even within this research, I saw that changes with sorghum 
consumption varied from individual to individual in a population despite a similar 
genetic makeup. Not all humans will show the same response to food interventions, as 
with drugs, and as genomics progresses we may be able to implement “designer” diets 
based on genetics (650).  
Scientifically, the limitations are that not all mechanisms of the changes could be 
identified. Although I hypothesised that there would be changes in intestinal 
permeability, occludin and claudin expression, which would translate to a reduction in 
LPS presence in the blood stream, this was not evident. This linear progression of 
following the changes in LPS through to implications for metabolic syndrome was not 
supported by the outcomes. Despite published studies showing that LPS can induce 
metabolic syndrome, and metabolic syndrome is linked to higher concentrations of 
circulating endotoxins, this is a very complex system and did not appear to be a driver 
of metabolic syndrome in this research.  
There is also the suggestion that circulating fatty acids can mimic the effect of LPS on 
TLR4-mediated inflammation that leads to metabolic syndrome. I tested only 
expression of TLR4, not the activation of TLR4 or the cytokines produced by TLR4 
activation. Further to this, I tested it only in the colon and liver. Further testing of 
expression of TLR4 as well as its activation in cardiac tissue, pancreas, small intestine 
and kidney would assist understanding whether sorghum alters TLR4-mediated 
inflammation leading to metabolic syndrome.  
The identification of individual compounds in the sorghum and products would have 
provided understanding of their contribution to health effects. Furthermore a 
quantitation of these would provide a baseline reference for building upon this 
research.    
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Consumption of sorghum likely altered the composition of the gut microbiome, as with 
consumption of other cereals. Unfortunately, I was unable to assess the changes, 
however future animal and human studies would greatly benefit from the 
understanding of changes in the composition of the gut microbiome with sorghum 
consumption, and how these changes correlate with metabolic and physiological 
changes. We need to acknowledge that the changes to the gastrointestinal tract in rats 
may not translate to humans. Notably, humans do not have a caecum while rats do. 
There is also a discrepancy in the relative surface areas of different gastrointestinal 
sections between humans and rats, in addition to differences in microbial populations 
and the ability to extract nutrients (651).  
Overall, this research has contributed to the knowledge base of how sorghum can affect 
health in a single scenario. While it has shown promise, realistically the development 
of metabolic syndrome is a long-term process which can be best changed by re-
education and more comprehensive changes in dietary habits and attitudes, and 
changes in physical activity. Future human clinical trials should incorporate sorghum 
into a more thorough diet change and aid in educating participants on making better 
dietary choices. Animal models do not necessarily translate to humans. Human trials 
are really the best way forward for researching sorghum as a functional food.  
The biggest barrier to inclusion of sorghum into diets is most likely going to be a lack 
of acceptance by the wider community. Generally, communities are resistant to 
changing their dietary traditions. Sorghum inclusion into products will be helped by 
the current trend of “gluten-free” foods, and it has already been incorporated into a 
number of products. These include bio-fortified sorghum cookies (652), porridges 
(653), “complete nutrition” foods (654, 655) and breads (656). Wheat flour is the 
primary grain consumed in Australia. Wheat flour has unique properties and has been 
bred and highly researched to have improved properties for baking or for flour 
production in the case of durum wheat.  
Sorghum does not possess all of these properties and so there will be a discrepancy in 
the sensory evaluation of products made with sorghum flour. Likewise, consumers are 
accustomed to wholegrains such as oats, but steam flaking of sorghum may be able to 
provide an oat substitute that suits consumer preferences. Research indicates that 
wholegrain breakfast cereals made from sorghum show higher sensory acceptance and 
bioactive content than a wheat counterpart (657). 
Sorghum wet-cake is likely incur the most resistance from consumers. Whilst the smell 
is highly appealing with a “caramel” scent, texturally it may incur resistance from 
consumers. This will be a challenge to food science technology. However, sorghum 
wet-cake has been incorporated into chocolate chip cookies, sugar cookies, molasses 
cookies, bread (646) and spaghetti (647) with little sensory aversion.  
7.1.3 Key recommendations for future studies 
Future research should focus on human studies. Let’s be honest, people love free food. 
If you offer them free sorghum products in exchange for a few blood tests, you’ll 
probably get a number of people on board. Sorghum should not only be researched in 
the context of metabolic syndrome, it should also be researched in the health and 
fitness area.   
Although it will be difficult to assess levels of expressed proteins in tissues, monitoring 
plasma indicators of dyslipidaemia, plasma LPS concentrations, and also monitoring 
intestinal permeability by the lactulose/mannitol test are all possible as they are non-
invasive options. In addition, plasma testing for cytokines that are TLR4-dependent 
will help construct a picture of whether sorghum alters TLR4 activation and alters 
metabolic syndrome. Metabolomic studies of blood markers where large scale screens 
are conducted will give a more comprehensive picture of the contributing processes 
which lead to metabolic syndrome, but also how sorghum consumption affects these 
biochemical pathways and markers.  
Further research should also focus on understanding how to process sorghum to 
receive a good response from consumers, while retaining the properties of components 
that produce sorghum’s effects.  
Sorghum is in its infancy in terms of breeding. In the future, research on specific effects 
of genotypes or “specialty” lines of sorghum such as those with high anthocyanidins, 
high tannins, high phenolics, high amylose and altered proteins for nutraceutical 
purposes will be possible.    
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Sorghum is a minor cereal grain for human consumption in Australia, but in Africa 
and India, it feeds millions of people. This research indicates that sorghum is not 
detrimental to health, and shows a great deal of promise in improving symptoms in 
patients with metabolic syndrome and possibly other ailments. The potential is much 
more far-reaching than simply altering metabolic syndrome. Incorporating sorghum as 
a human food source will add a market for Australian-produced sorghum which will 
then feed into plant breeding research, the food processing market and new product 
development.  
Clinical work which supports the findings in humans, and also promoting sorghum as 
a food, will increase its adoption as an accepted food. If this occurs, I hope that it will 
contribute to a reduced incidence of diabetes and cardiovascular disease.  
7.2 Conclusions and future directions for phloretin in diets 
7.2.1 Summary of key findings and their implications 
This thesis presents results on different interventions as possible treatments to reverse 
diet-induced metabolic syndrome. Compounds have been tested using a validated rat 
model of high-carbohydrate, high-fat diet to induce metabolic, cardiovascular and liver 
changes mimicking metabolic syndrome in humans. Further, a different rat model was 
characterised which allowed higher doses of interventions such as cereals which are 
used at higher amounts in the human diet. Phloretin showed dose-dependent effects, 
especially a normalisation of post-prandial glucose tolerance with a dose of 
200mg/kg/day. Thus, phloretin could be a suitable dietary supplement for patients with 
insulin resistance that may proceed to diabetes. This should be researched in a clinical 
trial situation before recommending to patients. The likely mechanism of action of 
phloretin is by SGLT2 inhibition. Although synthetic SGLT2 inhibitors are on the 
market with support from clinical trials, their adverse effects including effects on bone 
(658) need to be tested for phloretin. However, phloretin did not change other 
cardiovascular parameters and showed improvement in liver structure.  
Moving forward to a closely monitored clinical trial with phloretin would increase the 
knowledge and use of phloretin in metabolic syndrome. Other research in animal 
models has delivered phloretin by oral gavage or intraperitoneal injection, which are 
not appropriate for chronic dosage in humans. A dietary pill will be suitable, such as 
those in cellulose caps or pressed pills. This will alter the concentration in the 
gastrointestinal tract and likely alter the uptake of sugars depending on the 
concentration. This will differ from the chronic low dose in food delivered in this 
study.  
Considering the GLUT2 inhibiting potential of phloretin and SGLT1 inhibiting 
potential of phloridzin, it is surprising that these natural compounds have not been 
researched more extensively for their ability to alter insulin resistance. It is possible 
that more potent compounds such as dapagliflozin, canagliflozin and empagliflozin 
have taken centre stage (659). It may be time to shift focus and look at the potential of 
inhibitors of other sugar transport molecules, such as those inhibited by phloretin.  
Dysfunction of other sugar transporters including GLUT5 (660) and GLUT4 (661) has 
been implicated in metabolic syndrome, so the potential for research into preventing 
and reversing metabolic syndrome is just beginning. Prevention is better than cure, and 
although this research has focussed on reversing and minimising progression of 
metabolic syndrome, a healthy diet and exercise is paramount. Integrating whole foods 
into the diet to limit the risk of metabolic syndrome needs to be stressed, in addition 
to researching medications and supplements to reverse metabolic syndrome that is 
already occurring. Sugar transport inhibitors differ between rats and humans. The 
improvements in glucose tolerance in rats may not translate to humans, especially as 
human pancreatic glucose sensing is not mediated through GLUT2 as it is in rats. 
7.3 Post script 
The opportunity to study an underutilised wholegrain is what drew me to this PhD, 
especially considering sorghum is a crop grown on my family farm. My father 
introduced me to sorghum as a child, popping it in a similar fashion to popcorn. I had 
forgotten about this memory until the opportunity to study sorghum as a potential 
human food source with nutraceutical benefits came up.  
I am personally passionate about health, fitness and nutrition. Knowing that sorghum 
has a great potential and aiding to better the knowledge of its presence in the human 
food market is of personal satisfaction. I am a big believer that the whole diet and 
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lifestyle, not just one component, is what influences health. Spreading information and 
knowledge about this will be my focus in years to come. Having a PhD in health 
science after a career in agriculture will undoubtedly give rigour to the information 
and education I am hoping to spread, in addition to helping me make sense of the 
information and misinformation about nutrition and health that that is rife in the 
community.   
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